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Abstract 
Telomere shortening leads to eukaryotic cell senescence, whereas enhanced telomerase 
activity is associated with telomere expansion and growth of cancer cells. Several studies have 
suggested hnRNPs are important for telomere maintenance including their ability to bind 
telomeres, and telomerase. The hnRNPs A/B family are highly abundant multifunctional 
proteins that bind to single-stranded DNA and RNA and perform many roles in cellular 
regulation. In this study, affinity pull-down assays, biosensor and UV-cross-linking studies 
were used to confirm that recombinant hnRNPs A2 and A3, compared to recombinant hnRNP 
A1, specifically interact with single-stranded telomeric DNA repeat TTAGGG and hexamer 
repeat. Tandem RRMs are required for strong binding, which is little changed by exclusion of 
the glycine-rich domain (hnRNPs Δ GRD).  
 
Additionally, TRAP assays, that indicate telomerase activity, showed that hnRNPs A1, A2 
and A3 bind to telomerase in cell extracts. It is not clear whether this association is mediated 
by binding a specific nucleotide region within telomerase RNA, or a protein component such 
as dyskerin, or both. 
 
In this study I have confirmed and refined the interaction site between the hnRNP A/B 
proteins and telomerase RNA (hTR). Serial UV-cross-linking RNA electrophoretic mobility 
shifting assays (REMSA) have shown that hnRNP A2 binds specifically with to a 17nt region 
within the RNA telomerase template (hTR). Deletion analysis of the hnRNP A/Bs revealed 
that these proteins bind preferentially to the hTR segment encompassing nucleotides hTR57-
72mediated mainly through the RRM1 sequence. Importantly, I found that hnRNP A2 can 
interact simultaneously with telomeric ssDNA repeats. Both hnRNP A1 and hnRNP A3 
showed no binding to the short segments of hTR in this assay, yet they could form a complex 
with full-length hTR. This difference can be explained by the increased insolubility of A1 
and A3. 
 
Nevertheless, as the template region itself appears not to associate in vitro with hnRNPs A1, 
A2 and A3, protein binding may be to the single-stranded nucleotides 56-61, which border 
the template. My results show that hnRNP A2 and the other hnRNP A/Bs bind to a specific 
region of hTR that lies immediately 3ʹ of the hTR57-72 template sequence. The binding of both 
  
 III 
telomeric ssDNA and telomerase RNA by the hnRNP A/Bs could appropriately juxtapose 
these molecules for telomerase-mediated telomere extension. Moreover, hTR57-72 binds to 
hnRNP A2 in the presence of excess non-labeled Telo1, which indicates that the RNA-protein 
interaction is not displaced or diminished by high concentrations of Telo1 and points to 
independent binding sites on A2. Furthermore, I show that the second RNA-Recognition-
Motif (RRM2) of hnRNP A2 binds preferentially to the ssDNA telomeric repeats, whereas 
the first RNA-Recognition-Motif (RRM1) specifically interacts with nucleotides hTR57-72 of 
telomerase RNA. This result supports a model where there is an intimate association between 
hnRNP A2, hTR57-72 and telomeric DNA and predicts an important role for the hnRNP A/Bs 
in facilitating telomer extension. 
 
Additionally, this study has indicated that both RRMs of hnRNP A2 are essential for either 
DNA-protein, or RNA-protein interactions, or both for simultaneous binding. In the 
chromatography experiments, RRM1 and RRM2 on their own were not able to mediate a 
simultaneous binding with both telomeric DNA and telomerase RNA, while short variant 
UP2 was successful to maintain this kind of binding feature. 
 
The results suggest that hnRNP A2 may help recruit telomerase to the ends of chromosomes. 
These hnRNP A/B family members are highly abundant in the cell nucleus, perform many 
roles in the cell and potentially influence telomere biogenesis. From these studies a model was 
proposed where the hnRNP A2 binding site is adjacent, or close to the template segment of 
hTR. The close proximity of the hnRNP A2 binding site to the template region on hTR and 
necessarily, to the end of the ssDNA 3’ overhang, supports the proposal that these proteins 
play an active role in the addition of new telomeric repeats for cellular maintenance. 
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Chapter	1	
1 Introduction 
Telomeres and their associated proteins are specialized structures at the ends of linear 
chromosomes, which have a repetitive sequence of TTAGGG ranging from 3-15 kb long in 
human chromosomes (Moran-Jones et al., 2005). Telomeres serve as a molecular signal to 
prevent the cellular DNA repair machinery from mistaking chromosome ends for double-
stranded DNA breaks. This molecular signal prevents recombination or end-end fusion and 
DNA degradation that eventually would lead to loss of other coding DNA sequences 
(Mancini, 2009). Telomeres provide a means for complete replication of chromosomes, 
contribute to the functional organization of chromosomes within the nucleus, participate in 
the regulation of gene expression, and serve as a molecular regulator that controls the 
replicative capacity of human cells and their entry into senescence (Cong et al., 2002, Cong et 
al., 2002). Immune and other proliferating somatic cells, as well as germ cells, activate 
telomerase, which is a specialized telomeric enzyme, to elongate the telomeric DNA (Forsyth 
et al., 2002). Telomerase maintains chromosome ends by adding TTAGGG repeats to the 3’ 
ends of linear chromosomes (Hockemeyer et al., 2006), which in the absence of telomerase 
become shorter with each round DNA replication because of the end replication problem (De 
Lange, 2009). 
 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) regulate telomeres and thereby 
influence cell transformation (Ford et al., 2002). The most-studied protein among the wide 
range of proteins that bind telomeric single-stranded DNA (ssDNA) is hnRNP A1 and its 
proteolytic derivative UP1. The hnRNP A/B paralogs, hnRNP A1, A2 and A3, have 
multiple splicing isoforms, each of which has two RNA-recognition motifs (RRM1 and 
RRM2) and a glycine-rich domain. Although they have various roles in mRNA 
metabolism, their ability to bind single-stranded telomere repeats and their functional 
association with telomeres has been identified (Table 1.1) (Moran-Jones et al., 2005, Fiset 
and Chabot, 2001). The first genetic evidence to suggest a role for the hnRNP A/Bs in 
telomere biogenesis came from studies using an hnRNP A1-deficient mouse cell line. The 
transformed mouse erythroleukaemic cell line, CB3 contains two defective hnRNP A1 
alleles resulting in at least a 200-fold decrease in A1 transcripts and no detectable A1 
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protein. This cell line contains telomeres that are shorter than those of a related cell line 
(CB7) that expresses normal levels of A1. Reconstitution of A1 expression in CB3 cells 
promoted telomere elongation (LaBranche et al., 1998). Thus, A1 appears to be an 
important auxiliary component of telomere holoenzyme (Zhang et al., 2006). 
1.1 Telomere structure 
 
 A telomere is a region of repetitive nucleotide sequences at each end of a chromatid, which 
protects the end of the chromosome deterioration or from fusion with another chromosome 
(Fig 1.1). Scientists have identified a model for the unique structure of a telomere. 
Tetrahymena, a large unicellular protozoan, has two nuclei; a macronucleus and a 
micronucleus. The sequencing experiments for the ribosomal DNA minichromosome carried 
out by Blackburn and Gall (1978), amazingly found that the telomeres of this structure 
contained 20-70 tandem copies with the sequence 5´-CCCCAA-3´ of a simple hexanucleotide 
on one strand and 5´-TTGGGG on the complementary strand. This sequence can also be 
written CCCCAA/TTGGGG. The GT-rich strand represented the 3´-end of the 
minichromosome (Blackburn and Gall, 1978). The tandem repeats of short GT-rich sequences 
are characteristic of almost all eukaryotic telomeres (De Lange, 2004, Mcknight and Shippen, 
2004, Vega et al., 2003). Generally, telomeres consist of a 6-8 base-pair sequence that is 
repeated hundreds or thousands of times. 
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Table 1.1. hnRNP proteins family and their multi-task acts (Han et al., 2010). 
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Figure 1.1: The telomere in humans. The number and the actual sequence repeats vary 
between species. For example, human telomeres, range in size from 2-50 kilobases and 
consist of approximately 300-8,000 precise repeats of the sequence (CCCTAA/TTAGGG) 
figure was taken from (http://static.medicalnewstoday.com). 
 
By contrast, Saccharomyces cerevisiae, the budding yeast, has telomeres that are smaller and 
more heterogeneous in their composition. S. cerevisiae’s telomeres usually comprise about 60-
100 copies of the sequence C1-3A/TG1-3. A shared feature of all telomeres, however, is the 
orientation of the G-rich strand. In all cases, this strand makes up the end of the chromosome, 
and the terminal portion of the G-rich strand is single-stranded, generating a so-called "G-tail." 
The actual length of the G-tail is somewhat variable, averaging between 75-300 nucleotides in 
humans and 50-100 nucleotides in yeast (Cimino-Reale et al., 2001, Wellinger and Sen, 1997, 
Sabourin and Zakian, 2008). 
 
The telomeric DNA repeats constitute the cis-acting element, which is both necessary and 
sufficient for telomere function (Blackburn, 2000). By late 1980, telomeric DNA sequences 
from most eukaryotes were identified and it became evident that one of the most prominent 
features was the conservation of the tandem arrays amongst distantly related eukaryotes. The 
human telomeric sequence was also shown to be present not only in other vertebrates but also 
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in widely divergent species, ranging from several fungi, protozoa and plants (Muniyappa and 
Kironmai, 1998) (Table 1.2) 
 
Table 1.2. Telomeric repeat sequence. The repeats typically comprise a cluster of three or 
more guanine residues on one strand (G-rich strand), which is always orientated 5´ to 3´ 
towards the end of the chromosome. Within a given species, the ends of all chromosomes 
share the same repeat sequence. Table was taken from (Muniyappa and Kironmai, 1998). 
 
1.2 Mammalian telomeres and the end replication problem 
 
In 2009, the Nobel Prize in Physiology or Medicine was awarded to Elizabeth Blackburn, 
Jack Szostak and Carol Greider for their discovery of how chromosomes are protected by 
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Table 1.1).  The repeats typically comprise of a cluster of three or more guanine 
residues on one strand (G-rich strand), which is always orientated 5’ to 3’ towards the 
end of the chromosome.  Within a given species, the ends of all of its chromosomes 
share the same repeat sequence.  
 
Organism Telomeric Repeat Sequence References 
Protozoa   
Tetrahymena TTGGG (Blackburn and Gall, 
1978) 
Paramecium TT(GT)GGG (Baroin et al., 1987) 
Oxytrichia TTTTGGGG (Oka et al., 1980) 
Plasmodium TT(TC)AGGG (Ponzi et al., 1985) 
Trypanosoma TTAGGG (Blackburn and 
Challoner, 1984) 
Giardia TAGGG (Le Blancq et al., 
1991) 
   
Slime Molds    
Physarum TTAGGG (Forney et al., 1987) 
Didymium TTAGGG (Forney et al., 1987) 
Dictyostelium AG1-8 (Emery and Weiner, 
1981) 
   
Fungi    
Saccharomyces TG2-3(TG)1-6 (Shampay et al., 
1984) 
Kluyveromyces TCG2AT3GAT2AG2TATGTG2TGT (McEachern and 
Blackburn, 1994) 
Candida ACG2ATGTCTA2CT2CT2G2TGT (McEachern and 
Hicks, 1993) 
Schizosaccharomyces 
pombe 
T1-2ACA0-1C0-1G1-6 (Matsumoto et al., 
1987) 
Neurospora TTAGGG (S hechtman, 1990) 
P dospora TTAGGG (Javerzat et al., 1993) 
Cryptococcus AG3-5TT (Edman, 1992) 
Cladosporium TTAGGG (Coleman et al., 
1993) 
   
Invertebrates    
Caenorhabditis TTAGGC  
Ascaris TTAGGC (Muller et al., 1991) 
Parascaris TTGCA (Teschke et al., 1991) 
Bombyx; other insects TTAGG (Okazaki et al., 1993) 
   
Vertebrates    
 TTAGGG (Meyne et al., 1989) 
Plants    
Chlamydomonas  TTTTAGGG (Petracek et al., 1990) 
Chlorella TTTAGGG (Higashiyama et al., 
1995) 
Arabidopsis TTTAGGG (Richards and 
Ausubel, 1988) 
Tomato AA(TA)TGGG (Ganal et al., 1991) 
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telomeres and the enzyme telomerase. Telomere length and integrity maintenance are 
essential for extended cell proliferation and are predicted to play fundamental roles in 
suppressing cancer and ageing (Kim et al., 2008). Telomeric repeats are mainly double-
stranded, with a single-stranded overhang at the 3´ end. The number of repeats per telomere 
varies widely among species, from fixed 4-5 repeats of G4T4 in the ciliate Oxytricha nova to 
~350–500 bp in S. cerevisiae, and variable numbers of GGTTAG repeats encompassing 20–
50 kb in certain mouse and rat species (Palm and De Lange, 2008).  
 
In mammalian cells, dsDNA ranges from 3-15 kb long in human chromosomes (Palm and De 
Lange, 2008). During replication, the end of linear chromosomes pose a problem for the DNA 
replication machinery; the lagging strand of the chromosome is left with a non-replicated 
region during the replication process. Successive replication in the absence of a proper 
compensatory mechanism leads to essential DNA loss at the end of the chromosome (Moran-
Jones et al., 2005) (Figure 1.2). 
  
 7 
 
Figure 1.2: The DNA end-replication problem. 
 
 
Human telomeres are set to lose approximately 100 bp per population doubling (PD), leading 
to senescence after 50 PD. Thus, successive telomeric shortening limits the number of cell 
divisions, and consequently human cells undergo telomere attrition that is linked with cellular 
senescence, death and chromosome instability (Fig 1.3). This shortening is minimized by the 
structure of repetitive sequence of telomeres that caps the ends of the chromosomes (Bianchi 
and Shore, 2008, Creager, 2010).  
! 30!
 
CHAPTER ONE 
 
 
 
 
 
Figure 1.6: The DNA end-replication problem. 
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Figure 1.3: Regulation of telomerase. Germ line and totipotent stem cells have high 
telomerase activity, which is capable of maintaining telomere length. In contrast, many tissues 
and cells have either extremely low levels of telomerase or no detectable levels of telomerase 
activity, and these cell types may show the greatest rate of telomere loss. This figure adapted 
from (Shay and Wright, 2006). 
 
In mouse embryo fibroblasts, failure by cells to identify telomeres shortened beyond a critical 
length results in chromosome instability and initiates malignant transformation (Artandi and 
Depinho, 2000, Feldser et al., 2003). Shortening of telomeres was observed in human kidney 
cortex with increased age (Melk et al., 2000) and in progressive cell division in vitro (Cong et 
al., 2002). Somatic cells in normal mammals proliferate a limited number of times, with the 
extreme number being known as the Hayflick limit (Calado and Young, 2009). At the 
Hayflick limit (Figure 1.4), seriously shortened telomeres initiate an eternal growth arrest, 
referred to as mortality stage 1 (M1) or replicative senescence (Artandi and Depinho, 2000).  
 
Cells that were able to avoid replicative senescence by inactivation of a cell cycle gene such 
as p53 endure to divide and undergo further telomere loss until they reach the next 
proliferative crisis or mortality stage 2 (M2) (Lowden et al., 2011, Cong et al., 2002, Lowden 
et al., 2011) which is characterized by enormous cell death provoked by critically short and 
impaired telomeres. Exceptional survivor cells escaping from crisis are capable of sustaining 
telomere length, in most cases by stimulation of telomerase, resulting in unlimited 
proliferative capacity, that is, cellular immortalization (Cong et al., 2002).   
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1.8.1 Mechanism of telomere dysfunction 
The most common mechanism for telomere dysfunction results from the shortening of 
telomeres due to the end-replication problem.  In contrast to germ line and stem cells, 
which have high telomerase activity and maintain telomere length with age, most 
human somatic cells show progressive telomere attrition with age (Figure 1.9) (Shay 
and Wright, 2006).  This shortening of telomeres in somatic cells is thought to act as a 
‘mitotic clock’ regulating normal cellular lifespan (Harley et al., 1990; Vaziri et al., 
1993). Telomere shortening eventually leads to critically short telomeres, which fail to 
maintain a functional cap or end-protection, leading to genomic instability.  At this 
point, critically short telomeres trigger a DNA damage response pathway resulting in 
chromosome end-to-end fusion or cell arrest (senescence) and cell death (apoptosis) 
(Kim Sh et al., 2002).   
 
 
Figure 1.9:  Regulation of telomerase.  Germ line and totipotent stem cells have high telomerase 
activity, which is capable of maintaining telomere length.  In contrast, many tissues and cells have 
either extremely low levels of telomerase or no detectable levels of telomerase activity, and these cell 
types may show the greatest rate of telomere loss.  Figure adapted from (Shay and Wright, 2006). 
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Figure 1.4: Senescence crisis and immortalisation. When a few telomeres are short, end 
association triggers a DNA-damage signalling pathway leading to a long-term growth arrest 
(often referred to as replicative senescence, the Hayflick limit, or M1). In cells that have 
alterations in the p53/pRb signalling pathway there is a bypass of senescence leading to an 
extended life span. There are some instances where the abrogation of M1 senescence can lead 
directly to the cancer state, but in most instances there is eventually a second growth-arrest 
state referred to as crisis or M2. The vast majority of cells at M2 (crisis) have undergone 
terminal telomere shortening, frequently resulting in the induction of apoptosis. In rare cases, 
however, there is escape from M2, cellular immortality, and telomerase expression. Because 
most cancer cells are immortal and exhibit telomerase activity, this is the common pathway 
for oncogenic transformation. This figure adapted from (Shay and Wright, 2006). 
 
1.2.1 Telomere-associated proteins 
 
In mammalian cells, the best-characterized telomere-associated proteins are the shelterin 
components. For example, two proteins bind dsDNA telomeric repeats; TTAGGG repeat 
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Figure 1.10:  Senescence, crisis and immortalisation.  When a few telomeres are short, end 
association triggers a DNA-damage signalling pathway leading to a long-term growth arrest (often 
referred to as replicative senescence, the Hayflick limit, or M1.  In cells that have alteration in the 
p53/pRb signalling pathway, there is a bypass of senescence leading to an extended life span.  There 
ar  some instances where the abrogation of M1 senescence can lead directly to the cancer state, but in 
most instances, there is eventually a second growth-arrest sta e referred t  as crisis or M2.  The vast 
maj rity of cells at M2 (crisis) have u ergone terminal telomere shortening, frequently resulting in 
the indu tion of apoptosis.  In a rare ca e, however, th re is escape from M2, cellular immortality and 
expression of telomerase activity.  Because most cancer cells are immortal and express telomerase 
activity, this is the common pathway for oncogenic transformation.  Figure taken from (Shay and 
Wright, 2006). 
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binding factors (TRF1 and TRF2). Wild-type TRF1 over-expression results in reduced 
telomere length. In contrast, over-expression of dominant-negative TRF1 increases telomere 
length (Van Steensel et al., 1998), but does not affect telomerase activity globally in the cells 
(Smogorzewska and De Lange, 2004). TRF2 mediates formation or stabilization of T-loops, 
thus protecting mammalian telomeres (De Lange, 2005). Loss of TRF2 results in cell cycle 
arrest, telomeres end-to-end fusion and, in a subset of mammalian cell types, apoptosis (Van 
Steensel et al., 1998). Moreover, TRF1-interacting protein2 (TIN2) participates in regulation 
of telomere length through binding TRF1 and TRF2 directly, and protector of telomeres 1 
(POT1) indirectly via the intermediary protein (TPP1). Repressor activator protein 1 (Rap1) 
mainly interacts with TRF2. TIN2 is an important telomere-associated protein because its 
function appears to be crucial in forming telomere complexes, which in turn function in end 
protection (Kim et al., 2008). In contrast to TRF1 and TRF2, POT1 is abundant in the ssDNA 
regions. POT1 binds the telomeric repeats in the G-rich single-strand and is essential for both 
telomere capping and cell survival, possibly in association with TRF2 (Kendellen et al., 2009) 
(Figure1.5).
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Figure 1.5: Mammalian telomerase. Human and mouse telomeres are composed of long 
stretches of the repetitive sequence TTAGGG and a telomere-specific protein complex, 
shelterin (upper left). Shelterin derives its specificity for telomeric DNA from three DNA 
binding proteins (lower left). TRF1 and TRF2 are two similar proteins that bind to double-
stranded telomeric repeats while POT1 interacts with TTAGGG repeats in single-stranded 
form. TIN2 and TPP1 connect POT1 to TRF1 and TRF2. Rap1 is bound to TRF2. Telomeres 
are found in a lariat conformation (upper right), the T-loop, which results from the strand 
invasion of the 3' single-stranded overhang into the double-stranded telomeric DNA. Shelterin 
is sufficiently abundant to cover most of the double-stranded telomeric DNA, and there is 
sufficient POT1 to cover single-stranded telomeric DNA either in the 3' overhang or in the D 
loop. This figure was taken from (De Lange, 2004). 
 
1.2.2 Telomere protective structure 
 
Two principal models have been advanced for the mechanism of preservation of chromosome 
ends, both of which avoid their recognition as dsDNA breaks that would otherwise initiate the 
DNA damage response and result in strand degradation and recombination (Ford et al., 2002). 
The initial understanding of DNA damage response came when linear DNA introduced into 
eukaryotic cells was found to be unstable because the DNA ends recombine with the 
endogenous genome (Orr-Weaver et al., 1981). More recent work has shown that introduced 
linear DNA is exposed to two essential DNA repair pathways that restore broken 
chromosomes: first, homology-directed repair (HDR) and second, nonhomologous end 
joining (NHEJ).  
 
End-protection in mammalian cells can be referred to in more specific terms, based on current 
information on the molecular pathways that distinguish and repair double-strand breaks. Two 
independent signaling pathways in mammalian cells are activated by double-strand breaks: 
(1) the ATM (ataxia telangiectasia mutated) kinase pathway, which is activated directly by 
DNA ends, and (2) the ATR (ataxia telangiectasia and Rad3 related) kinase pathway, which is 
activated by the single-stranded DNA formed when the 5' end of a double-strand break is 
trimmed back or resected (Fig. 1.6) (De Lange, 2009).  
 
Solving the end-protection problem requires mechanisms that keep both kinases at telomeres, 
because mammalian telomeres have features (both a DNA end and a constitutive region of 
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single-stranded DNA) that could activate ATM and ATR. In human immortal cells, stalled 
replication forks increased telomerase recruitment in an ATR-dependent manner. Moreover, 
increased telomerase recruitment was observed upon phosphorylation of the shelterin 
component TRF1 at an ATM/ATR target site (S367). This phosphorylation leads to loss of 
TRF1 from telomeres and may consequently increase replication fork stalling. ATM and ATR 
reduction reduced assembly of the telomerase complex, and ATM was required for telomere 
elongation in cells expressing POT1ΔOB, an allele of POT1 that disrupts telomere-length 
homeostasis. These data establish that human telomerase recruitment and telomere elongation 
are regulated by DNA-damage-transducing kinases (Tong et al., 2015).  
 
The end-protection problem in mammalian and other organism with linear chromosomes cells 
thus involves escaping the potential harmful effects of four different pathways. An inability to 
do so will cause cell cycle arrest (under the command of ATM and/or ATR), chromosome 
end-to-end fusions (a product of NHEJ), or sequence exchanges (mediated by HDR) that 
involve two telomeres or a telomere and another part of the genome (De Lange, 2009).  
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Figure 1.6: The end-replication problem. When a mammalian chromosome breaks (top), the 
exposed DNA ends can activate two signalling pathways (the ATM and ATR kinase 
pathways) that arrest the cell division cycle and can induce cell death. The broken 
chromosome is usually repaired by one of two different DNA repair pathways (NHEJ and 
HDR), allowing cells to continue their divisions with an intact genome. The presence of these 
DNA damage response pathways poses a problem for the ends of linear chromosomes 
(telomeres, bottom) because activation of DNA damage signalling or DNA repair at telomeres 
would be disastrous. Mammalian telomeres solve this end-protection problem through the use 
of a telomere-specific protein complex (shelterin) and an altered structure (the T-loop) that 
together ensure that all four pathways remain blocked. This figure was taken from (De Lange, 
2004).  
 
1.2.2.1 T-loop  
 
One model has the linear chromosome ends capped by DNA-binding multi-protein complexes 
(including the shelterin complex: (Figure 1.5) that protects their ends from nuclease digestion, 
whilst other proteins associate directly with ssDNA repeats or other repeat-associated proteins. 
In the second model, it has been proposed that in vertebrates the single-stranded telomere end 
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is protected by folding back with insertion into the double-stranded segment of the telomere. 
This gives rise to D- (displacement) and T- (telomere) loops in which the ssDNA is shielded 
from the action of telomerase, thereby preventing telomere extension (Griffith et al., 1999).  
 
Electron microscopy and indirect biochemical experiments with human and mouse 
telomeres have revealed that telomeres end in large lariat-type structures termed T-loops. 
The T-loop forms through strand invasion of the single-stranded 3' overhang into the duplex 
part of the telomere (Griffith et al., 1999). The size of the loop can be large (up to 25 kb in 
mice) and its configuration is thought to not only protect the 3' overhang from degradation, 
but also limit the ability of telomerase to access its substrate (Griffith et al., 1999). It is 
unclear whether telomeres of all or many species terminate with a T-loop structure. However, 
in Trypanosoma brucei (single-cell protozoa) telomeres are also organized into T-loops, 
which suggests that they may be evolutionarily conserved (Munoz-Jordan et al., 2001). 
During DNA replication passage of the replication fork may unwind and open the T-loop 
structure, thereby exposing the 3' overhang to telomerase and other proteins required for 
DNA replication (Wei and Price, 2003). 
 
In a previously proposed model the terminal telomeric structure can either exist in a closed, 
protected form or an open, unprotected form. Short telomeres would favour the open form, 
and given that telomerase may recognise, or have access to, only the open form, the short 
telomeres would be preferentially acted upon. In the absence of telomerase the shortest 
telomeres would not be elongated to facilitate the ‘closed’ form. Consequently, cells could 
distinguish these shorter ‘open’ forms as dysfunctional telomeres, stimulating a signaling 
cascade that results in senescent arrest or cell death depending on the integrity of the genes 
controlling and implementing these pathways (e.g. p53/pRb) (Blackburn, 2000). 
 
De Lange proposed that chromosome ends in the first eukaryotes could have been stabilized 
using the T-loop structure. If the ends contained a few terminal repeats, T-loops could have 
been generated by factors that were involved in recombination-dependent replication (RDR), 
a form of DNA replication that was in existence before eukaryotes evolved. The presence of 
T-loops in present-day telomeres and their association with proteins that have evolved from 
RDR factors might be remnants of the original telomere system. The relative ease with which 
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many eukaryotes can maintain telomeres without telomerase might reflect this ancient system 
of chromosome-end replication. This proposal ends with a discussion of the advantages of the 
telomerase-based system that could explain the emergence of this almost universal 
mechanism for telomere maintenance (De Lange, 2004).  
1.2.2.2 G-Quadruplex structures 
 
G-quadruplexes are nucleic acid sequences that are rich in guanine and are capable of forming 
a four-stranded structure. In a variety of organisms telomeric repeats have been shown to 
form G-quadruplex structures in vitro, and in some cases in vivo (Paeschke et al., 2005). The 
quadruplexes formed by this structure have been well-studied by Nuclear Magnetic 
Resonance (NMR) and X-ray crystal structure determination (Paeschke et al., 2005). The 
formation of these quadruplexes in telomeres have been shown to decrease the activity of 
telomerase, which is responsible for maintaining adequate length and involved in around 85% 
of all cancers (Collins, 2006). This is an active target of drug discovery (Fig. 1.7) (Wang et 
al., 2011). In addition, Quan Wang and his colleagues have shown that G-quadruplexes tend 
to form at the farthest 3´ end of telomere DNA (Wang et al., 2011, Kruger et al., 2010). The 
addition of telomeres using a minimum of four TTAGGG repeats can be extende by 
telomerase, while shorter than 4 repeats pose no extension (Zahler et al., 1991).  
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1.2.3 hnRNPs and G-quadruplex structure 
 
The role of telomerase is for chromosome stability by telomere extension and cell vitality by 
gaining access to ss-telomeric DNA. hnRNP A2 has shown that its actively to unfolds 
telomeric G-quadruplex DNA, exposes 5 nucleotides of the 3′ telomere tail and significantly 
enhances the catalytic activity of telomerase. Telomere DNA comprises a four-stranded G-
quadruplex structure (Lipps and Rhodes, 2009) that can be either intermolecular or 
intramolecular. In vertebrates, intramolecular G-quadruplexes form at the furthest 3' end of 
telomeric DNA (Tang et al., 2008), rendering it inaccessible to telomerase. Consequently, this 
structure hinders telomere extension (Wang et al., 2011). Only a few proteins have been 
recognised that can disrupt G-quadruplexes. One such protein is Protection of Telomeres 1 
(POT1) (Baumann and Cech, 2001), an element of the telomere shelterin complex that binds 
telomere overhangs with high specificity (Lei et al., 2004). Despite its ability to disrupt the G-
quadruplex POT1 inhibits telomere extension by binding to the telomere overhang and 
obstructing telomerase access to it (Wang and Lei, 2011).  
 
farthest possible 30 end of telomere DNA will have a 30 tail
of no more than 5 nt (TTAGG), our results argue that
G-quadruplex formation on telomere overhang can inhibit
such lomere end proc ssing reactions hat require a free
30 tail. Therefore, we propose that G-quadruplex can play
a role in regulating telomere end processing and, as a
result, serve as eff ctive drug target for intervening
telomere function.
MATERIALS AND METHODS
Telomere extension by telomerase
Telomerase activity was assayed using reconstituted
h man tel m rase (11,12) nd the TRAP-G4 m thod
(13) with a TSNT internal standard (IS) (14,15). Briefly,
hTR RNA was transcribed using the T7 transcription kit
(Fermentas, Lithuania) a d double- tranded (dsDNA)
template amplified from nucleotides +1–+388 in the
plasmid pUC119-hTR(+1–451) with sense primer 50-CC
CCAGGCTTTACACTTTATGC and antisens primer
50-ACTCGCTCCGTTCCTCTTCC. hTERT was expressed
using the TnT quick coupled transcription/translation kit
(Promega, USA) with the pET-28b-hTERT plasmid.
Both plasmids were kind gift from Dr Lea Harrington at
the Department of Medical Biophysics, University of
Toronto, Canada. Reconstitution was carried in a 50-ml
volume containing 40 ml of TnT Quick Mix, 2 ml PCR
enhancer, 1 ml of 1mM methionine, 1 mg
pET-28b-hTERT plasmid. After incubation at 30!C for
90min, 2ml 0.5 mg/ml purified hTR RNA was added to
the reaction mixture, and the incubation extended for
another 90min.
Telomerase extension was carried out with 0.05 pmol
G-quadruplex or control substrate (Figure 2A) in a
volume of 44 ml containing 20mM Tris–HCl (pH 8.3),
100mM dNTP, 1.5mM MgCl2, 63mM KCl, 1mM
EGTA, 0.005% Tween 20, 100 mg/ml bovine serum
albumin (BSA) and 5 ml diluted telomerase. After 5min
incubation at 25!C, the reaction was terminated by heating
at 94!C for 5min followed by addition of 6ml PCR mixture
containing 14pmol of upstream primer 50-TTGATTGGGA
TTGGGATTGGGTT-30 and 15 pmol of downstream
primer 50-GTGCCCTTACCCTTACCCTTACCCT-30
for the extended products, 8.3 pmol of primers TS (50-A
ATCCGTCGAGCAGAGTT-30) and NT (50-ATCGCTT
CTCGGCCTTTT-30), 1 amol of TSNT (50-AATCCGTC
GAGCAGAGTTAAAAGGCCGAGAAGCGAT-30)
template for internal standard, and 1U of Taq DNA poly-
merase (Ex Taq HotStart, TaKaRa, Dalian, China). The
samples were subjected to 34 PCR cycles of 94!C for 30 s,
55!C for 30 s. Ten microliter PCR products were resolved
on 12% polyacrylamide gel with an Acryl/Bis ratio of 19:1
(w/w), stained with ethidium bromide and recorded on a
ChemiImager 5500 (Alpha Innotech, USA). The telomer-
ase products for each substrate were normalized to the
co-amplified internal standard and the activity ratio of
G-quadruplex over control substrate was calculated to
judge the effect of G-quadruplex on telomerase activity.
Dimethyl sulfate footprinting
Footprinting was carried out essentially as described (16).
FAM-labeled oligonucleotide was made in 10mM Tris–
HCl (pH 7.4) buffer containing 1mM ethylenediaminete-
traacetic acid (EDTA) and 150mMKCl or LiCl, heated at
95!C for 5min and then cooled on ice for 10min. Ten
picomoles of FAM-labeled oligonucleotide in 100 ml
volume were then mixed with 4 ml of 10% (v/v) dimethyl
sulfate (DMS) in ethanol and incubated for 6min at room
temperature. The reaction was stopped by addition of
100 ml stop buffer (0.6M NaOAc, 0.1M b-mercapto-
ethanol, 20 mg sperm DNA). After a phenol/chloroform
extraction and ethanol precipitation, the oligonucleotide
was dissolved in 50 ml water and mixed with 50 ml of 20%
(v/v) piperidine in water. The samples were heated at 90!C
for 30min, followed by phenol/chloroform extraction and
ethanol precipitation. The precipitated oligonucleotide was
dissolved in 50% (v/v) deionized formamide in water,
denatured at 95!C for 5min and resolved on a denaturing
15% polyacrylamide gel.
Telomere strand invasion and extension
Telomere strand invasion and extension were analyzed as
previously described (17,18) with modifications, using a
pGEM-T plasmid carrying 80 T2AG3 repeats. Double-
stranded human telomeric DNA was obtained by PCR
amplification using synthetic primers 50-(T2AG3)5-30 and
50-(C3TA2)5-30 as described (19) and inserted into the
plasmid pGEM-T Easy (Promega). The construct was
transformed into Escherichia coli TOP10 and verified by
sequencing. The plasmid (120 ng/ml) was incubated for
15min at 25!C in extension buffer of 50mM HEPES,
pH 7.9, containing 100 mg/ml BSA, 1mM DTT, 2%
glycerol, supplied with 150mM KCl, 15mM MgCl2,
100 mM dTTP, 100 mM dATP, 200 nM Cy5-ddGTP (GE,
USA) in a volume of 9ml. Telomeric G-rich oligonucleo-
tide (Figure 3A) in extension buffer was heated at 95!C for
5min, cooled on ice for 15min. Then 2ml of 500 nM
(Figure 3) or 3mM (Figure 4) oligonucleotide and 1 ml of
Figure 1. Extension of telomere by telomerase depends on the size of
single-stranded tail at the 30 side of the farthest distal G-quadruplex on
telomere overhang. A telomere tail of less than four T2AG3 repeats
(0–23 nt) will stay in single-stranded form. Those with tails long
enough but unable to form G-quadruplex can be extended (top)
while others without or with too short tails may not be extended
(bottom).
2 Nucleic Acids Research, 2011
 at University of Queensland on May 4, 2011
nar.oxfordjournals.org
Downloaded from 
Figure 1.7: Telomere extention by telomeras depends on the size of the single-stranded DNA 
at the 3´ end of the distal G-quadruplex on the telomere overhang. A telomere length less 
than four T2AG3 repeats will remain in single-stranded form. Those with ends long enough but 
unable to form G-quadruplex can be extended (top) while others with or without ends that are 
too short may not be extended (bottom). This figure was taken from (Wang et al., 2011). 
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Other proteins such as members of the hnRNP family are also able to unfold telomeric G-
quadruplexes (Nakagama et al., 2006). These proteins interact with telomeric ssDNA (Ford et 
al., 2002) and telomerase (Fiset and Chabot, 2001, Ford et al., 2000) in vitro, which suggests 
that they play roles in telomere biology. In cajal body, splice variant hnRNP A2*, which lacks 
residues encoded by exons 7-9 actively unfolds telomeric G-quadruplex DNA in vitro, 
exposes 5 nt of the 3' telomere tail, and significantly enhances the catalytic activity of 
telomerase. The level of expression of hnRNP A2* in tissue positively correlates with 
telomerase activity, and overexpression of hnRNP A2* leads to telomere elongation in vivo. 
Thus, hnRNP A2* plays a positive role in unfolding telomere G-quadruplexes and in 
enhancing telomere extension with telomerase (Fig 1.8) (Wang et al., 2012). hnRNP A2/B1 
recognizes N(A,C,T)(C,T)(A,G)G(C,G,T)(A,T)NNN, a consensus sequence that encompasses 
and aligns “in phase” with the telomere repeat TTAGGGTTAG (Moran-Jones et al., 2005) 
and is also believed to block the telomere end and render it inaccessible to telomerase. This 
could also be true for other abundant hnRNPs (Dallaire et al., 2000, Huang et al., 2008, 
Tanaka et al., 2007). hnRNP A2* may be unique in its ability to actively unfold telomere G-
quadruplexes while leaving 3' telomere ends accessible (Wang et al., 2012). 
 
Figure 1.8: Proposed working model of hnRNP A2. A single-stranded telomere overhang 
forms intramolecular G-quadruplex. hnRNP A2 assembled in Cajal body with telomerase (1); 
binds to the telomere end to facilitate telomere end-telomerase alignment (2), for telomere 
extension (3), POT1 can also bind to the telomere end (4), making it inaccessible to 
telomerase. Competition between POT1 and hnRNP A2 (5) determines the accessibility of the 
sequence added to it by telomerase, allowing PCR ampliﬁcation
using TSG4-speciﬁc primers (40). hnRNP A2* stimulates telo-
merase activity to a greater extent when the TRAP assay is per-
formed with this substrate (Fig. 3E and Fig. S2B) than with the
TS substrate (Fig. 3D and Fig. S2A), whereas POT1 does not
stimulate telomerase activity with either DNA substrate (Fig. 3
D and E). These data suggest that hnRNP A2* promotes
telomerase function by unfolding G-quadruplex during telome-
rase extension.
Although human telomerase can processively add multiple
telomeric repeats to a single primer (41), processive DNA syn-
thesis by telomerase is inhibited by G-quadruplex, because it
interferes with telomerase translocation (9, 10, 42). Therefore,
we examined the impact of hnRNP A2* on telomerase proc-
essivity using a modiﬁed TRAP assay (43). In dilute solution,
telomerase showed a relatively high processivity (Fig. 3F and Fig.
S2C, ﬁrst lane). We reported previously that in the presence of
PEG 200, a crowding agent widely used to mimic the molecularly
crowded intracellular environment, the thermal stability of
telomere G-quadruplex increases and the processivity of human
telomerase decreases (44–46) (Fig. 3F and Fig. S2C, second
lane). hnRNP A2* stimulated telomerase processivity in the
presence of PEG 200 (Fig. 3F and Fig. S2C, third lane), but
POT1 did not (Fig. 3F and Fig. S2C, fourth lane). Because both
hnRNP A2* and POT1 can disrupt G-quadruplex, this difference
may reﬂect the fact that hnRNP A2* exposes a free 3′ end when
it binds to telomeric DNA, but POT1 does not.
hnRNP A2* Localizes to the Nuclear Matrix and Associates with
Telomerase at Telomeres and in Cajal Bodies in Vivo. The protein
region encoded by exons 7–9 in hnRNP A2, which is missing
from hnRNP A2*, is entirely hydrophilic (Fig. S3A). As a result,
hnRNP A2* is more hydrophobic than hnRNP A2. hnRNP A2
localizes predominantly to the nucleoplasm (27), whereas sub-
cellular fractionation of cells expressing tagged hnRNP A2*
shows that hnRNP A2* localizes exclusively to the nuclear matrix
(Fig. S3B). This suggests that hnRNP A2 and hnRNP A2* have
distinct cellular functions.
Some proteins from the hnRNP family interact directly with
telomerase, as well as with telomeric DNA, in vitro (20, 21). We
found that hnRNP A2* could pull-down telomerase activity from
cell lysate (Fig. 4A) as did hnRNP A2 (Fig. S4A), demonstrating
that hnRNP A2* can physically interact with telomerase. In
addition, hnRNP A2* directly binds the RNA component of rTR
in vitro (Fig. 4B). This binding is dependent on the size/sequence
and possibly the secondary structure of rTR, because hnRNP A2
binds to the 0–269 fragment of rTR (Fig. S4B), whereas hnRNP
A2* does not (Fig. 4B).
To examine whether hnRNP A2* interacts with telomeres and
telomerase in vivo, we expressed HA-tagged hnRNP A2* in rat
cells and performed immunoﬂuorescence experiments. The re-
sults showed that a fraction of hnRNPA2* colocalized withRAP1,
a component of the telomere-associated shelterin complex, and
with TERT, the catalytic component of telomerase (Fig. S5A, top
and middle images). Control experiments showed that the anti-
body to HA-hnRNP A2* only stains HA-hnRNP A2*–expressing
cells (Fig. S5B) and that suppression of TERT expression by
siRNA dramatically reduced the ﬂuorescence in the cells (Fig.
S5C). Interestingly, hnRNP A2* can also colocalize with Coilin,
a marker of Cajal bodies (Fig. S5A, bottom images). Because
Cajal bodies are involved in the processing and positioning of
telomerase at telomeres (47), we hypothesized that hnRNP A2*
may play a role in these processes.
The interactions between hnRNP A2*, telomerase, telomeres,
and Cajal body were further examined using multicolor immu-
noﬂuorescence. The results can be summarized as follows (Venn
diagrams in Fig. 4C, Right): about half of the TERT at telomeres
or in Cajal bodies was associated with hnRNP A2*. More im-
portantly, out of the 39 hnRNP A2*/RAP1 foci observed, 37 were
also positive for telomerase (hnRNP A2*/RAP1/TERT foci).
Similarly, of the 21 hnRNP A2*/Coilin foci observed, 20 were also
positive for TERT (Fig. 4C and Fig. S6 A and B). The prevalent
colocalization of hnRNP A2* with telomerase at telomeres and in
Cajal bodies strongly suggests that hnRNP A2* is a close partner
of telomerase. It is possible that hnRNP A2* is assembled into
the telomerase holoenzyme at Cajal bodies and delivered to
telomeres. Our ﬁnding that the binding of hnRNP A2* with rTR
(Fig. 4B) involves the 3′ region of rTR (269–419 nt), which
contains the Cajal body box (CAB) motif responsible for its
mobilization to the Cajal body (38, 48), supports this hypothesis.
hnRNP A2* Expression Correlates with Telomerase Activity, and
Overexpression of hnRNP A2* Increases Telomere Length in Vivo.
To explore whether hnRNP A2* inﬂuences telomerase func-
tion in vivo, the amount of hnRNP A2* and telomerase mRNA
A
B
Fig. 5. In vivo correlation of hnRNP A2* expression with telomerase ac-
tivity and telomere length. (A) Expression of hnRNP A2*, hnRNP A2, TERT,
and telomerase activity in 7-wk-old rat tissues. Expression was analyzed by
RT-PCR. Telomerase activity was assayed by TRAP. Relative abundance was
obtained by normalizing band intensity to actin and then to brain. IS, In-
ternal standard. (B) Overexpression of hnRNP A2* increases telomere length
in HeLa cells. Cells were drug-selected and cultured to the indicated pop-
ulation doublings (PDs) after they were transfected with HA-hnRNP A2* or
empty control vector. Telomere restriction fragments were detected by
Southern blot (Left) and then digitized for quantiﬁcation (Right). M, marker.
Fig. 6. Proposed working model of hnRNP A2*. A single-stranded telomere
overhang forms intramolecular G-quadruplex. hnRNP A2* assembled in Cajal
body with telomerase (1) binds to the telom r end upon unfolding telo-
mere G-quadruplex to facilitate telomere end-telomerase alignment (2) for
telomere extension (3). POT1 can also bind to the telomere end (4), making
it inaccessible to telomerase. Competition between POT1 and hnRNP A2* (5)
determines the accessibility of the telomere end to telomerase and its sub-
sequent extension.
4 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1200232109 Wang et al.
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telomere end to telomerase and its subsequent extension. This figure adapted from (Wang et 
al., 2012). 
 
The hnRNP A1 and its shortened derivative, unwinding protein 1 (UP1), are active in 
telomere length regulation and proposed that hnRNP A1 stimulates telomere elongation 
through unwinding of a G-quadruplex structure (Zhang et al., 2006). Moreover, both A1 and 
UP1 bind well to the G-quadruplex telomeric DNA and UP1 can unwind G-quadruplex 
structures (Paramasivam et al., 2009). Ensemble and single molecule fluorescence energy 
transfer (FRET) measurements have provided further insight into the molecular conformation 
of telomeres: the telomeric DNA overhang is in a folded state in the absence of hnRNP A1 
and remains predominantly in a compact state when complexed with hnRNP A1 (Kruger et 
al., 2010). This finding is in contrast to the previously reported crystal structures of UP1-
telomere DNA complexes (Ding et al., 1999), where the DNA oligonucleotide within the 
protein-DNA complex is in a fully open conformation.  
  
Moreover, Le and colleagues have shown that the inhibition of shelterin associated DNA 
dependent protein kinase catalytic subunit (DNA-PKcs) and its phosphorylation target has 
resulted in accumulation of TElomeric Repeat containing RNA (TERRA) at telomeres. 
TERRA is a non-coding RNA that forms basic part of telomric hetrochromatin along with 
telomeric binding proteins. It has a role in maintaining telomeric structure during cell 
differentiation and development. Le and colleagues have proposed that human telomerase 
RNA (hTR) stimulated DNA-PKcs and phosphorylated hnRNP A1 influences the cell cycle 
dependent distribution of TERRA at telomeres by participating in the removal of TERRA 
from telomeres, which is a crucial action for progression of DNA replication at s-phase (stage 
of cell cycle for major event of accurate DNA replication, occurring between G1 and G2 
phase), and thus facilitating efficient telomere replication and end-capping (Le et al., 2013). A 
recent study has shown that purified protection of telomere protein (POT1) and its functional 
partner tripeptidyl-peptidase 1(TPP1) are unable to prevent replication protein A (RPA) 
binding to telomeric ssDNA efficiently. hnRNPA1 and hnRNP A2/B1 have been noticed to 
play a role in RPA displacement. Purified hnRNP A1 displaced RPA from ssTEL (telomeres) 
containing four or more telomeric repeats, indicating that a DNA length-dependent binding 
mode of hnRNP A1 may be needed to displace replication protein A (RPA). The RPA 
displacing activity is inhibited by TERRA, but is then unleashed in the late stage of cell cycle 
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when TERRA levels are decreased at telomeres. Le et al. have suggested that POT1, hnRNP 
A1 and TERRA act in concert to displace RPA from telomeric ssDNA after DNA replication, 
and therefore facilitate telomere capping (Flynn et al., 2011).  
 
 
1.3 hnRNP A/B family 
 
hnRNPs are multi-tasking proteins that form a complex structure with RNA polymerase II 
transcripts (Krecic and Swanson, 1999). They are known for their diverse cellular activities 
ranging from transcription to pre-mRNA processing such as splicing, and are crucial 
determinants of mRNA translation, localization, stability and export (Dreyfuss et al., 2002). 
Moreover, it has been proposed that some hnRNPs shuttle between nucleus and cytoplasm, 
indicating a conceivable role for these proteins in mature mRNA export (Pinol-Roma and 
Dreyfuss, 1992). Thus, they bind to pre-mRNA molecules and serve as signals that the pre-
mRNA is not yet completely processed and prepare for export to the cytoplasm (Chaudhury et 
al., 2010). Additionally, they prevent pre-mRNA from folding into a secondary structure and 
facilitate its interaction with other proteins and transport of mRNA out of the nucleus (Moran-
Jones et al., 2009).  
 
hnRNP A1, D, E, F/H, and K are present in both the nucleus and the cytoplasm, suggestive of 
cytoplasmic roles for these hnRNPs (Dreyfuss et al. 2002). At least 20 abundant hnRNPs 
have been identified in human (HeLa) cells, using a combination of two-dimensional gel 
electrophoresis and immunopurification to explore the composition of hnRNP complexes 
(Pinol-Roma et al., 1988). Predominant hnRNP proteins have been designated as hnRNP A1 
through hnRNP U, with molecular weights varying from 34 kDa to 120 kDa (Dreyfuss et al., 
1993, Kamma et al., 1995) (Table 1.3). hnRNPs, especially when complexed to hnRNAs, are 
estimated to comprise nearly 100,000,000 copies per nucleus (Dreyfuss et al., 2002, Kamma 
et al., 1995). Based on their nonselective association with nascent transcripts, Beyer et al. 
(1977) identified hnRNPs A1, A2/B1, B2, C1 and C2 as major hnRNPs and termed them 
“core” hnRNPs. Minor hnRNPs tend to bind unstably to hnRNAs or are associated with a 
specific subset of hnRNAs (Dreyfuss et al., 2002, Krecic and Swanson, 1999). 
As the “core” hnRNPs, such as A1, are very abundant, each of these proteins is likely to be in 
vast excess over available specific binding sites on their target RNAs. In addition to their 
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sequence-specific binding, hnRNPs also exhibit nonspecific interactions with transcripts. A 
systematic immunohistochemical survey showed that hnRNPs are expressed in all tissue types 
at varying abundance levels and that their relative stoichiometry across cell types is not fixed 
(Kamma et al., 1995). 
  
Table 1.3 Major hnRNPs. Alternative names have been included in parentheses. Receptor 
binding domain (RBD), RNA-binding domain or RNA recognition motif (RRM); RGG, 
arginine/glycine-rich box; KH-K homology domain; EJC, exon junction complex; GAIT, 
interferon-g-activated inhibitor of translation. Molecular mass (kDa) has been determined 
from SDS-polyacrylamide gel electrophoresis (Chaudhury et al., 2010). 
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 Table. 1.2: Alternative names have been included in parentheses. RBD, RNA-binding domain or 
RNA recognition motif (RRM); RGG, arginine/glycine-rich box; KH-K homology domain; EJC, 
exon junction complex; GAIT, interferon-g-activated inhibitor of translation. Molecular mass (kDa) 
has been determined from SDS-polyacrylamide gel electrophoresis (Chaudhury et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
each hnRNA dictated by the specific RNA sequence and
relative expression of the hnRNPs (including abundance
levels and post-translational modifications) (Habelhah et al.
2001; Mandal et al. 2001). However, as the ‘‘core’’ hnRNP
proteins, such as A1, are extremely abundant, each protein is
likely to be in vast excess over its respective binding sites.
Therefore, in addition to their sequence-specific binding,
nonspecific interactions are also prevalent among the hnRNP
proteins. A systematic immunohistochemical survey revealed
that hnRNP proteins are ubiquitously expressed in all tissue
types to varying abundance levels and that their relative
stoichiometry across cell types is not fixed (Kamma et al.
1995). Furthermore, hnRNP A1, D, E, F/H, and K were
demonstrated to be present in both the nucleus and cy-
toplasm, suggestive of cytoplasmic roles for these hnRNPs
(Dreyfuss et al. 2002).
Structure of hnRNP proteins
cDNA sequence analysis of the hnRNP proteins has revealed
a modular structure consisting of one or more RNA-binding
motifs and at least one auxiliary domain that regulates
TABLE 1. Major hnRNP proteins
Protein
Molecular
weight
(kDa)
Domain/functional
motif
Preferred
binding
sequence
Reported
function
Shuttling
capacity
A1 34 2X RBD, RGG UAGGG(A/U) Splicing +
Export
Telomere biogenesis
A2/B1 36/38 2X RBD, RGG (UUAGGG)N Splicing +
Localization
C1/C2 41/43 1X RBD U6 Splicing !
Stability
D (AUF) 44–48 2X RBD, RGG AU rich Telomere biogenesis +
Stability
Recombination
E1/E2/E3/E4
(aCP1-4 or PCBP1-4)
38, 39 3X KH C rich Stability +
Translation
F 53 3X RBD GGGA Splicing Not known
G 43 1X RBD, RGG CC(A/C) Splicing !
H/H9 (DSEF-1) 56 3X RBD GGGA Splicing Not known
Polyadenylation
I (PTB) 59 4X RBD UCUUC Splicing +
Localization
Polyadenylation
K/J 62 3X KH, RGG C rich Transcription +
Stability
Translation
L 68 4X RBD CA repeat Export Not known
Stability
Riboswitch
M 68 4X RBD G or U rich Splicing +
P2(FUS/TLS) 72 RBD GGUG Avid binding to poly(A) +
Autoantibody target
Q1NSAP 55–70 3X RBD, RGG GAIT element Splicing +
Translation
R1/R2 82 RBD Not known Retinal development +
U 120 RGG Not known Nuclear retention !
Alternative names have been included in parentheses. RBD, RNA-binding domain or RNA recognition motif (RRM); RGG, arginine/glycine-rich
box; KH-K homology domain; EJC, exon junction complex; GAIT, interferon-g-activated inhibitor of translation. Molecular mass (kDa) has been
determined from SDS-polyacrylamide gel electrophoresis (Pinol-Roma et al. 1988; Dreyfuss et al. 1993, 2002; Hassfeld et al. 1998; Krecic and
Swanson 1999; Guil et al. 2003; Singh and Valcarcel 2005; Hovhannisyan and Carstens 2007; Heinrich et al. 2009; Ray et al. 2009; Anderson
2010).
Heterogeneous nuclear ribonucleoprotein E1
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1.3.1 hnRNP A/B subfamily 
 
The A/B-type hnRNP polypeptides (A1/A1b, A2/B1/A2b/B1b, A3/A3a/A3b (Papadopoulou 
et al., 2012)) are structurally related basic proteins with molecular masses ranging from 30 to 
40 kDa (Dangli et al., 1996, Kamma et al., 1999). 
 
They possess multiple charged isoforms (due to alternative pre-mRNA splicing and post-
translational modifications) in addition to having a high glycine (~20%) and low cysteine 
content. They also contain the unusual amino acid, dimethylarginine (N-methylation), and 
have a blocked N-terminus (Kumar et al., 1986). It is believed members of the A/B 
subfamily arose through a single gene duplication, from an ancestral RNA-binding protein 
(Kim and Baker, 1993). As a result, members not only possess extremely high sequence 
identity (A1 and A2, 70%; A1 and A3, 80%; and A2 and A3, 75% identity across the 
tandem RRMs at the protein level) but also some conservation of exon/intron boundaries 
(Burd et al., 1989). 
 
There are three A/B hnRNP genes from which isoforms are generated by splicing out one or 
two exons during RNA processing. The paralogs are referred to as A1, A2 and A3 after the 
most abundant human isoforms. A1 has a larger isoform (A1B), A2 has a larger (B1) and two 
smaller (B1b and A2b) isoforms, while A3 has two isoforms (A3a and A3b) of similar 
abundance. The hnRNP A/B paralogs are structurally similar but differ markedly in their 
alternative splicing patterns (Figure 1.9) (Han et al., 2010). 
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Figure 1.9: Structure of hnRNPs at gene, transcript, and protein level. Comparison of 
exons in A1*, A2/B1, and A3 in mouse mRNA and approximate alignment with protein 
domains. A1* is alternatively spliced to produce the transcripts A1 and A1b, A2/B1 is spliced 
to produce transcripts B1, A2, A2b, and B1b, and A3 is spliced to produce transcripts A3a 
and A3b. Each numbered rectangle represents an exon, with lengths adjusted to align 
homologous exons. Vertical dashed lines highlight the structural similarity in terms of exon 
lengths, the correspondence of exons to functional protein domains, and the location of 
alternative exons relative to the entire mRNA. Major transcripts (A1, A2, and A3b) are in 
boldface. Alternative exons are in a darker shade. RRM = RNA recognition motif; GRD = 
glycine-rich domain; M9 = nuclear localization domain. This figre was taken from (Han et al., 
2010). 
1.3.1.1 hnRNP A1 
 
hnRNP A1 is the most abundant and best characterised member of the A/B family. Human 
hnRNP A1 is a single polypeptide of 320 amino acids, 31 kDa in mass, that has been shown 
to not only play an active role in nucleo-cytoplasmic mRNA transport, but also in alternative 
splicing and telomere biogenesis. Variant forms of hnRNP A1 protein (A1/A1b) have also 
been identified, with A1b containing a 50 amino acid insert in the glycine-rich domain 
(Dreyfuss et al., 1993). 
 
1995; Akindahunsi et al. 2005). The hnRNP A/B paralogs
are structurally similar (Fig. 1A), but differ markedly in
their alternative splicing patterns (Fig. 1B). To date, the
terms A1 and A2 have been used to represent either com-
bined or individual isoforms, depending on whether their
alternative splicing has been taken into consideration. To
prevent confusion, we will use A1* when referring to both
A1 and A1b proteins, while A2 will strictly refer to the
A2/B1 isoform that excludes exon 2. The levels of exon
inclusion for the homologous cassette exons 7b, 9, and 8 of
A1*, A2/B1, and A3 vary between paralogs. While exon 2 of
A2/B1 is an alternative cassette exon, exon 1b of A3 arises
from an alternative 59ss; these exons do not have equiva-
lents in A1* (Buvoli et al. 1990; Hatfield et al. 2002; Ma
et al. 2002). Importantly, A1 modulates splicing of its own
pre-mRNA by recognizing consensus sequences in the introns
flanking its alternative exon (Chabot et al. 1997; Hutchison
et al. 2002). Thus, the hnRNPs A/B are both regulators and
targets of alternative splicing.
While the hnRNP A/B isoforms have been described,
their functional and regulatory significance and evolution-
ary history have remained largely unexplored. In particular,
species-specific variations in splicing patterns and isoform
expression have not been investigated to date. In vitro
assays have shown that the distal splice site selection, RNA
annealing, and RNA binding properties of A1 differ from
those of A1b (Mayeda et al. 1994). A2/B1 isoforms have
different intracellular localization patterns, and A2b ap-
pears to be the predominant isoform involved in mRNA
trafficking in neuronal cells (Han et al. 2010). In addition,
the levels of B1 mRNA and protein are up-regulated in
nonsmall cell lung cancer, while levels of the other A2/B1
isoforms remain stable (Wu et al. 2003; Sueoka et al. 2005).
Finally, expression levels of A1* and A2/B1 isoforms vary
between tissue types and across developmental and cell
cycle stages (Kamma et al. 1999, 2001; Matsui et al. 2000;
Hatfield et al. 2002; Maggipinto et al. 2004; He et al. 2005).
These data suggest that the observed differences in alter-
native splicing are the result of distinct selection pressures
acting on hnRNP paralogs and isoforms in various cellular
contexts. Thus, further investigation of isoform-specific
variation in the expression and function of the hnRNPs A/B
is crucial for understanding of their roles in regulating
multiple steps of mRNA metabolism.
In this study, we used computational and experimental
analyses to reconstruct the evolutionary mechanisms that
led to the variation in splicing patterns of hnRNPs A/B in
six vertebrates. We show interspecies differences in splicing
patterns and demonstrate the effects of alternative exons on
protein function and expression. Our results indicate that
the hnRNP A/B family of proteins has increased its func-
tional diversity through the evolution of dynamic and highly
regulated, species-specific alternative splicing patterns.
RESULTS
Identification of splicing regulatory cis-elements
The hnRNPs A/B are consistently more conserved across
orthologs than across paralogs, suggesting that there has
been limited concerted evolution within each species (Fig.
2). These results were further confirmed by phylogenetic
analyses (Supplemental Fig. S1). Comparison of mouse A2/
B1 and A3 showed that there is no similarity between their
N-terminal alternative exons (AEs), indicating that these
exons arose independently. These AEs are almost perfectly
conserved within mammals (Table 1), suggesting that they
may be functionally significant, while their absence from
chicken and Xenopus sequences indicates that they arose
only after the divergence of mammals.
Multiple alignments of the intronic regions flanking the
C-terminal AEs revealed the presence of sequences corre-
sponding to or resembling known A1* binding sequences
(Chabot et al. 1997; Hutchison et al. 2002; Wang and
Rothnagel 2004; Venables et al. 2008; Supplemental Fig.
S3A). However, motifs resembling A1* binding sites were
present only in rodent A2/B1 sequences, and in human A3
FIGURE 1. Structure of hnRNPs A/B at gene, transcript, and protein
level. (A) Comparison of exons in A1*, A2/B1, and A3 in mouse
mRNA and approximate alignment with protein domains. A1* is
alternatively spliced to produce the transcripts A1 and A1b, A2/B1 is
spliced to produce transcripts B1, A2, A2b, and B1b, and A3 is spliced
to produce transcripts A3a and A3b. Each numbered rectangle
represents an exon, with lengths adjusted to align homologous exons.
Vertical dashed lines highlight the structural similarity in terms of
exon lengths, the correspondence of exons to functional protein
domains, and the location of alternative exons relative to the entire
mRNA. Major transcripts (A1, A2, and A3b) are in boldface.
Alternative exons are in a darker shade. RRM, RNA recognition
motif; GRD, glycine-rich domain; M9, nuclear localization domain.
(B) Splicing of alternative exons in hnRNPs A/B in mouse. Boxes
represent exons and black horizontal lines represent introns. Bold blue
and faint green lines represent major and minor splicing patterns,
respectively. Note that exon 7b is mostly excluded from A1* exon 7b,
while the corresponding exon 9 in A2/B1 is generally included and
exon 8 in A3 appears to be constitutively present in mouse.
Alternative splicing of hnRNPs A/B
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hnRNP A1 contains a C-terminal 38-amino acid nuclear localization signal, termed M9, the 
sequence (QSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGYG) which is both 
necessary and sufficient for nuclear import and export of A1. This, in addition to the 
observation that A1 binds to poly (A)+ RNA in both the nucleus and cytoplasm, suggests an 
involvement in the transportation of mature mRNA from the nucleus leading to its translation 
in the cytoplasm (Ding et al., 1999). hnRNP A1 was tested for whether it could bind directly 
to double stranded-DNA (dsDNA), comparing the nucleotides covered by hnRNP A1 in each 
DNA/protein complex. Rossen Donev and his colleagues (2002), using PCR amplification of 
target DNA sequences from human chromosome 11q13 followed by their incubation with 
hnRNP A1 and atomic force microscopy (AFM) of the DNA/protein complexes, found that 
hnRNP A1 molecules bound directly to dsDNA after being confirmed by EMSA. However, 
they did not find any binding between this protein and the DNA sequences outside the 36 bp 
element (which is a random DNA fragment located on human 11q13 and purified from total 
genomic DNA by PCR using specific primers). This sequence was found widely dispersed 
throughout the genome. There was no overlap between the 36 bp sequence and known target 
sequences in RNA for binding hnRNP A1 (Donev et al., 2002). 
 
The similarities between hnRNPs A1 and A2 extend past their homology, with A2 carrying 
out similar functions to that of hnRNP A1. Both proteins have been implicated in binding 
telomeres and telomerase, and both are involved in the regulation of alternative pre-mRNA 
splicing by antagonizing splicing factors and promoting distal 5´ splice site selection at high 
concentrations (Weighardt et al., 1996). 
 
 
1.3.1.2 hnRNP A2 
 
hnRNP A2 is a 36 kDa protein, which is highly conserved across species (Mayeda et al., 
1994). It shares the characteristic 2 x RRM-Gly A/B family structure with an overall sequence 
identity to A1 of 68%, rising to 80% over their RRMs, whilst their C-terminal glycine-rich 
domain is more divergent (30%) (Krecic and Swanson, 1999). hnRNP A2 and B1 proteins are 
the result of an alternatively spliced single-copy gene and differ from each other by a 12-
amino acid insertion at the N-terminus of B1 (Burd et al., 1989). Like A1, hnRNP A2 has 
been shown to shuttle between the nucleus and cytoplasm, with an M9-like signal located 
within the glycine-rich motif (Pinol-Roma and Dreyfuss, 1992). 
  
 24 
 
hnRNP A2 has been identified as the predominant trans-acting factor binding to the cis- 
acting element contained within the UTR of myelin basic protein (MBP) mRNA, termed the 
hnRNP A2 Response Element (A2RE) (Hoek et al., 1998). Once hnRNP A2 binds the 11-
nucleotide A2RE, it directs myelin basic protein-mRNA (MBP-mRNA) in transport granules, 
from the nucleus to the peripheral processes of oligodendrocytes, where localised translation 
of the message takes place (Munro et al., 1999); (Landsberg et al., 2006).  
 
1.3.1.3 hnRNP A3 
 
The newest identified hnRNP A/B family member, hnRNP A3, was first identified in 
Xenopus oocytes. Compared to the extensively studied hnRNPs A1 and A2, relatively little is 
known about hnRNP A3. The 37.5, 39, 40 and 41-kDa rat hnRNP A3 isoforms share the 
consensus A/B family structure (2 x RRM-Gly) and also contain a designated RGG box 
(Dangli et al., 1996, Plomaritoglou et al., 2000, Takiguchi et al., 1993). It remains to be 
determined whether the four different rat hnRNP A3 isoforms arise from alternative splicing 
of the single or different mRNA transcripts, from post-translational modifications, or from a 
combination of the two. At least two different alternatively spliced products from the same 
gene have been identified, giving rise to the 39 and 41 kDa protein isoforms (Ma et al., 2002, 
Shan et al., 2000). 
 
The hnRNP A/B paralogs show extensive sequence identity, mainly within the highly 
conserved RRM domains and the auxiliary glycine-rich motif (Plomaritoglou et al., 2000). An 
examination of the glycine-rich domain revealed the presence of a highly conserved 38 amino 
acid sequences that were termed as M9 domain, which acts as a nuclear localisation signal 
that is recognised by transportin (Pollard et al., 1996). There is now some debate about 
whether these proteins actually shuttle. Other work suggests that the nuclear A/Bs move into 
the nucleus after translation and stay there and the cytoplasmic ones (A2b) never go into the 
nucleus (Weighardt et al., 1995, Siomi and Dreyfuss, 1995) hnRNP A3, like A2, is pulled 
down by sequences bearing the A2RE. It has been identified in A2RE-containing transport 
granules in the processes of oligodendrocytes (Ma et al., 2002; Shan et al., 2000). Direct 
comparisons between hnRNP A3 and hnRNP A1/A2 in Xenopus oocytes indicate that A3 is 
expressed at one-tenth the level of the other hnRNPs, which are expressed in roughly equal 
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amounts. This observation suggests that hnRNP A3 is a minor component of hnRNP 
complexes (Good et al., 1993). 
 
1.3.2  hnRNPs modular structure  
 
All hnRNPs share structural motifs, with the most common being the RNA binding domain 
(RBD; also termed RNA recognition motif (RRM)). This is generally located near the N-
terminus of these proteins whereas auxiliary domains of unusual amino acid composition, for 
instance arginine-glycine-rich (RGG) and lysine-histidine-rich (KH) domains are found at the 
C-terminus (Dreyfuss et al., 1993). It has been noticed that  one of hnRNPs/RRMs was able to 
bind to telomerase RNA and confirmed by multipl assays (Dreyfuss et al., 1993), and it was 
correspondingly suggested that the hnRNP complex compositions could vary, based on the 
pre-mRNA sequence (Bennett et al., 1992). In fact, these proteins could define regions in pre-
mRNAs through their RRMs interactions (Matunis et al., 1993). A typical modular structure 
has been noticed for several hnRNPs, using cDNA sequence analysis in which single or more 
RNA binding domains are associated with other auxiliary domains that regulate protein-
protein interactions and subcellular localization.  
1.3.2.1 RNA recognition Motifs (RRMS) 
 
The most common RNA binding domain motif which known as a RNA-binding domain 
(RBD) or ribonucleoprotein domain (RNP), is a motif found commonly in all organisms. 
Which is the best characterized among the hnRNPs and known as RNA Recognition Motif 
(RRM). RRMs, which are abundant in higher vertebrates, are the most extensively studied 
RNA-binding domain, both in terms of structure and biochemistry (Maris et al., 2005). This 
motif is composed of 90 amino acids that include two short highly conserved sequences, 
RNP1 (consensus K/R-G-F/Y-G/A-F/Y-V/I/L-X-F/Y) and RNP2 (V/I/L-F/Y-V/I/L-X-N/L), 
separated by 30 amino acids and other conserved residues interspersed within the RRMs 
(Dreyfuss et al., 1993, Weighardt et al., 1996). The three dimensional structure of this motif 
has been revealed. The N-terminal binding domain (RRM) folds into a (β1-α1-β2-β3-α2-β4) 
structure (Fig 1.10). An important distinction for strength of nucleic acid binding is that 
RNP1 is highly conserved segment of RRM than RNP2; this distinction is based on sequence 
similarity between hnRNP A1 and the poly A-binding protein (PABP) (Nagai et al., 1995). 
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RNP1 and RNP2 correspond to the β3 and β1 strands, respectively, in order to make a direct 
contact with the interacting RNA. The β-sheet of the RRM establishes a platform for RNA 
binding, that leave the bound RNA supposedly exposed and ready for interaction with other 
nucleic acids or/and proteins (Gorlach et al., 1992). The specificity of the RRM region of 
hnRNPs was determined to exist mainly in the variable regions of the loop connecting the β 
strands and the terminal region (Gorlach et al., 1992). Members of the RRM protein family 
bind a variety of RNA/DNA molecules, have a spectrum of affinities, and participate at many 
levels in RNA biosynthesis and processing (Auweter et al., 2006, Haynes, 1992, Kenan et al., 
1991). Binding studies have shown sequence-specific binding of hnRNPs to elements in ss 
DNA and RNA is mediated largely through the RRMs (Ding et al., 1999, Shan et al., 2000, 
Dreyfuss et al., 1993, Moran-Jones et al., 2005) In addition to nucleic acid binding, the RRMs 
of certain hnRNPs have been reported to mediate protein-protein interactions (Hay et al., 
2001). 
 
RNA-protein interactions play critical roles in a variety of important cellular processes, such 
as mRNA processing, transport, and translation. Many RNA-binding proteins including those 
that specifically bind to pre-RNAs, lncRNAs pre-mRNAs, mRNAs and small nuclear RNAs 
(snRNA), contain an RNA binding domain of around 90 amino acids. RRMs, which are the 
most common RNA-binding domain in higher vertebrates, have been extensively studied in 
terms of both structure and biochemistry (Maris et al., 2005). Over 1,000 different RRM-
containing proteins have been identified in organisms ranging from cyanobacteria to higher 
eukaryotes (Haynes, 1992). Sequence comparisons between members of the RRM-containing 
protein family have shown that many contain multiple, non-identical RRMs that display both 
low and high affinities, as well as sequence-specific nucleic acid binding (Nagai et al., 1995). 
Each RRM appears to have been evolutionary conserved independent of others in the same 
protein, implying that each may serve different function (Good et al., 1993, Tang et al., 2012). 
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Figure 1.10: RRM structure. A representation of the three-dimensional structure of RRM. 
This figre was taken from (Varani and Nagai, 1998). 
 
1.3.2.2 Glycine-rich domains 
 
The RGG box has been identified as a sole RNA binding element in hnRNP U (Kiledjian and 
Dreyfuss, 1992) (Fig 1.11). It is characterized by closely spaced clusters of Arg-Gly-Gly 
repeats interspersed with other aromatic residues such as Phe and Tyr in hnRNP A1 
(Biamonti and Riva, 1994). Both the spacing and numbers of RGG repeats differ in different 
proteins. The three-dimensional structure of the RGG domain is still uncertain, although a β-
spiral form has been suggested for the extended RGG box (Gly/Arg-rich domain) of nucleolin 
(Ghisolfi et al., 1992). The RGG box is necessary for RNA-binding activity in hnRNP U, 
which suggests that it has a role to contributing to protein-protein binding (Chaudhury et al., 
2010). For example, in hnRNP A1 and A2/B1, the Gly-rich domain has multiple functions: it 
is able to bind RNA through an RGG box, consists of the factors that control the strand 
annealing activity, also shuttling the protein through nucleo-cytoplasm and enhancing protein-
protein interaction (Biamonti and Riva, 1994, Weighardt et al., 1996). 
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Figure 1.11: RGG-box. A consensus RGG domain sequence derived from comparisons of 
RNA binding proteins. 
 
1.3.2.3 K-homology motif 
 
The K-homology motif (KH) was first identified in hnRNP K as a triple repeat. It was later 
found in other RNA-binding proteins isolated from evolutionary different organisms (Siomi. 
H et al., 1993). Originally, the KH domain was predicted to be 45 amino acids long (Gibson. 
et al., 1993), but this has been revised to a ~70 amino acid domain comprising a triple-β-sheet 
platform supporting three α-helical segments (βααββα fold) (Lewis et al., 1999, Lewis et al., 
2000, Musco et al., 1997, Musco et al., 1996). The KH domain has two subgroups based on 
the N-terminal and C-terminal extensions; type one consists of a C-terminal βα extension, 
type two consists of an N-terminal αβ extension (Grishin, 2001). Crystal structure analysis 
has revealed that a GXXG-tetrapeptide loop between the first two helices, α1 and α2, 
precisely interacts with a 4-5 nucleotides stretch in RNA (Jensen et al., 2000). 
The binding cleft of the KH domains is versatile but accommodates only four nucleic acid 
bases. Other auxiliary domains such as RRMs and G-rich domains (see section 1.3.2.1 and 
1.3.2.2) are also necessary for binding by hnRNPs. 
 
1.4 hnRNP cellular functions 
1.4.1  hnRNPs and pre-mRNA packaging 
 
The hnRNPs presumably have several different functions, but these are not yet well known. It 
has been suggested that hnRNPs help package the pre-mRNA into functional complexes. For 
example, hnRNPs may be involved in presenting the pre-mRNA to the splicing machinery. It 
is known that hnRNP A1 protein can influence the choice of splice sites in pre-mRNA 
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(Damgaard et al., 2002). Three hnRNPs have been shown to be involved in the transport of 
mRNA to the cytoplasm. The hnRNP C protein contains a retention sequence that appears to 
prevent mRNA from being transported out of the nucleus and both hnRNP A1 and hnRNP K 
contain an export signal as part of their amino acid chain (Nakielny and Dreyfuss, 1996). It is 
also possible that hnRNPs play a role in the cytoplasm. The hnRNP A1 protein has been 
shown to accompany the mRNA into the cytoplasm and is present during translation. 
In HeLa cells, the 40S RNP core particles (hnRNPs A, B and C) have been identified as 
complexing with and packaging 700 nt stretches of pre-mRNA (Barnett et al., 1989). These 
core particles are composed of monoparticle subunits consisting of tetramers of hnRNP pairs, 
with a defined stoichiometry, composed of 3:1 ratios of either A1/A1b, A2/B1, or C1/C2. Pre-
mRNAs that are packaged in such a manner are more efficiently spliced and are less subject 
to exonuclease activity (Huang et al., 1994). 
1.4.2 hnRNPs and splicing 
The hnRNP family form a structurally diverse group of RNA binding proteins involved in 
various functions in metazoans. They can suppress splicing by directly antagonizing the 
recognition of splice sites, or can interfere with the binding of proteins bound to enhancers. 
Recently, hnRNPs have been shown to obstruct communication between factors bound to 
different splice sites. Conversely, many reports have defined a positive role for some hnRNPs 
in pre-mRNA splicing. Moreover, cooperative interactions between bound hnRNPs may 
encourage splicing between specific pairs of splice sites while simultaneously hindering other 
combinations. Thus, hnRNPs use a variety of strategies to control splice site selection in a 
manner that is important for both alternative and constitutive pre-mRNA splicing (Martinez-
Contreras et al., 2007). 
Exon splicing is regulated by trans-acting factors recognizing highly conserved intronic cis-
elements that include 5' and 3' splice sites, branch sites and a polypyrimidine tract (Berget, 
1995). In contrast to constitutive exons, alternatively spliced exons often have divergent 
splice site sequences resulting in suboptimal splicing signals. Consequently, additional cis-
acting elements are present in alternatively spliced exons or flanking introns that either 
positively or negatively influence the selection of the alternative splice site. Exonic splicing 
enhancers (ESEs) are recognised by 39 specific members of the SR protein family. These 
factors promote the inclusion of the exon containing the ESE by recruiting the splicing 
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machinery complex and promoting the use of the intron-proximal alternative splice site 
(Caceres and Kornblihtt, 2002, Mayeda and Krainer, 1992). The majority of alternative 
splicing events, on the other hand, seem to be regulated by the relative abundance or activity 
of generally expressed antagonistic SR factors and hnRNPs through a combinatorial 
mechanism, with several positive and negative factors and sequence elements influencing the 
final outcome of the splicing reaction, this is demonstrated by antagonistic SF2/ASF, an SR 
factors, and hnRNP A1 proteins; high levels SF2/ASF induce exon inclusion while high 
levels of hnRNP A1 induce exon skipping. 
 
hnRNP-bound splicing silencers occur frequently throughout the human genome and 
influence constitutive and alternative splicing events (Wang and Burge, 2008). Alternative 
splicing in hnRNPs A/B contributes to the diversity of their roles and has added an 
unexpected layer of regulatory complexity to transcription in vertebrates (Han et al., 2010). 
Conversely, hnRNPs A1 and A2 antagonise the actions of SR protein family members (also in 
a concentration-dependent manner) by outcompete SR for binding exonic splicing silencers 
(ESS) compared to exonic splicing enhancer (ESEs) and promoting the selection of intron-
distal 5' splice sites, resulting in exon skipping (Caceres and Kornblihtt, 2002, Mayeda and 
Krainer, 1992). hnRNPs A1 and A2 regulate the splicing of the hnRNP A1 transcript by 
promoting skipping of an exon flanked by optimal ESS elements bound by both hnRNPs 
(Simard and Chabot, 2000). 
 
A recent study has concluded that the occurrence of alternative splicing in the hnRNPs A/B 
has contributed to the expansion of their roles in the regulation of alternative splicing and 
added more level of regulatory involvedness to transcription in vertebrates (Han et al., 2010). 
hnRNP 1 is an additional hnRNP member that is strongly implicated in pre-mRNA splicing. It 
binds U-rich polypyrimidine tracts in introns and results in skipping of an exon (Bothwell et 
al., 1991). In addition, Five of these U-rich small nuclear RNPs (U1, U2, U4, U5, and U6 
snRNPs) function with a plethora of non-snRNP protein factors to accurately identify the ends 
of each intron prior to the assembly of an active spliceosome at these sites. It is estimated that 
>70 polypeptides contribute to the functional complex. Analysis of purified splicesome 
complexes has identified the association of distinct hnRNPs with the assembly and the 
formation of these complexes: H complex (Jurica et al., 2002, Zhou et al., 2002), A complex 
(Hartmuth et al., 2002), B complex (Makarov et al., 2002) and C complex (Jurica et al., 2002, 
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Rappsilber et al., 2002). (Table 1.4).This table shows the number of polypetides of hnRNPs 
family contribute for formatiom of splicesome complex H and C. 
 
Table 1.4: hnRNP proteins identified by mass spectroscopy. H and C complexes: hnRNP 
detected proteins linked to splicing and/or RNA metabolism listed along with the number of 
unique peptides identified for each (Jurica et al., 2002). 
Human name MW H C 
hnRNP A1 38.8 5 3 
hnRNP A2/B2 41.4 3 1 
hnRNP A3 39.7 4 2 
hnRNP C 32.3 11 12 
hnRNP F 45.7 4 1 
hnRNP G 47.4 3 2 
hnRNP H 49.2 4 2 
hnRNP K 51.0 3 2 
hnRNP L 60.2 6 _ 
hnRNP M 77.5 9 14 
hnRNP R 70.9 5 6 
hnRNP U 90.5 13 2 
hnRNP RALY 32.2 2 4 
 
Furthermore, hnRNP G is expressed in different concentrations in various tissues and 
interacts with other splicing regulatory proteins. It is part of the supra spliceosome that 
regulates alternative splice site selection in a concentration-dependent manner. Its action on 
alternative exons can occur without a functional RNA-recognition motif by binding to other 
splicing regulatory proteins. The RNA-recognition motif of hnRNP G binds to a loose 
consensus sequence containing a CC (A/C) motif, and hnRNP G preferentially regulates 
alternative exons where this motif is clustered in close proximity (Heinrich et al., 2009). 
1.4.3 hnRNPs and translation 
 
The translation of mRNA into protein can be either inhibited or enhanced by specific 
elements contained within the mRNA itself. Many hnRNPs, including K, E1 and E2, bind to 
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CU-rich repeats in mRNAs to induce translational silencing. Though many RNA-binding 
proteins have been shown to bind AU-rich elements which is a region with frequent Adenine 
and Uradine bases in mRNA (mostly targeted mRNA for degredation) (AREs) in vitro, trans-
acting factors that involve in vivo destabilization of cytoplasmic RNA by AREs still unknown 
(Ostareck et al., 1997, Ostareck-Lederer et al., 1998). Conversely, the same hnRNPs, along 
with hnRNP C (Kim et al., 2003), hnRNP Q and hnRNP D (Paek et al., 2008) interact with 
another element, an internal ribosome entry site (IRES), which is a specialized RNA structure 
responsible for the recruitment of ribosomes to the mRNA (Kim et al., 2011). Addition of 
these proteins in an in vitro system enhances translation of an mRNA reporter containing the 
IRES (Kim et al., 2013). This phenomenon has also been determined in vivo where co-
transfection of hnRNPs E1, E2 and K stimulates translation of a c-myc-IRES reporter vector 
(Evans et al., 2003). 
 
It is emerging that the effects of hnRNPs on translation are controlled by post-translational 
modifications. Phosphorylation of hnRNP K dramatically reduces its affinity for LOX 
mRNA, resulting in its increased translation of the message (Ostareck et al., 1997). On the 
other hand, hnRNP K phosphorylation of both tyrosine and serine residues activates the 
binding of the vascular endothelial growth factor (VEGF) mRNA (Feliers et al., 2007). 
However, some hnRNPs contain a nuclear localization signal (NLS) enabling them to shuttle 
continuously between the nucleus and cytoplasm (Pinol-Roma, 1997). Phosphorylation of 
some isoforms such as hnRNPs A1 and I has been shown to change their cellular localization 
pattern, causing an accumulation in the cytoplasm. This could be one potential mechanism for 
controlling their nuclear or cytoplasmic functions (Van Der Houven Van Oordt et al., 2000, 
Xie et al., 2003). 
 
1.4.4 Transcriptional regulation 
 
hnRNPs A1, A2/B1 and C1/C2 are associated with small activating RNAs (saRNAs) which is 
a double strande RNA associate with gene promoters to initiat transcriptional gene activation. 
hnRNPA2/B1 interacts with saRNAs in vivo and in vitro and is required for RNA 
transcriptional activity. These findings indicate that RNA activation results from specific 
targeting of promoters and reveals additional mechanistic details of RNA activation (Hu et al., 
2012). The association of hnRNPs with small regulatory RNAs mediates a wide range of 
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biological processes. For example, a special RNP may transport siRNAs into the nucleus to 
facilitate nuclear RNAi in C. elegans (Guang et al., 2008). The K subfamily of hnRNPs 
(hnRNP K) is involved in transcriptional regulation mediated by promoter-targeted dsRNA or 
saRNA in human cells (Schwartz et al., 2008) 
 
hnRNPs, especially hnRNP K, have been identified as a transcription factor (Michelotti et al., 
1996). hnRNP K enhances transcription of human proto-oncogenes c-Src (Ritchie et al., 
2003) and c-myc (Michelotti et al., 1996), and in contrast represses α-1 acid glycoprotein 
(Ritchie et al., 2003). Also it is assumed that hnRNP K post-transcriptionally regulates 
multiple transcripts of proteins that organize the axonal cytoskeleton; suppressing its 
expression in Xenopus laevis embryos yields terminally specified neurons with severely 
disorganized microtubules, microfilaments and neurofilaments (Liu and Szaro, 2011, Liu et 
al., 2012). An earlier study has supported the idea about translation of at least a subset of 
RNAs involved in axon development in Xenopus laevis is controlled by post-transcriptional 
regulatory modules that have hnRNP K as an essential element (Liu et al., 2008). Another 
hypothesis suggested that the transcriptional regulation by hnRNP K is capable of 
remodelling chromatin architecture, thereby facilitating interactions between transcription 
factors (Shnyreva et al., 2000). 
 
1.4.5 Telomere elongation  
 
Certain hnRNPs have been connected with mediating DNA repair following damage due to 
external stimuli or cellular processes. hnRNP B1 was shown to interact with DNA-PK, a 
multi-protein complex which controls DNA repair (Iwanaga et al., 2005). It acts as a negative 
regulator of DNA repair in vitro by inhibiting the activity of DNA-PK following irradiation. 
This observation was supported in vivo by small interfering RNA (si-RNA) mediated 
knockdown of hnRNP B1, which resulted in enhanced repair of DNA strand breaks caused by 
irradiation (Iwanaga et al., 2005). 
 
In vitro experiments have revealed a subgroup of hnRNPs capable of interacting with 
telomeric DNA and/or telomerase, suggesting that they also have a role in telomere 
metabolism. The first evidence for the association of hnRNPs with telomeric DNA was 
obtained during attempts to isolate mammalian homologs of the Oxytricha telomere end-
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binding protein (On-TEBP) from mouse liver nuclear extracts (Ishikawa et al., 1993, Mckay 
and Cooke, 1992). Since then, hnRNPs A1 (Labranche et al., 1998, Zhang et al., 2006, Choi 
et al., 2012), hnRNP A2/B1 (Kamma et al., 2001, Moran-Jones et al., 2005, Wang et al., 
2012), hnRNP A3 (Huang et al., 2010), hnRNP D (Enokizono et al., 2005, Eversole and 
Maizels, 2000), hnRNP E (Ford et al., 2002) and hnRNP K (Denisenko and Bomsztyk, 2002), 
have all been shown to interact with single-stranded oligonucleotides containing T2AG3 
repeats. The binding of UP1 (proteolytic fragment of hnRNP A1; Labranche et al., 1998), 
A2 (Moran-Jones et al., 2005) and D (Eversole and Maizels, 2000) to single-stranded 
telomeric sequences confers protection against nucleolytic degradation but the role of this 
interaction with the telomere repeat is not clear. 
 
 
Immunoprecipitation and pull-down experiments have also demonstrated that hnRNP 
A1/UP1, A2, A3, D, C1 and C2 are all capable of interacting with telomerase (Choi et al., 
2012, Enokizono et al., 2005, Ford et al., 2000, Huang et al., 2010, Wang et al., 2012). 
Moreover, mouse cell lines deficient in hnRNP A1 expression are characterized by shorter 
telomeres than a related mouse cell line expressing normal levels of hnRNP A1 protein 
(Labranche et al., 1998). Ford and colleagues (2002) have proposed a model whereby 
hnRNPs bind telomeric single-stranded overhangs and recruit telomerase activity for telomere 
extension (Fig 1.12). Although, other ssDNA binding proteins such as POT1 proteins have 
ben left out for clarity, hnRNP A1 shows its ability to bind the ss-telomeric DNA and in way 
or another separate Pot1 from telomere in order to recruit telomerase to telomere for 
elongation. 
 
In 2006, Zhang and colleagues proposed that hnRNP A1 stimulated telomere elongation 
through unwinding of a G-quadruplex or G-G hairpin structure formed at each translocation 
step and helped to recruit telomerase to the telomeric ends (Zhang et al., 2006). Recently, 
hnRNP A1 has been identified as a novel substrate for vaccinia-related kinase 1 (VRK1), a 
cell cycle regulating kinase. Phosphorylation by VRK1 potentiates the binding of hnRNP A1 
to telomeric ssDNA and telomerase RNA in vitro and enhances its function for telomerase 
reaction (Choi et al., 2012). 
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Figure 1.12: Connecting the telomerase RNP to the telomere. This figure shows a proposed 
model by Ford et al. (2002) in which hnRNPs bind telomeric single-stranded overhangs and 
recruit telomerase activity for telomere extension. The human telomerase holoenzyme is 
shown with hTR, hTERT, and shaded circles represent the hnRNPs, p23/hsp90, TEP1, Box 
H/ACA snoRNA binding proteins, La and other proteins that can bind to the telomerase 
holoenzyme. The telomere is shown in two distinct structures. The upper panel shows a 
telomere containing a T-loop structure where the hnRNPs are bound to the displaced strand. 
The lower panel depicts the telomere with a free 3' G-rich overhang that is bound directly by 
hnRNPs. An arrow is drawn from the hnRNPs on the telomerase holoenzyme to the hnRNPs 
on the telomere, to indicate that multimeric complex formation by the different hnRNPs may 
help recruit telomerase to the telomeres. Figure  was taken from (Ford et al., 2002). 
 
1.5 hnRNP A/B and cancer 
 
The hnRNP A/B subfamily plays multiple roles. Based mostly on studies of hnRNP A1 and 
hnRNP A2, these paralogs have been shown to contribute to DNA repair, packaging and 
processing of nascent hnRNA, transcription, telomere maintenance, cytoplasmic trafficking of 
mRNA, alternative pre-mRNA splicing, localized translation and nucleocytoplasmic 
shuttling. Aberrant expression of hnRNPs A/B has been linked with cancer; for example, 
overexpression of B1 isoform is correlated with the eventual development of lung cancer 
(Carpenter et al., 2006, Pu et al., 2009) and may have a part to play in DNA repair. While this 
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Figure 1.11:  Connecting the telomerase RNP to the telomere.  The human telomerase holoenzyme 
is shown with hTR, hTERT, and shaded circles representing the hnRNPs, p23/hsp90, TEP1, Box 
H/ACA snoRNA binding proteins, La and other proteins that can bind to the telomerase holoenzyme.  
The telomere is shown in two distinct structures.  The upper panel shows a telomere containing a t-
loop structure where the hnRNPs are bound to the dis laced s r nd.  The lower panel depicts the 
telomere with a free 3' G-rich overhang that is bound directly by hnRNP proteins.  An arro  is drawn 
from the hnRNPs on the telomerase holoenzyme to the hnRNPs on the telomere, to indicate that 
multimeric complex formation by the different hnRNPs may help recruit telomerase to the telomeres.  
Figure taken from (Ford et al., 2002). 
 
 
1.9.2 Modular structure of hnRNPs 
All hnRNPs share some structural motifs, with the most common being the RNA 
binding domai  (RBD; also te med RNA r cognitio  motif (RRM)), which are 
normally located at the N-terminus in addition to containing auxiliary domains 
composed of unu ual amino acid composition, for instance arginine-glyci e-ri h (RGG) 
and lysine-histidine-rich (KH) domains (Dreyfuss et al., 1993). 
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protein combines with and inhibits the DNA-dependent protein kinase (DNA-PK) complex 
that mediates the repair of DNA double-strand breaks, hnRNPs A1 and A2 have no influence 
(Iwanaga et al., 2005).  
 
Laboratory observations from Smith, R. (2005) and Chabot, B. (2004) have suggested that 
hnRNPs A1 and A2/B1 are associated with increased cell proliferation. However, it is unclear 
how these proteins modulate cell proliferation, and whether they directly trigger cellular 
transformation or not. Data for a subset of these genes were validated by using Real-time 
PCR followed by microarray, and their expression, confirmed by immune-precipitation real-
time polymerase chain reaction (IP-RT-PCR), was regulated by hnRNP A2 associated 
complex. These remarkable results support the assumption that hnRNP A2/B1 performs a task 
in the regulation of the cell growth and cell cycle determined in previous studies (He et al., 
2005).  
 
Tumor cells generally express pyruvate kinase M2 isoform (PKM2). Converting from PKM1 
to PKM2 promotes aerobic glycolysis and provides a selective advantage for tumor 
formation. The PKM1/PKM2 isoforms are generated through alternative splicing of two 
mutually exclusive exons. David et al (2010) investigated the mechanism of PKM alternative 
splicing, first by searching proteins that bind to the two alternative exons and their flanking 
region. Using UV crosslinking and RNA affinity purification with HeLa cell extracts, hnRNP 
family members hnRNPA1, hnRNPA2, and polypyrimidine tract binding protein (PTB; also 
known as hnRNPI) were found to bind to intronic sequences flanking exon 9 contained in 
PKM1 (David et al., 2010). Other workers have suggested that overexpression of hnRNP A1 
plays a key role in the regulation of cell cycle progression and the pathogenesis of oral 
squamous cell carcinoma (OSCC), by regulating the expression of a number of target genes 
associated with G2/M phase (Yu et al., 2015). These findings not only provide additional 
evidence that alternative splicing plays an important role-in tumourgenesis, but also shed light 
on the molecular mechanism by which hnRNPs regulate cell proliferation in cancer (Chen et 
al., 2010). 
 
Ingenuity pathways analysis showed plausible molecular paths between tumour suppressor 
Annexin-A7 (ANXA7) and the hnRNPs (A1, A2/B1 and K) associated network in prostate 
cancer progression. Thus, a multi-hnRNP complex can be responsible for aberrant ANXA7 
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transcription and splicing, thereby affecting ANXA7 expression pattern and tumour 
suppressor function in prostate cancer (Torosyan et al., 2010). Moreover, Golan and 
colleagues have found that the splicing factor hnRNP A2/B1 is overexpressed in 
glioblastomas and is correlated with poor prognosis. Additionally, they also identified several 
tumour suppressors and oncogenes that are regulated by hnRNP A2/B1, among them c-FLIP, 
BIN1, and WWOX, and the proto-oncogene RON. Contrary, patients who harbour deletions 
of the hnRNP A2/B1 gene show a better than average prognosis. Knockdown of hnRNP 
A2/B1 in glioblastoma cells hindered tumour formation in mice, whereas overexpression of 
hnRNP A2/B1 in immortal cells led to malignant transformation, suggesting that hnRNP 
A2/B1 is a putative proto-oncogene. Their results propose that HNRNPA2B1 is a novel 
oncogene in glioblastoma and a potential new target for glioblastoma therapy (Golan-Gerstl et 
al., 2011). The function of hnRNPs and their alternative splicing generate a large number of 
hnRNP isoforms that contribute uniquely in cells during cell mitosis or division, and are 
thereby associated with telomeric ssDNA, telomeric RNAs, and telomere-associated proteins 
(Huang et al., 2010). 
 
1.6 Telomerase 
 
Apart from regulating telomere ends by shelterin proteins, telomeric DNA repeat maintenance 
requires telomerase throughout many cycles of cell division. It is a telomere-specific 
ribonucleoprotein (RNP) reverse transcriptase that adds single-stranded telomeric repeats to 
the 3´ ends of the chromosomes (Fig 1.13). Telomerase has an integral RNA template 
sequence AAUCCC complementary with telomeric DNA, associated complementary-strand 
synthesis capable of equalizing the telomere erosion inherent in incomplete end-replication, 
allowing telomere length homeostasis (Collins, 2000). Telomerase activity was initially 
discovered in Tetrahymena thermophila in 1985 (Greider and Blackburn, 1985, Mason et al., 
2011).  
 
Telomerase has three essential components that participate in the vital activity of telomerase: 
one is the functional RNA component called Human Telomerase RNA Component (hTERC) 
or Human Telomerase RNA (hTR), which acts as a template for telomeric DNA synthesis; the 
second is a catalytic protein with reverse transcriptase activity called Telomerase Reverse 
Transcriptase (TERT); while the third is a telomerase component called dyskerin that is 
essential for telomerase RNA stability (Cong et al., 2002, Huang, 2005, Loayza and De 
  
 38 
Lange, 2004, Luke and Lingner, 2009). Mass spectrometric sequencing of purified human 
telomerase has revealed that telomerase is composed of two molecules each of telomerase 
reverse transcriptase, telomerase RNA, and dyskerin (Cohen et al., 2007). There are 
significant variances in sequence and size of the telomerase elements among species, mostly 
prominent in the RNA portion of the enzyme (Mason et al., 2011). 
 
 
Figure 1.13: The ends of linear chromosomes are maintained by the action of the 
telomerase enzyme. This figure was taken from (http://openstaxcollege.org).  
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1.6.1 Telomerase RNA template (hTR) 
 
In humans, RNA polymerase II transcribes hTR to generate a mature transcript of 451 nt 
(Feng et al., 1995). The reverse transcription template lies near the 5' end of the molecule (46 
nt to 53 nt), and specifies synthesis of the telomeric DNA sequence. Although there are 
discrepancies in the primary sequences of telomerase RNAs, it is remarkable that 10 helical 
regions of telomerase RNA secondary structure in a variety of vertebrate species are 
universally conserved, which indicates a major role for RNA structure in telomerase function 
(Jiunn-Liang et al., 2000). 
 
The secondary structure was predicted to contain four conserved functional components, 
comprising domain known as pseudoknot (CR2/ CR3), CR4/CR5 domain, box H/ACA 
(CR6/CR8) domain, and CR7 domain. The hTR box H/ACA motif resembling a box H/ACA 
small nucleolar RNA (snoRNA) has been noticed to be crucial for hTR 3´ end processing, 
hTR accumulation and for telomerase activity in cells (Dragon et al., 2000). However, in 
lower eukaryotes the hTR H/ACA domain is not present. 
 
The hTR conserved domains are recognition sites for hTR binding proteins. A group of RNA 
binding proteins, such as dyskerin, hTERT and hnRNP C1/ C2, interact with hTR and are 
involved in hTR stability, accumulation, assembly and function of the telomerase RNP 
complex, and maturation (Dez et al., 2001, Dragon et al., 2000, Ford et al., 2001, Ford et al., 
2000). Two regions within the hTR molecule (nucleotides 1 to 209 conserve the template 
region, and nucleotides 241 to 330 the box H/ACA domain and CR4-CR5 domain) interrelate 
individually in a non-cooperative manner with the catalytic component of telomerase 
(hTERT) (Mitchell and Collins, 2000).  
 
In accord with this statement, telomerase reconstitution experiments suggest that a region 
from nucleotides 10 to 159 is the minimal sequence requirement for telomerase activity 
(Bachand et al., 2001, Tara L et al., 1998) and two inactive fragments of hTR, nucleotides 33 
to 147 and nucleotides 146 to 325, contribute for telomerase activity. Thus, it is proposed that 
telomerase RNA structure or sequence participating in binding to hTERT and its catalysis are 
functionally separated (Fig. 1.14) (Mitchell and Collins, 2000, Bachand et al., 2001). 
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Figure 1.14: Schematic structure of the human telomerase RNA (hTR) with the 
functionally important sequence elements is showen. The template sequence of hTR (purple) 
recognizes the terminal nucleotides of the telomeric G-rich strand and dictates its elongation 
by the associated telomerase reverse transcriptase (hTERT). The nascent telomeric DNA is in 
green. The CAB box (blue) and 3′ end-processing signal (orange) of hTR are indicated. This 
figure was taken from (Kiss et al., 2010). 
 
1.6.2 Catalytic Subunit (hTERT) of Telomerase 
 
A catalytic subunit of telomerase was first purified from Euplotes aediculatus (Lingner et al., 
1997) and shown to contain several reverse transcriptase motifs. Sequence analysis revealed 
that the subunit, termed p123, is homologous to yeast Est2p, a protein required for telomere 
maintenance that was initially identified by genetic screening of yeast mutants with reduced 
telomere length and a senescent phenotype (Lendvay et al., 1996). Introduction of single-
amino-acid substitutions within the reverse transcriptase motifs lead to telomere shortening 
and senescence in S. cerevisiæ, indicating that these motifs are important for catalysis of 
telomere elongation in vivo (Counter et al., 1997). Cohen and colleagues (Cohen et al., 2007) 
developed a purification scheme that achieved nearly 108-fold enrichment of active telomerase 
using different human immortal cell lines. They concluded that human telomerase is 
composed solely of two protein components, hTERT and dyskerin, and the RNA template 
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hTR. This study represents a restricted view of telomerase complexity. Other proteins 
associated with telomerase are thought to be involved in telomerase biogenesis, trafficking, 
recruitment to the telomere, and degradation, but are not required for nucleotide addition. 
 
Based on the conserved sequence information within the reverse transcriptase motifs from 
p123, the cDNA encoding the human homologue of the catalytic subunit of telomerase 
(hTERT) was identified nearly simultaneously by four groups (Harrington et al., 1997, Kilian 
et al., 1997, Meyerson et al., 1997, Nakamura et al., 1997). It has since been identified in 
mice, other yeasts, ciliated protozoa, and worms. Telomerase catalytic subunits from different 
organisms are phylogenetically conserved in their reverse transcriptase motifs with other 
reverse transcriptases (Nakamura Tm et al., 1997), but are more related to each other than to 
other reverse transcriptases and therefore form a distinct subgroup within the reverse 
transcriptase family (Eickbush, 1997, Nakamura Tm and Cech., 1998, Nakamura Tm et al., 
1997). 
 
Several features distinguish the telomerase catalytic subunit: (i) all of the reverse transcriptase 
motifs are located in the C-terminal half of the proteins; (ii) a conserved telomerase-specific 
region, termed the T motif, is located near the N-terminal of the reverse transcriptase motifs; 
and (iii) a large N-terminal region contains conserved, functionally important domains 
(Moriarty et al., 2002, Nakamura Tm et al., 1997). Experiments in both humans and S. 
cerevisiae indicate that telomerase might function in a complex containing more than one 
catalyst and one RNA subunit (Beattie et al., 2001, Mitchell and Collins., 2000, Moriarty et 
al., 2002, Wenz C et al., 2000).  
 
It is likely that elongation of telomeres by telomerase requires a multistep process and is 
precisely regulated, including the maturation, processing, and accumulation of hTR, nuclear 
transport, post-translational modifications of hTERT, ribonucleoprotein assembly, substrate 
recognition, and coordinated synthesis of the C-strand (Aisner et al., 2002). The telomerase-
associated proteins involved in each of these processes may be required for the full activity 
and biological function of the enzyme. Affinity purification, mass spectrometry and subunit 
tagging assays have identified eight telomerase-specific, communally co-purifying subunits of 
Tetrahymena telomerase holoenzyme, each essential for telomere length maintenance. For 
instance, Tetrahymena telomerase processivity factor (Teb1) is required for the particularly 
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high DNA product interaction stability of an endogenously assembled Tetrahymena 
telomerase holoenzyme, evident as high repeat addition processivity (RAP) in vitro (Jiang et 
al., 2013). A recent study presented the three-dimensional structure of the active full-length 
human telomerase dimer and showed that in vivo-assembled human telomerase contains two 
TERT subunits and binds two telomeric DNA substrates. Importantly, catalytic activity 
requires both TERT active sites to be functional, which demonstrates that human telomerase 
functions as a dimer (Sauerwald et al., 2013). Although this study provided the initial point 
for investigating the structural basis and the significance of telomerase dimerization, catalysis, 
and function, a higher resolution of the telomerase structure is needed to reveal the fold of the 
telomerase RNA and its specific interaction with the various TERT domains, and the 
functional states of the telomerase catalytic cycle. 
 
1.6.3 TERRA 
 
One of the most exciting recent findings in telomere biology is that telomeric tandem repeats 
are transcribed into a large non-coding RNA molecule called TERRA (telomeric repeat-
containing RNA), which forms an integral part of telomeric heterochromatin. TERRA 
consists of multiple repeats of —5'-UUAGGG-3'— which are complementary to the template 
sequence of telomerase RNA (Redon et al., 2010). TERRA is transcribed at most, if not all, 
chromosome ends, by RNAPII polymerase and is initiated from the sub-telomeric region. 
There is evidence that TRF1 supports TERRA transcription since siRNA-depletion of TRF1 
resulted in a two-fold decrease in TERRA levels (Schoeftner and Blasco, 2008). 
 
TERRA is regulated in response to changes in telomere length and appears to be involved in 
the regulation of telomerase. Accumulation of TERRA at telomeres can interfere with 
telomere replication and may lead to a sudden loss of telomeres: it mainly accumulates in 
adult tissues that lack telomerase activity. TERRA may mediate several crucial functions at 
the telomeres, including regulation of cell lifespan. It may bind to the template sequence in 
telomerase and block its ability to add repeats to the end of the G-rich strand (Azzalin et al., 
2007, Schoeftner and Blasco, 2008). The telomere ssDNA, which has the same sequence, 
could do likewise. It has been suggested that hnRNP A1 might function as a molecular bridge 
between telomeric DNA and TERRA (Luke and Lingner, 2009, Zhang et al., 2006). Telomere 
purification also has suggested association with other RNA-binding proteins including FUS, 
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RNA-binding protein 14, cold-induced RNA-binding protein and RNA-binding protein 8A 
(Déjardin and Kingston, 2009), all of which could be involved in TERRA localization to 
telomeres. The TERRA-mimicking RNA oligonucleotide (UUAGGG)3 inhibits telomerase 
activity in vitro (Schoeftner and Blasco, 2008), and TERRA is more abundant when telomeres 
are long (Azzalin et al., 2007). In vivo expression data support a role for TERRA in the 
negative regulation of telomerase activity, presumably by base pairing of UUAGGG repeats 
with the template region of Telomerase RNA Component (TERC), the RNA component of 
telomerase. This raises the possibility that TERRA regulates telomerase activity at 
chromosome ends. 
 
1.7 hnRNPs and telomeres 
 
Although the major focus of the roles played by hnRNPs in telomere maintenance has been 
on hnRNP A1, several of the hnRNPs bind single-stranded, G-rich telomere ends. Several of 
these hnRNPs are known to cause disruption of G-G pairing, thus destabilizing G-quartets or 
G-G hairpin structures and facilitating telomere extension by telomerase. G-quartets and other 
tetraplex structures are believed to be critical for the regulation of DNA replication, through 
stimulation of DNA polymerase and flap endonuclease-1, inhibition of Okazaki fragment 
formation, transcription, and telomere maintenance (Vallur and Maizels, 2010). 
 
hnRNP A1, C1/C2 and D and TRF1 are integral components of the nuclear matrix (a putative 
attachment site for telomeres), making it possible that hnRNPs and telomeres are in close 
proximity if not directly associated (Ford et al., 2002). It has been anticipated that the 
capability of telomerase to function on telomeres depends on association of these hnRNP 
factors (Eversole and Maizels, 2000, Ford et al., 2002, Zhang et al., 2006, Eversole and 
Maizels, 2000).  
 
The capability of hnRNP A2 to interact with both telomerase and telomeric DNA makes it an 
ideal protein to recruit telomerase to telomere ends (Fig 1.15). Telomerase does not extend 
the telomeric G-quadruplex unless it carries a single-stranded 3´ tail of at least 8 nt (Wang et 
al., 2011). During excessive extension, hnRNP A2 may intercept newly synthesized telomeric 
repeats, preventing them from forming G-quadruplexes, which consequently deters 
telomerase (Wang et al., 2012). 
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A recent study has reported that AUF1 (hnRNP D) counteracts telomere shortening by 
stimulating TERT expression (Pont et al., 2012). AUF1 binds single-stranded telomeric DNA 
and TERRA (Feuerhahn et al., 2010). AUF1 may have additional roles at telomeres and be 
involved multiple biological processes. There is also increasing interest in the hnRNP A1 
paralogs hnRNPs A2/B1 and A3 (Ma et al., 2002). Similar to hnRNP A1, hnRNP A2 also 
binds single-stranded telomeric repeats (Moran-Jones et al., 2005), as does A3. It also 
promotes telomerase activity and telomere lengthening. It is potentially an adapter that can 
bring the ssDNA telomeric repeat in close apposition to the telomerase RNA subunit (TR) 
and promote extension of the 3' G-rich telomere overhang. 
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Figure 1.15: A proposed model for recrutment of telomerase to tolemere by hnRNP A2. The 
human telomerase enzyme is shown with its components, hTR. hnRNP A2 binds to both 
Telomerase and single-strand telomeric DNA and localizes telomerase to telomere end. (A) 
The region of the human hTR that binds hnRNP A2, this region is single-stranded when not 
associated with other molecules. The telomeric template sequence (C50-A55) is presented in 
bold font. The section of hTR nucleotide sequence that, based on experimental data, is single-
stranded in vitro is in capital and flanking double-stranded RNA is in lower case. The first 
evolutionarily conserved sequence (CR1) in hTR is marked by a horizontal bar above the 
sequence. (B) A model representing the association of the hnRNP A2 with hTR and the 
nascent ssDNA telomeric 3’ overhang repeat. (1) During DNA replication ss-telomere is open 
and hnRNP A2 comes to bind to it. (2) hnRNP A2 binds the 3’ telomeric single-stranded 
repeat using RRM2, holding it in a site that allows it to function as a substrate for hTR-
template-driven and telomerase-catalyzed telomere extension. (3) hnRNP A2 simultaneously 
binds telomeric DNA and telomerase RNA where telomerase then adds successive telomere 
repeats. 
 
1.8 Scope of thesis 
 
The aim of this thesis was to understand the interactions and functions of the hnRNPs A/B in 
telomere biology. Thus, it is required to characterize their interaction with telomeric DNA and 
with telomerase. The hypothesis model in which hnRNPA2 serves to tether telomeric DNA to 
hTR to facilitate extension of the former by the TERT component of telomerase is the central 
focus of my research plan. At the initiation of this project, several hnRNPs, in particular the 
better characterised hnRNP A1, had been propositioned to fulfil a role in telomere biogenesis. 
The hnRNP A/B possess moderate sequence identity, and while they fulfil similar roles, their 
functions are by no means redundant. In this study I show that hnRNPs A1, A2 and A3 bind to 
the telomeric single-stranded repeat TTAGGG in vitro and in vivo, an interaction that was 
found earlier to protect the telomere ends from degradation by nucleases (Moran-Jones et al., 
2005). 
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In Chapter 3, expression and purification of recombinant hnRNPs, in addition to several 
deletion constructs of the proteins, was achieved using several techniques. All proteins 
were purified to homogeneity. An A/B hnRNP protein alignment indicating residues 
involved in telomeric contact, in addition to an in vitro affinity pull-down assay, were 
initially employed to confirm an interaction between the hnRNP A/B paralogs and telomeric 
DNA. Subsequent experiments including non-competitive and competitive binding assays 
and surface plasmon resonance (SPR) experiments, were used to characterize this 
interaction. Chromatin immunoprecipitation (ChIP) experiments were utilized to investigate 
whether the interaction can take place in vivo. 
 
In Chapter 4, the possible association of the hnRNP A/B paralogs with telomerase was 
investigated. This was achieved using techniques such as immunoprecipitation followed 
by telomeric repeat amplification protocol (TRAP) assays, and in vitro transcription of 
the human telomerase RNA template (hTR) followed by RNA electrophoretic mobility 
shift assays (REMSA). Simultaneous binding of hnRNP A2 with telomeric DNA and 
telomerase RNA was also investigated using labeled agarose magnetic beads with (Telo4) 
column chromatography. 
 
Finally, deletion analysis of hTR revealed that hnRNP A2 binds preferentially to the hTR 
segment encompassing certain nucleotides and can bind simultaneously to telomeric ssDNA 
repeats. The results show that full-length hnRNP A2 and short derivatives containing both 
RRMs of A1, A2 and A3 can all bind to the region immediately 3' of the hTR template. We 
hypothesise that binding of both telomeric ssDNA and telomerase RNA by the hnRNP A/Bs 
could appropriately position these molecules for telomerase-mediated telomere extension. 
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Chapter	2	
2 Material and method:  
2.1 Molecular techniques 
Molecular biology is based on understanding the interactions between the various systems of 
cells, including the interactions between RNA, DNA and protein synthesis and also studying 
how these interactions are regulated. These interactions can be measured by various 
techniques based on methods and reagents described in Sambrook or current protocols in 
molecular biology (Ausubel, 1997, Lundblad, 2007, Sambrook et al., 1989). 
 
2.1.1 Polymerase chain reaction 
 
The primers utilised for polymerase chain reaction (PCR), which are highlighted in 
Appendix, Table A, were synthesised by either Genset Oligos (Lismore, Australia) or by 
GeneWorks (Adelaide, Australia). All PCR reactions were carried out using a Perkin Elmer 
2400 thermal cycler (Perkin Elmer Life Sciences, CT, USA). The composition of PCRs 
varied according to manufacturer’s specifications. Typically, all reactions contained 2.5 Units 
Amersham Taq (Amersham Biosciences; Sydney, Australia), 0.2 mM deoxynucleotide 
triphosphates (dNTPs; Roche Applied Science; Sydney, Australia) and 0.2 µM of each primer 
(Appendix, Table A). Normally, 0.1–5 ng plasmid DNA template was added to the reaction. 
The cycling conditions varied depending on the primer sets, template and enzyme used, but 
generally were as follows: 
Initial denaturation    94 °C for 5 min 
Denaturation              94 °C for 30 s 
Annealing                  50-65 °C for 30 s 
Extension                   68-72 °C for 1 min per kb of predicted amplicon size 
Final Extension          68-72 °C for 7-10 min 
 
2.1.2 Automated DNA sequencing 
 
DNA was sequenced using the ABI Big Dye Terminator sequencing kit (Applied Biosystems, 
Melbourne, Australia), version 2 or 3.1, depending on availability. Generally, 50-200 ng 
plasmid DNA was sequenced directly by mixing 2 µl terminator ready reaction mix, 3 µl 5x 
terminator ready reaction mix buffer, 0.8 pmol sequencing primer and diluting to a final 
30–35 
cycles 
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volume of 20 µl with double distilled water. The cycling conditions for DNA sequencing 
were as follows:  
 
Initial denaturation           94 °C for 5 min 
Denaturation                    96 °C for 10 s 
Annealing                         50 °C for 5 s 
Extension                          60 °C for 4 min 
 
Sequencing reactions were cleaned before submission to the Australian Genome Research 
Facility (AGRF; Brisbane, Australia) following their sequencing clean-up protocol. Briefly, 
sequencing reactions were precipitated with 80 µl 75% isopropanol and incubated at room 
temperature for 15 min. Following this, reactions were centrifuged at 12000 g for 30 min at 4 
°C. The pellet was washed once with 75% isopropanol and centrifuging at 12000 g at room 
temperature for 5 min before air-drying for 10 min. 
 
2.1.3 Bacterial strains  
 
For general cloning procedures, E.coli DH5α and XL1-Blue cells (Invitrogen, Melbourne, 
Australia) were routinely used. Some constructs failed to transform in these cells and so 
JM109 cells (Promega, Sydney, Australia) were used. The BL21 (DE3) T7 expression system 
was used for protein expression. The bacterial strains of these E. coli cells are as follows: 
 
DH5α: F-Φ80lacZΔ15ΔlacZYA-argF) U169 deoR recA1 endA1 hsdR17(rk-,mk+)gal- phoA 
supE44 λ- thi-1 gyrA96 relA1 
JM109: e14-(McrA-) recA1 endA1 gyrA96 thi-1 hsdR17(rK- mK+) supE44 relA1 Δ (lac-
proAB) [F’traD  36 proAB lacIqZΔ M15]  
XL1-Blue: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacIqZΔ M15 
Tn10 (Tetr)] 
BL21 (DE3): F– ompT hsdSB(rB–mB–) gal dcm (DE3) 
T7 Express: fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 R(mcr-73::miniTn10--TetS)2 
[dcm] R(zgb-210::Tn10--TetS) endA1 Δ(mcrC-mrr)114::IS10 
 
35 cycles 
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2.1.4 Preparation of electro-competent E.coli cells 
 
Electro-competent E.coli DH5α and XL1-Blue cells were prepared using the same procedure. 
Glycerol stocks of these cells were streaked onto Luria Bertani (LB; 1% bactotryptone, 0.5% 
yeast, 1% sodium chloride, pH 7.5) agar (1.5%) plates without antibiotic selection and 
incubated at 37 °C overnight. Single colonies were picked and used to inoculate 3 ml of LB 
broth grown at 37 °C overnight. These overnight cultures were used to inoculate 200 ml LB 
broth and grown until their absorbance at 260 nm (A260), was 0.5-0.7. Once this absorbance 
was reached, cells were stored for 1 h at 4 °C before centrifugation in pre-chilled tubes at 
2800 g for 15 min at 4 °C. The resulting cell pellet was washed by gently re-suspending in the 
1x original culture volume of ice-cold 10% glycerol before centrifugation at 2800 × g for 15 
min at 4 °C. This procedure was repeated again by washing with 0.5x and 0.25x original 
culture volume with ice-cold 10% glycerol. Finally, the cell pellet was re-suspended to a cell 
density of ~3×1010  cells/ml with ice-cold 10% glycerol and 50-100 µl aliquots were snap 
frozen in liquid nitrogen and stored at -70 °C. 
2.1.5 Ligation reactions 
 
General cloning techniques initially utilised the pGem-T Easy Vector System (Promega). 
Ligation reactions contained an insert: vector molar ratio of 3:1 unless otherwise stated, 1 µl 
10 x Ligation Buffer (Promega), 1 µl T4 DNA Ligase (Promega) and made up to a final 
volume of 10 µl with Milli-Q water. Ligation reactions were either incubated at room 
temperature for 1 h or at 4 °C overnight. 
 
2.1.6 Transformation of bacterial cells 
 
Depending on the E. coli bacterial strain used, two different methods were used for 
transformation. 
 
2.1.6.1 Transformation by electroporation 
 
Ligation reactions that were to be transformed via electroporation (DH5α and XL1-Blue 
bacterial strains) were semi-purified to remove salts. Typically, 1 µl tRNA (10 µg/µl) was 
used as a carrier molecule and added to the ligation mix, which was diluted to a final volume 
of 100 µl with Milli-Q water. Ten microliters of 3 M sodium acetate, pH 5.2, and 250 µl 
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absolute ethanol were added to the diluted ligation mix and incubated at -70 °C for 20-120 
min before centrifugation at 1200 × g for 30 min at 4 °C. Ligation pellets were washed once 
with 500 µl 70 % ethanol and centrifuged at 12000 × g for 5 min at room temperature before 
air-drying the pellet for 5-10 min. Pellets were re-dissolved in 6 µl Milli-Q water. Then, 30-50 
µl electro-competent DH5α or XL1-Blue cells (Section 2.1.3) were thawed on ice for 5 min 
and mixed with 3 µl semi-purified ligation product before transferring the mixture to a gene 
pulsar cuvette (Bio-Rad, Sydney, Australia). The cuvette was placed into a Gene Pulser II 
electroporator (Bio-Rad) and transformed at 200 Ω, 25 uFD and 1.8 kV. Then, 950 µl LB 
broth was added to the cuvette to collect transformed cells and then transferred to a 10 ml 
tube were it was allowed to recover by incubating at 37 °C for 90 min with shaking at 150 
rpm. 100 µl of the transformation mix was plated onto LB Agar plates containing the 
appropriate antibiotic and incubated at 37 °C for 16 h. The resulting colonies were screened 
for ligated plasmid. 
 
2.1.6.2 Transformation by heat-shock 
 
Transformation into E. coli JM109 cells was achieved by the heat shock method. The cells 
were thawed on ice for 5 min before the addition of 2 µl ligation reaction (Section 2.1.5). The 
mixture was transferred to a Falcon 2059 tube (BD Biosciences, MA, USA) and incubated on 
ice for 20 min before heat shocking the cells for 45-50 sec at 42 °C in a water bath. Tubes 
were incubated on ice for 2 min before the addition of 450 µl LB broth. Cells transformed 
with the ligation reaction were incubated at 37 °C for 90 min with shaking at 150 rpm. Then 
100 µl of the transformation mix was plated onto an LB agar plate as above (Section 2.1.6.1). 
 
2.1.7 Isolation and purification of plasmid DNA 
 
Plasmid DNA was screened for recombinant clones using a modified alkaline lysis protocol. 
200 µl of lysis buffer (0.2 M sodium hydroxide, 1% SDS) was added to 200 µl of overnight 
bacterial culture and mixed. Plasmid DNA was neutralised by the addition of 200 µl of 3 M 
potassium acetate, pH 4.7, and the solution was centrifuged at 12,000 g for 5 min at room 
temperature. The plasmid DNA was precipitated by removing the supernatant and transferring 
it to a tube containing 500 µl isopropanol. The reaction was mixed and centrifuged at 12,000 
× g for 1 min at room temperature. The supernatant was removed and the wet pellet was 
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dissolved in 20 µl Milli-Q water. Higher purity plasmid DNA that was required for 
procedures such as automated sequencing, restriction digestion, in vitro transcription or 
transfection, was purified using the High Pure Plasmid Purification Kit (Roche Applied 
Science) or the Plasmid Midi Kit (QIAGEN). Plasmid DNA concentration was measured 
either by agarose gel electrophoresis (Section 2.1.9) using a molecular mass standard (Bio-
Rad) as a reference or readings at A260 nm using a NanoDrop-100 spectrometer (Biolab Ltd; 
Melbourne, Australia). 
 
2.1.8 Restriction enzyme digestion 
 
DNA was digested with restriction enzymes obtained from New England Biolabs (NEB, 
distributed by Genesearch, Gold Coast, Australia) under conditions specified by the 
manufacturer. Typically, 1 µg plasmid DNA was digested with 10-20 units of the appropriate 
enzyme in a final concentration of 1x buffer for 3 h at 37 °C. Bovine serum albumin (BSA, 
final concentration 1 mg/ml; NEB, Genesearch) was added to the reaction, if required. 
Digested products were analysed by agarose gel electrophoresis (Section 2.1.9) and by 
comparison with a DNA ladder (Fermentas Life Sciences, distributed by Quantum Scientific, 
Brisbane, Australia). 
 
2.1.9 Agarose gel electrophoresis 
 
DNA was typically analysed using 0.8-2.5% agarose gels. Agarose (Progen, Brisbane, 
Australia) was dissolved in 50 ml 1x tris-acetate EDTA buffer (TAE; 40 mM Tris-HCl, pH 
7.8, 10 mM sodium acetate, 1 mM EDTA, 28 mM acetic acid) by heating in a microwave 
oven and allowing it to cool to room temperature. Ethidium bromide (Sigma-Aldrich, Sydney, 
Australia; final concentration 0.5 µg/ml) was added to the gel prior to casting. 6 x DNA 
loading buffer (30% (w/v) sucrose, 0.35% Orange G (Sigma-Aldrich)) was added to the 
samples and the gels were run in 1x TAE buffer at a constant 100 V for 15-45 min depending 
on fragment size. DNA samples were visualised using an ultraviolet transilluminator. The 
Qiaquick gel extraction kit (QIAGEN, Melbourne, Australia) was used to purify fragments 
excised from gels. 
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2.2 Mammalian cell culture and analysis 
2.2.1 Growing HeLa cell  
 
A mammalian cell line, HeLa (human cervical epithelial), was used (Gey et al., 1952). The 
cell line was maintained in Dulbecco’s Modified Eagle’s Medium (D-MEM; Gibco; 
Invitrogen), supplemented with 10% Foetal Bovine Serum (FBS; Gibco; Invitrogen), 10 mM 
HEPES, pH 7.6, 100 U/ml penicillin (Gibco; Invitrogen), 100 µg/ml streptomycin (Gibco; 
Invitrogen) and 2 mM L-glutamine (Gibco; Invitrogen). Cells were incubated at 37 °C in a 
humidified 5% CO2 atmosphere incubator and grown on T-25 or 75 cm2 flasks (Nunclon 
Surfaces; Nunc) or 10 cm culture dishes (TPP; MIDSCI, MO, USA). Cells were propagated 
by trypsinising confluent cells (70-100% density) for 10 min at 37 °C and diluting 1:10 
(HeLa) with supplemented D-MEM.  
2.2.2 Splitting HeLa cells 
 
All cell media (DMEM) contained 50 ml new calf serum (NCS), 10 ml 1 M HEPES pH 7.4 
and 5 ml Pen/ Strep/ Glu antibiotics, PBS, and trypsin brought to room temperature. Frozen 
cells were thawed and centrifuged for 5 min at 500g. Cells were resuspended in new T75 
flasks and incubated at 37 °C. Old media was aspirated and washed with 2 ml PBS and then 
aspirated. To cover the surface of the dish 2 ml of trypsin/EDTA was added to the cells. Cells 
were returned to the incubator for ~5 min and 8 ml of cell media was added. The media and 
cells were mixed using a pipette to move fluid up and down, and around the surface of the 
dish to remove adherent cells from the surface. One ml of media was transferred into each 10 
cm culture dish and topped up to 10 ml with new media; the cells were spread evenly by 
rocking the dish/ plate back and forth, and placed in the incubator to grow to the desired 
confluence. Spreading the cells by swirling the media in a circular motion was avoided; this 
results in clumping of cells in the middle of the dish. 
 
2.2.3 Transfection 
 
For transfection experiments, cells were trypsinised the day before and plated on either 24- or 
12-well plates to reach a desired density of 20-70% confluency at the time of transfection. 
Transient transfection was achieved using Lipofectamine 2000 (Gibco; Invitrogen), according 
to the manufacturer’s specifications. Briefly, 600 ng DNA was transfected with 1 µl 
Lipofectamine 2000 per well of a 24-well plate. Both DNA and Lipofectamine 2000 reagent 
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were diluted with Opti-MEM medium (Gibco, Invitrogen), and following transfection, cells 
were incubated in Opti-MEM supplemented with 10% FBS and processed 48-72 h post-
transfection. 
 
2.3 Recombinant Protein expression and purification 
 
The expression vectors encoding full-length hnRNP A2 cDNA and full-length hnRNP A3 
were kindly provided by Dr. A. Krainer (Cold Spring Harbor Laboratory, New York, NY) 
and A. Ma (University Of Queensland, Australia), respectively. hnRNP A1 was commercially 
available (PROSPEC protein specialists) while hnRNP A2 deletion constructs encompassing 
various combinations of its domains, and truncated hnRNP A3 with only the two RRMs, were 
provided by Dr K. Moran-Jones (University of Queensland). These vectors were used to 
transfect E. coli BL21 (DE3) cells, which were lysed under native or denatured conditions, 
cells and genomic DNA were distributed by sonication and the lysate cleared by 
centrifugation at 12,000 g for 15 min at 4 °C. With the exception of full-length hnRNP A2 
(Munro et al., 1999), each protein was expressed using a modified pET30a plasmid. These 
His-tagged proteins were isolated by Immobilised Metal-Affinity Chromatography (IMAC) 
and their purity verified by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) (Ma et al., 2002, Shan et al., 2000). Three His-tagged constructs of hnRNP A1 
variants, (N-His-tagged, C-His-tagged and N/C-His-tagged recombinant proteins), were 
provided by Dr Munro. 
 
2.3.1 Design of a construct from Geneart to enable production of recombinant hnRNP 
A1 RRM domains. 
 
Using a plasmid containing cDNA of human hnRNP A1 (kindly donated by Dr Munro) as a 
template, PCR amplification was used to generate a series of fragments of it. Primers were 
designed to contain restriction endonuclease recognition sites to allow their single-orientation 
insertion into the vector pET-19b. Diagrammatic representation of the recombinant hnRNP 
A1 proteins to be expressed can be seen in Figure 2.1. The additional 10 amino acids at the C-
terminus of RRM2 were chosen based on reports that exclusion of the corresponding residues 
from hnRNP A1 decreases the affinity of the two RRMs for RNA 100-fold (Shamoo et al., 
1994). 
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Construct Design, which assumes use of “WT” hnRNP A1. 
 
 
 
  10                                     20                                30                                40                                    50          
 
MSKSESPKEP        EQLRKLFIGG      LSFETTDESL     RSHFEQWGTL       TDCVVMRDPN  
        60 
TKRSRGFGFV  
  
        70                                   80                                 90                                100                                110         
TYATVEEVDA     AMNARPHKVD     GRVVEPKRAV       SREDSQRPGA     HLTVKKIFVG  
         120 
GIKEDTEEHH  
 
       130                                   140                                150                               160                               170        
LRDYFEQYGK       IEVIEIMTDR        GSGKKRGFAF       VTFDDHDSVD     KIVIQKYHTV  
       180 
NGHNCEVRKA  
 
 
       190                                  200                             210                              220                                 230         
LSKQEMASAS      SSQRGRSGSG      NFGGGRGGGF      GGNDNFGRGG      NFSGRGGFGG  
        240 
SRGGGGYGGS  
 
       250                                   260                            270                               280                                290  
GDGYNGFGND      GGYGGGGPGY    SGGSRGYGSG      GQGYGNQGSG      YGGSGSYDSY  
        300 
NNGGGGGFGG  
pET-19 hnRNP A1 RRMs Nde1 BamH1 C and N His tags
6333 bp
Amp Res
hnRNPA1 cds 2-199
T7 Promoter
LacI Coding
RRM1
RRM2
RNP1
RNP2
RNP1
RNP2
6xHis tag
T7 promoterpBR322 origin
T7 Terminator Primer
BamHI (782)
NcoI (87)
NdeI (156)
  
 55 
 
       310                                     320                            330                               340                                350  
GSGSNFGGGG        SYNDFGNYNN     QSSNFGPMKG       GNFGGRSSGP       YGGGGQYFAK  
       360                                   370 
PRNQGGYGGS        SSSSSYGSGRR 
 
 
Figure 2.1: The planned constructs to express residues 1-196 in pET-19b. (Top) pET-19b 
vector map and multiple cloning sites. (Bottom) the construct was designed to allow a 6× His 
tag to be incorporated at both the N- and/or the C-terminal depending on the restriction sites 
used. The RRMs residues are highlighted in yellow and in green. 
2.3.1.1 Sequence Design for Geneart: 
 
Two common restriction enzymes containing ATG in their recognition sequence were 
used to cut at CCATGG and CATATG nt respectively for cloning. Xho1 is a 
restriction endonuclease that recognises the sequence C^TCG_G; BamH1 recognises a 
short 6bp sequence of DNA and specifically cleaves at the target site (Figure 2.2). 
- Using Residues 2-199 of hnRNP A1 
- 5' add Nco1 and Nde1 sites for in frame cloning into pET19b 
- 3' add Xho1, 6 × His, Stop and BamH1 sites for cloning into pET19b 
2.3.1.2           Cloning Strategy: 
 
- Use Nco1/BamH1 to give C-terminal His tag 
- Use Nde1/Xho1 to give N-terminal His tag and retain EK cleavage signal from pET19. 
- Use Nde1/BamH1 to give C-terminal and N-terminal His tags. 
5´-addition 
 
Nco1             Nde1 
ATGGGCCATATG 
 M        G     H    M 
 
hnRNPA1 amino acids 2-199: 
SKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGF
VTYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKED
TEEHHLRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNG
HNCEVRKALSKQEMASASSSQRGRSGS 
 
3´- addition 
 
 Xho1   6 × His C-Term     BamH1 
CTCGAGCATCATCATCATCATCACTAAGGATCC 
    L    E      H     H     H      H     H     H   Stop 
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2.3.1.3 Geneart optimised sequence as ordered: 
 
LOCUS       hnRNPA1-RRMs             641 bp DNA     linear 
FEATURES             Location/Qualifiers 
     CDS             15.608 
                     /label="ORF1" 
ORIGIN   
1       CCATGGGCCA TATGAGCAAA AGCGAAAGCC CGAAAGAACC GGAACAGCTG CGTAAACTGT  
61  TTATTGGTGG TCTGAGCTTT GAAACCACCG ATGAAAGCCT GCGTAGCCAT TTTGAACAGT  
121 GGGGCACCCT GACCGATTGT GTTGTTATGC GTGATCCGAA TACCAAACGT AGCCGTGGTT  
181 TTGGTTTTGT TACCTATGCA ACCGTTGAAG AGGTTGATGC AGCAATGAAT GCACGTCCGC  
241 ATAAAGTTGA TGGTCGTGTT GTTGAACCGA AACGTGCAGT TAGCCGTGAA GATAGCCAGC  
301 GTCCGGGTGC ACATCTGACC GTGAAAAAAA TCTTTGTGGG TGGCATTAAA GAGGATACCG  
361 AAGAACATCA TCTGCGCGAT TATTTTGAGC AGTATGGCAA AATTGAAGTG ATCGAGATTA  
421 TGACCGATCG TGGTAGCGGT AAAAAACGCG GTTTTGCATT TGTGACCTTT GATGATCATG  
481 ATAGCGTGGA CAAAATCGTG ATCCAGAAAT ATCACACCGT GAATGGTCAT AATTGCGAAG  
541 TTCGTAAAGC ACTGAGCAAA CAAGAAATGG CAAGCGCAAG CAGCAGCCAG CGTGGTCGTA  
601 GCGGTAGCCT CGAGCATCAT CATCATCATC ACTAAGGATC C// 
 
 
Figure 2.2: hnRNP A1 schematic showing the position of restriction enzyme sites used for 
cloning. 
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2.3.1.4 Geneart Optimized hnRNP primer sequences:
 
Figure 2.3: Optimized hnRNP A1 protein sequence. 
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2.3.1.3 The addition of His tags to hnRNP A1 
  
The cloning of the hnRNP A1 sequence into various plasmids containing His tags utilized 
conveniently-placed restriction endonucleases sites as follows. 
 
• Use Nco1/BamH1 to give a C-terminal His tag 
msksespkepeqlrklfigglsfettdeslrshfeqwgtltdcvvmrdpntkrsrgfgfvty
atveevdaamnarphkvdgrvvepkravsredsqrpgahltvkkifvggikedteehhlrdy
feqygkievieimtdrgsgkkrgfafvtfddhdsvdkiviqkyhtvnghncevrkalskqem
asasssqrgrsgslehhhhhh* 
MW: 23559 Da, pI : 7.27 
 
• Use Nde1/Xho1 to give N-terminal His tag and retain EK cleavage signal from pET19. 
mghhhhhhhhhhssghiddddkhmsksespkepeqlrklfigglsfettdeslrshfeqwgt
ltdcvvmrdpntkrsrgfgfvtyatveevdaamnarphkvdgrvvepkravsredsqrpgah
ltvkkifvggikedteehhlrdyfeqygkievieimtdrgsgkkrgfafvtfddhdsvdkiv
iqkyhtvnghncevrkalskqemasasssqrgrsgsledpaankarkeaelaaataeq* 
MW: 27540 Da, pI : 6.57 
 
• Use Nde1/BamH1 to N-terminal and C-terminal His tags 
mghhhhhhhhhhssghiddddkhmsksespkepeqlrklfigglsfettdeslrshfeqwgt
ltdcvvmrdpntkrsrgfgfvtyatveevdaamnarphkvdgrvvepkravsredsqrpgah
ltvkkifvggikedteehhlrdyfeqygkievieimtdrgsgkkrgfafvtfddhdsvdkiv
iqkyhtvnghncevrkalskqemasasssqrgrsgslehhhhhh* 
MW: 26326 Da, pI: 6.82 
 
2.3.2 Expression of hexa-His tagged hnRNP A2 and A3 
 
The pET-9c (Novagen, WI, USA) expression construct encoding the full-length hnRNP A2 
cDNA was kindly donated by Professor Adrian Krainer (Cold Spring Harbor Laboratory, NY, 
USA). The plasmid was transformed into competent E. coli BL21 (DE3) by electroporation 
(Section 2.1.6.1). Overnight bacterial cultures were propagated at 37 °C with shaking at 220 
rpm in LB medium with 30 µg/ml kanamycin added. For expression, a 1/20 volume of 
overnight culture was added to fresh LB medium and allowed to grow with shaking at 37 °C 
until an A600 of 0.6-0.8 was reached. Cultures were then induced with the addition of 
isopropyl-beta-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM for hnRNP 
A2 and 0.5 for hnRNP A3, and grown for a further 4 h at 37 °C. 
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2.3.3  Expression of hexa-His tagged proteins hnRNP A1 
 
The pET-19 (Novagen) expression vector containing the hnRNP A1 cDNA, a truncated 
version with only two RRMs, was kindly provided by Dr Munro. Plasmids were transformed 
into competent E. coli BL21 (DE3) and T7 express by heat-shock (Section 2.1.6.2). The 
expression of the hexa-His tagged proteins were as described in Section 2.3.2, with the 
exception that cells expressing hnRNP A1 were induced with a final IPTG concentration of 
0.5 mM, and allowed to grow for a further 3 h at a lower temperature of 27 °C. 
2.3.4 Production of bacterial lysates 
 
Cells were harvested by centrifugation at 5000 × g for 15 min at 4 °C. The resulting cell 
pellets were lysed either under native or denaturing conditions in a 1/10 culture volume. For 
native conditions, lysis buffers for the hexa-His tagged proteins contained 20-50 mM Tris-
HCl, pH 7-8.5, 100 mM NaCl, 100 µg/ml lysozyme, 0.1% Triton X-100 and 5 µg/ml DNase1 
(Sigma-Aldrich), and 5 mM imidazole. For lysis under denaturing conditions, the cell pellet 
was re-suspended in buffer containing 50 mM sodium phosphate, pH 7, 300 mM NaCl, and 6 
M guanidine-HCl. The lysis buffer for untagged hnRNP A2 consisted of 50 mM Tris-HCl, pH 
8, 2 mM EDTA, 100 µg/ml lysozyme, 0.1% Triton X-100 and 5 µg/ml DNase 1 (Sigma-
Aldrich) whilst the lysis buffer for the GST-tagged hnRNP A2 was phosphate-buffered saline 
(PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3). Lysis of 
cell pellets was carried out for 30 min in a 37 °C incubator with shaking, followed by 15 min 
incubation on ice. Cells and genomic DNA were disrupted by sonication with a Branson 
Sonifier 250 microtip sonicator (Branson, CT, USA) and the cleared lysate collected by 
centrifugation at 12,000 × g for 15 min at 4 °C. For hnRNP A1, cells were lysed by 
BugBuster Master Mix buffer (Merck Millipore), which contains protein extraction reagent 
with Benzonase, Nuclease and stabilised recombinant lysozyme (rLysozyme). It allows for 
maximum recovery of active soluble protein from both Gram-negative and Gram-positive 
bacteria. 
2.3.5  Immobilised-metal affinity chromatography (IMAC) 
 
Cleared lysates containing His-tagged proteins (pET-19 expression vector fusion proteins) 
were loaded onto a His-trap Ni Sepharose IMAC resin (GE Healthcare Life Sciences) 
operated with chromatography system AKTA. Lysates were packed in 1 ml columns, pre-
equilibrated with native extraction buffer (20–50 mM Tris-HCl, pH 7–8.5, 100 mM NaCl, 5 
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mM imidazole). Resins were washed with 15 bed volumes of the appropriate extraction buffer 
to remove any non-specifically bound proteins, followed by elution of bound proteins using 
elution buffer (appropriate extraction buffer containing 150–300 mM imidazole). All fractions 
were collected and analysed by SDS-PAGE (Section 2.4.2). Resin was regenerated with 20 
mM MES, pH 5.0, 100 mM NaCl and stored in 20% EtOH. For Ni2+-NTA spin column 
(Qiagen), the columns were equilibrated with Buffer B (8 M Urea, 0.1M NaH2PO4, 0.01M 
Tris-HCl pH 8.0) and centrifuged for 2 min at 700g, 2000 rpm. 600 µl of cleared lysate 
supernatant was loaded onto a pre-equilibrated Ni-NTA spin column and centrifuged for 2 
min at 700g, and the flow-through collected. Resins were washed with 600 µl with buffer C (8 
M Urea, 0.1M NaH2PO4, 0.01M Tris-HCl pH 6.3) and centrifuged for 2 min at 700g to 
remove any non-specifically bound proteins; this step was repeated 3 times and the washes 
saved. Then elution of bound proteins was carried out using Elution Buffer E 2 x 200 µl (8 M 
urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl pH 4.5) and centrifuged for 2 min at 700 g. All 
fractions were collected and analysed by SDS-PAGE (Section 2.4.2). 
2.3.6 Size-exclusion chromatography 
 
Fractions with the highest A280  readings were pooled and applied to a 10 ml of SephadexTM G-
25 Medium, PD-10 Desalting size-exclusion column (GE Healthcare Life Sciences) pre-
equilibrated in Buffer A. The column was run at 0.5 ml/min, collecting 10 ml fractions. The 
elution of bound protein was again followed at A280 and confirmed by SDS-PAGE, Western 
blot and mass-spectrometry (Section 2.4.4). 
 
2.3.7 High-performance liquid chromatography 
 
Fractions containing semi-purified protein were acidified to a final trifluoroacetic acid (TFA) 
concentration of 0.1%, filtered though 0.22 µm filter (Sartorius, Goettingen, Germany) and 
purified by reverse-phase High-Performance Liquid. Chromatography (HPLC). A linear 
gradient of 10-60% acetonitrile in 0.1% TFA at a flow rate of 1 ml/min over 30 min was 
passed though a C
4 reverse-phase analytical HPLC column (250 x 4.6 mm, 5 µm particle size, 
300 Å pore size; Grace Vydac, CA, USA). Protein elution was monitored at 214 nm. Purified 
protein was collected, lyophilised twice and dissolved in Milli-Q water before storing at -20 
°C. 
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2.4 Protein analysis techniques 
2.4.1 Quantification of protein concentration 
 
Protein concentration was determined by the method of Bradford (Bradford, 1976) using 96-
well flat-bottom plates (Nunclon Surfaces; Nunc, NY, USA). Protein samples were diluted to 
40 µl with distilled water and mixed with 200 µl of assay reagent which was prepared 
according to the manufacturer’s instructions (Bio-Rad). Absorbance was measured at 595 nm 
using a Spectramax 250 plate reader (Molecular Devices, CA, USA). Protein concentrations 
were calculated by constructing a standard curve utilising BSA solutions of known 
concentrations. Alternatively, A280 readings were obtained using a NanoDrop ND-1000 
spectrophotometer (Biolab) and concentrations calculated using the Beer- Lambert Law: 
A= ε c l  
The Molar Absorption Coefficient (ε; M-1cm-1) was calculated using the formula: 
ε = 5500nW + 1490nY + 125nC 
Where W, Y and C represent the amino acids tryptophan, tyrosine and cysteine, respectively, 
whilst n represents the number of residues (Fasman, 1989, Gill and Von Hippel, 1989).  
 
2.4.2 SDS-polyacrylamide gel electrophoresis 
 
Protein samples were separated by SDS-PAGE, which is based on the methods of Laemmli 
(1970), and was carried out as described in Hames (1981) and Sobieszek (1994) (Sobieszek, 
1994, Laemmli, 1970, Hames, 1981). Protein analysis was achieved by separation though a 
15 x 15 cm 12% polyacrylamide (19:1 acrylamide:bis- acrylamide) gel containing Tris-
glycine, pH 8.8. Sample wells (150 µl capacity) were formed in a 1 cm deep stacking gel 
containing 5% polyacrylamide. Protein samples were diluted with a 4 x loading dye (62.5 
mM Tris-HCl, pH 6.8, 2% w/v SDS, 72 mM β-mercaptoethanol, 0.12% w/v bromophenol 
blue, 25% v/v glycerol) and heated at 65 °C for 15 min prior to loading. Gels were 
electrophoresed in Running Buffer (25 mM Tris-HCl, 192 mM glycine, 0.1% SDS, pH 8.3) 
until the dye front had reached the bottom of the gel. Pre-cast 9 x 7 cm 10-12% 
polyacrylamide gels (Gradipore, Sydney, Australia) were also utilised. These gels were 
electrophoresed using the same Running Buffer as above at a constant voltage of 120-150 V 
on Hoefer Mighty Small units (Amersham Biosciences). The molecular weights of the 
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electrophoresed proteins were estimated by comparison with mass markers (Sigma-Aldrich). 
Following electrophoresis, gels were stained for 45 min with Coomassie Brilliant Blue R250 
(Sigma-Aldrich) containing 10% glacial acetic acid and 40% methanol followed by de-
staining in 10% glacial acetic acid until a clear background was achieved. 
 
2.4.3 Western blotting 
 
For Western blotting, proteins were resolved on 12% polyacrylamide gels (Section 2.4.2) 
before transfer, which was performed in a Bio-Rad Mini Trans-Blot Electrophoretic transfer 
apparatus (Bio-Rad). Polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore, 
MA, USA) were activated by rinsing with methanol for 20 sec followed by incubation in 
transfer buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine) for 20 min. Proteins were blotted 
onto PVDF membranes in transfer buffer at a constant 100 V for 60-90 min. 
 
Following blotting, membranes were incubated for either 1 h at room temperature or 
overnight at 4 °C in blocking solution (phosphate-buffered saline (1 x PBS containing 3% 
Fish skin gelatine (FSG); Sigma-Aldrich) on roller mixers. Membranes were then probed for 
3 h at 4 °C with specific primary antibodies diluted in 1 x PBS containing 3% FSG, 0.1% 
tween-20) solution. Unbound primary antibodies were removed by washing three times at 5 
min intervals in PBS containing 0.1% Tween-20. Secondary antibody (conjugated to alkaline 
phosphatase), which was appropriately diluted in blocking buffer containing 0.1% tween-20, 
was added to the membrane and incubated for 1-2 h at 4 °C. Unbound secondary antibodies 
were removed by washing three times at 5 min intervals in PBS containing 0.1% tween-20. 
Western samples were detected using the Odyssey imaging system (LI-COR Biosciences, NE, 
USA).  
 
2.4.3.1 Antibodies 
Primary antibodies were polyclonal α-rabbit hnRNP (raised in rabbits; A1, A2/B1, B1 or A3-
N and -C terminal, generated by previous laboratory members Drs T. Munro and K. Moran- 
Jones) at 1:1000 to 1:5000 dilution, monoclonal α-mouse hnRNP A1 (Sigma, 1:5000 
dilution), and polyclonal α-rabbit POT1 (Abcam, 1:5000 dilution). Secondary antibodies were 
goat α-rabbit alkaline phosphatase conjugate (Sigma-Aldrich; 1:2000 dilution), goat α-rabbit 
Alexa 680 (Invitrogen, 1:20,000 dilution), goat α-mouse IRDye800 (Rockland 
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Immunochemicals Inc, PA, USA; 1:20,000 dilution), goat α-rabbit Alexa488 and Alexa546 
(Life technologies, 1:10,000 dilution). 
2.4.4 Mass Spectrometry  
2.4.4.1 Preparation for samples from gel slices 
After electrophoresis and destaining of the gel, each piece containing the band of interest was 
cut using a scalpel blade and placed in an Eppendorf tube. The protein band stained with 
Coomassie Blue was excised and cut into smaller pieces to maximise the amount of the 
protein and minimise the amount of excess gel. Gel pieces were further destained with 50 mM 
ABC (ammonium bicarbonate) and 50% ACN (acetonitrile) 2 × 500 µl with shaking for 2–5 h 
or overnight until the Coomassie Blue colour was removed from the gel. 
 
2.4.4.2 Reduction and alkylation  
As the samples were from a 2D gel, some steps were not necessary because the equilibration 
steps should have reduced and alkylated the sample. Instead all destaining solutions were 
removed from the gel pieces and dehydrated with 100% ACN for 5 min until the gel pieces 
turned white by vortexing.    
 
2.4.4.3 Enzymatic digestion  
The dehydrated gel pieces were rehydrated with 8 µl trypsin (10 ng/µl in 50 mM ABC) for 
10-20 min and incubated on ice. Then an additional 6 µl-16 µl 50 mM ABC buffer was added 
depending on the size of the gel to keep it moist overnight at 37°C.  
 
2.4.4.4 Peptide extraction 
50 µl of 50% ACN and 0.1% TFA (trifluoroacetic acid) was added to the gel pieces which 
were sonicated in a water bath for 10 min, prior to be spun briefly and the supernatant 
transferred to a new tube. Another 50 µl aliquot of 50% ACN/0.1% TFA was added to the gel 
pieces, sonicated and combined with the first round of supernatant. Samples were lyophilised 
in a speed vacuum at 45 °C to decrease the drying time and to remove ACN. 
2.4.4.5 Sample preparation for ESI-MS 
All dried samples were resuspended in 10 µl 5% ACN/ 0.1% TFA and cleaned using a 
Millipore C18 Ziptip, without allowing air to pass through the ziptip in between steps, as it 
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would dry out the resin. The tip was moistened with 100% ACN 3 x 10 µl, and then 
equilibrated with 5% ACN/0.1% TFA 3 x 10 µl. Samples of 20 µl were loaded by first 
pipetting up and down at least twice to mix the sample then tip washed with 5% ACN/0.1 
TFA 3 x 10 µl. Samples of 10 µl were finally eluted with 80% ACN/0.1% TFA into new 
vials. 
2.5 DNA-protein analysis technique 
2.5.1 Possible contact points between hnRNPs and telomeric DNA 
 
The ClustalW protein alignment programme was used to illustrate the high degree of 
sequence identity amongst the hnRNP paralogs, especially whether the 31 amino acid 
residues of hnRNP A1 that are in direct contact with telomeric DNA would be conserved 
within the hnRNP paralogs. 
 
2.5.2  Identification of single-strand telomeric DNA binding proteins 
2.5.2.1 HeLa cells protein extraction 
HeLa cells were extracted using lysis buffer (10 mM Tris pH 7.4, EDTA 0.25 M, 1% IGPAL, 
1 mM PMSF and 3 mM NaCl) containing a protease inhibitor cocktail (Sigma-Aldrich) and 
then centrifuged at 17,530 × g for 30 min at 4 °C. The top layer of the supernatant was 
collected and either used immediately in subsequent bead-binding reactions or stored at -70 
°C. 
 
2.5.2.2 Labelling of magnetic particles with telomeric DNA repeats 
Meanwhile, 50 µl streptavidin (SA)-coated magnetic particles (Roche Applied Science) were 
washed 2 × in 700 µl high-salt buffer (0.1 M NaOH, 0.5 M NaCl), 1 × in 700 µl low-salt 
buffer (0.1 M NaCl), then resuspended in 250 µl of TEN (10 mM Tris-HCl, pH 7.5, 1 mM 
EDTA, 0.1 M NaCl) buffer (RNA binding buffer). Telo2, Telo4 and non-specific DNA 
sequence NS (100 pmol/µl of each; highlighted in Appendix, Table B) were added and the 
mixture incubated for 15 min at 25 °C with rotation. Beads were washed with 1 M TEN 
buffer (same as TEN buffer with 1 M NaCl) and 1 × RNA polymerase (RNAP) buffer (10 
mM HEPES, 5M NaCl, 100% glycerol). Five times RNAP and 100µl heparin (100 mg/ml) 
were added to the beads prior to adding clear lysate. Non-specific DNA-protein interactions 
were minimised by including heparin in all samples. The mixture was incubated for 2 h on a 
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roller at 4 °C. Beads were then washed with 1 × RNAP buffer. Elution of telomeric DNA-
binding proteins was achieved by incubating the beads with 30% ACN, 0.1% TFA for 10 min 
at 65 °C. Bound proteins were loaded onto and resolved on 12% SDS-PAGE gels using a 
Mini Trans-Blot Electrophoretic transfer apparatus (Bio-Rad) prior to being visualised in an 
Odyssey scanner system. 
 
 
Figure 2.4: Affinity pull-down assay. Process outline for affinity pull-down of native hnRNP 
A/B proteins from HeLa cell lysate using biotinylated single-strand telomeric DNA bound to 
streptavidin-coated magnetic beads. 
 
2.5.3  Analysis of predominant hnRNPs proteins by western blot 
 
Eluted bound proteins of Telo4 from the previous experiment were loaded onto and resolved 
on SDS-PAGE gels and transferred to a nitrocellulose membrane for Western blot. Proteins 
were resolved on 12% polyacrylamide gels in a Mini Trans-Blot Electrophoretic transfer 
apparatus (Bio-Rad). A PVDF membrane (Immobilon-P, Millipore, MA, USA) was activated 
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by rinsing with methanol for 20 sec followed by incubation at RT in transfer buffer (25 mM 
Tris-HCl, pH 8.3, 192 mM glycine) for 20 min and then by water for 20 min. Proteins were 
blotted onto PVDF membranes in transfer buffer at a constant 100 V for 60-90 min. PVDF 
membranes were blocked in PBS containing 3% FSG (Sigma-Aldrich). Five micrograms of 
primary polyclonal anti-rabbit antibodies (directed against hnRNPs A1, A2, A3C and A3N) in 
1µl, 0.5µl, 5µl of Abs respectively were diluted in 5ml blocking buffer containing 0.1% 
Tween-20, and incubated with membranes for 1 h at room temperature followed by 3 × 5 min 
washes with PBS containing 0.1% Tween-20. Five micrograms of secondary antibodies, goat 
anti-rabbit Alexa 680, was diluted in blocking buffer containing 0.1% Tween-20 and 0.01% 
SDS and incubated for 60 min at room temperature. Membranes were washed (3 × 5 min) 
with PBS followed by visualisation on an Odyssey imaging system. 
 
2.5.4 EMSA-UV-crosslinking experiments with recombinant protein 
 
Protein concentrations were determined by NanoDrop ND-100 spectrophotometer (Biolab). 
Recombinant proteins (0.0, 0.5, 1.0, 1.5, 3.5, 7.5, 15 and 30 pmol) were mixed with 0.5 pmol 
labelled oligonucleotide Telo1 and Telo6 and with labelled 0.5 pmol Anti1, Anti6 and NS in 
binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 4% (v/v) glycerol) and incubated for 
20 min on ice. DNA probes without protein were included as controls. For competition 
experiments 75-150 pmol of unlabelled oligonucleotides were added prior to the addition of 
protein. Following incubation, the reaction mixtures were irradiated with 500 MJ of 254 nm 
light in a Hoefer UVC500 UV Crosslinker (CA, USA). Four x loading dye was added and the 
samples run on 10% SDS-PAGE for 2 h at 130V. Following SDS-PAGE separation, gels 
were exposed to a PhosphorImager screen for 4 h. Then the PhosphoImager screens were 
scanned using a Typhoon scanner. 
 
2.5.5 Immunocytochemistry (ICC). 
 
HeLa cells were grown on trypsinized plates to around 75–85% confluence. Cells were then 
trypsinized and aliquoted onto a Millicell EZ slide (Millipore). Early S-phase synchronization 
was achieved at 25–30% confluency of HeLa cell culture washed twice with 1×PBS and then 
incubated in DMEM (10%FCS, 1% Pen-Strep, 1% Glutamine) containing 2 mM Thymidine 
for 18 h. After the first thymidine block step, thymidine was removed by washing the cells 
with 1 × PBS and then DMEM (10%FCS, 1% Pen-Strep, 1% Glutamine) was added for 9 h to 
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release cells from their mitotic block. After releasing the cells, DMEM (10%FCS, 1% Pen-
Strep, 1% Glutamine) + 2 mM Thymidine was added for 17 h for the second block. 
Thymidine was then removed by washing with 1 × PBS and then fixing the cells with ice-cold 
methanol for 10–15 min prior to be washed twice with ice-cold PBS. Cells were 
permeabilised by incubating with PBS containing 0.25% Triton x100 for 10 min at RT and 
then washed 3 × 5 min in the same buffer. The cells were then incubated in 1%  BSA in 
Phosphate-buffered saline containing Tween-20 (PBST) for 30 min at RT to block non-
specific binding sites. Primary antibodies (polyclonal, generated in rabbit directed against 
hnRNP proteins A1, A2, A3 and POT1) were diluted in 1% BSA in PBST for 1 h at room 
temperature before washing with PBS 3 × 5 min. Secondary antibodies (Goat anti Rb Alexa 
546 and Alexa 488) were diluted in 1% BSA in PBST for 1 h at room temperature in the dark 
before washing with 3 x 5 PBS in the dark. For counter-staining, cells were incubated with 
0.1–1 µg/ml Hoechst or DAPI (DNA stain) for 1 min and rinsed with PBS. The slides were 
mounted with a coverslip using a drop of mounting medium and sealed with nail polish prior 
to being visualised by confocal microscopy. 
 
2.5.6 Chromatin-immuno-precipitation (ChIP) assay 
2.5.6.1 ChIP lysates Preparation   
HeLa cells (a total of 1x107 cells) were grown on T75 flasks (Nunc). Cells were trypsinised, 
washed with ice-cold PBS and subsequently cross-linked by the addition of formaldehyde, at 
a final concentration of 1%, for 10 min at room temperature. Following cross-linking, cells 
were once again washed 2 x with ice-cold PBS (containing 1mM PMSF) and centrifuged at 
2000 rpm for 5 min at 4 °C. Cells were lysed with 200 µl chromatin immunoprecipitation 
(ChIP) lysis buffer (50 mM Tris pH 8, 1% SDS, 10 mM EDTA, 1 mM PMSF) for 10 min on 
ice followed by shearing of DNA to less than 300 nt with a 250 microtip sonicator (Branson) 
using 3-4 sets of 10 s pulse, using 30% maximum power. Sonicated samples were centrifuged 
at 13,000 × g for 10 min at 4 °C and the cleared lysate collected and stored at -70 °C. 
 
2.5.6.2 Chromatin Immunoprecipitation 
Each immunoprecipitation (IP), 200 µl cleared, sonicated lysate was diluted 10-fold (2 ml 
final volume) with ChIP dilution Buffer (16.7 mM Tris pH 8, 0.01% SDS, 1.1% Triton X- 
100, 1.2 mM EDTA, 150 mM NaCl, 1mM PMSF). Ten percent of the diluted, cleared lysate 
was removed for input controls and the remaining 90% utilised in the IP reaction. Non-
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specific background was decreased by pre-incubating the 90% lysate with Protein A agarose 
beads (Dynal Biotech ASA) containing salmon sperm DNA (1.5 µg per 20 µl beads) for 30 
min at 4 °C with agitation. Agarose beads were briefly centrifuged at 1000 rpm at 4 °C and 
supernatant collected. Antibody (10 µg) was added and reactions were placed at 4 °C 
overnight with rotation. Negative controls were included which either had no antibody or 
rabbit IgG antibody. Following overnight incubation, 60 µl of Protein A agarose beads 
(containing salmon sperm DNA) was added to each IP and incubated at 4 °C for 90 min with 
rotation. Agarose beads were briefly centrifuged to remove unbound, non-specific DNA and 
washed 1 x with Wash Buffer 1 (20 mM Tris pH 8, 0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 150 mM NaCl), 1 x Wash Buffer 2 (20 mM Tris pH 8, 0.1% SDS, 1% Triton X-100, 
2 mM EDTA, 500 mM NaCl), 1 x Wash Buffer 3 (10 mM Tris pH 8, 0.25 M LiCl, 1% NP-
40, 1% sodium deoxycholate, 1 mM EDTA) and 2 x Wash Buffer 4 (10 mM Tris pH 8, 1 mM 
EDTA). 
 
Protein/DNA pulled down by the antibody was eluted off the beads with 250 µl freshly 
prepared ChIP Elution Buffer (1% SDS, 0.1 M NaHCO3) and incubated for 15 min at room 
temperature with rotation before collecting eluted complexes after brief centrifugation. A 
second round of elution was completed and pooled (500 µl) before adding 20 µl 5 M NaCl to 
reverse the cross-links for 4 h at 65 °C. Input samples were also reverse cross-linked and 
processed alongside IP samples. Ten microlitres 0.5 M EDTA, 20 µl 1 M Tris pH 6.5 and 20 
µg DNase-Free RNase A was added to all reactions followed by incubation for 30 min at 37 
°C. Following incubation, 40 µg Proteinase K was added and incubated for 45 min at 65 °C. 
DNA that had been pulled down with immunoprecipitated proteins, were recovered by 
phenol/chloroform extraction and re-suspended in Milli-Q water. 
 
2.5.6.3 Dot Blotting 
Prior to dot blotting samples on hybond-N nylon membranes (Amersham Biosciences), 
samples were denatured by the addition of 40 mM NaOH/1 mM EDTA (final concentration) 
followed by heating at 100 °C for 5 min. Ice-cold 2 M ammonium acetate pH 7 was added 
and samples were dot blotted using Bio-Dot microfiltration apparatus (BioRad, NSW, 
Australia) according to the manufacturer’s instructions. Membranes were UV cross-linked 
(Hoefer UVC 500) with 250 MJ of 254 nm light. 
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2.5.6.4 Telomeric DNA probe hybridisation and detection 
Membranes were incubated in hybridisation bottles containing 20 ml pre-hybridisation buffer 
(5x SSC, 20 mM NaH2PO4, 7% SDS, 0.5% skim milk) for 4 h at 37 °C in a rotating 
hybridisation oven. 32P-labelled Telo6 probe was added and allowed to hybridise overnight. 
Subsequently, membranes were washed with 6 x SSC for 15 min at 55 °C before exposure of 
the membrane to a phosphor-screen and visualisation by Typhoon scanner.   
 
2.5.7 Surface Plasmon Resonance (SPR) experiments 
2.5.7.1 Instrument and reagents 
Surface Plasmon Resonance (SPR) is a real-time kinetic measurement of the interaction of  
unlabelled biological molecules at surfaces. This technique was used to investigate the 
interaction between hnRNPs (A1, A2 and A3) and telomeric DNA using a BIAcore 3000 SPR 
biosensor instrument (BIAcore AB, Uppsala, Sweden) in order to calculate the rate constants 
and affinities for the interactions between hnRNP paralogs and telomeric DNA. The 5’ 
biotinylated oligonucleotides were anchored on research grade SA-coated Chips (BIAcore). 
All buffers used for BIAcore, which include Conditioning Buffer (1 M NaCl in 50 mM 
NaOH), Running Buffer; HBS-T (10 mM Hepes, pH 7.4, 150 mM NaCl, 3.4 mM EDTA and 
0.005% Tween-20), and Regeneration Buffer (0.125% SDS), were filtered and degassed. 
 
2.5.7.2 Immobilisation of 5’biotinylated oligonucleotides to the SA sensor chip 
Prior to immobilisation, SA sensor Chips were first washed with HBS-T buffer for 6 min and 
then unconjugated SA was removed with three consecutive 1 min injections of Conditioning 
Buffer at a flow rate of 50 µl/min. Each 5’ biotinylated oligonucleotide (Appendix, Table B) 
was diluted to 2 nM in HBS-T and manually injected across a flow cell at a flow rate of 5 
uL/min. One flow cell was routinely left unmodified to correct for refractive index changes, 
non-specific binding and instrument drift. The amount of DNA immobilised on the chip 
surface was such that the saturation of hnRNPs bound to immobilised DNA was 50 to 100 
response units (RU). Because the SPR response is directly proportional to the mass 
concentration of the material at the surface, the analyte’s binding capacity of a given surface 
is related to the amount of ligand immobilised, and as such can be expressed by the following 
formula: 
Rmax = (analyte MW/ ligand MW) x ideal response (RU) x stoichiometry 
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This typically resulted in the immobilisation of ~5-10 RU of biotinylated DNA (molecular 
weights of Telo and Antibiotinylated DNA were 3951 and 3840 g/mol, respectively, whereas 
the molecular masses of hnRNP A1, A2 and His-tagged A3 were 36,000. 37,000 and 44,000 
g/mol respectively). 
2.5.7.3 Binding of hnRNPs to immobilised telomeric sequences 
hnRNP proteins were diluted in HBS-T to concentrations ranging from 0-100 µM, and each 
concentration injected simultaneously across the desired flow cells at a flow rate of 40 µl for 3 
min. Following injection, bound proteins were allowed to dissociate in HBS-T for 3 min 
before regenerating the binding surface with a single injection of regeneration buffer for 40 s 
at a flow rate of 40 µl/min. The results were plotted in a sensogram and expressed in RU 
against time. 
 
2.5.7.4 Data Analysis for surface plasmon resonance 
All sensograms were analysed for mass transport and linked-reaction-influenced kinetics. 
Additionally, sensogram data was reference subtracted from an unmodified flow cell and 
analysed using the BIAevaluation 4.1 software as recommended by the manufacturer. For all 
experiments, the sensogram data were fitted using a 1:1 Langmuir binding interaction model, 
which describes a 1:1 binding interaction between analyte (hnRNPs; A) and ligand 
(immobilised DNA; B). 
 
2.6 RNA-protein analysis techniques 
2.6.1 IP-TRAP ASSAY 
 
HeLa cells (1x106) were washed once with ice-cold PBS and lysed with 200 µl 1x CHAPS 
lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM Benzamidine, 5 
mM β-mercaptoethanol, 0.5% CHAPS, 10% glycerol) containing protease inhibitor. The 
lysate was incubated on ice for 30 min and centrifuged at 14,000 × g for 30 min at 4 °C. 
Twenty microliters of magnetically-labelled protein A-agarose beads (Dynal A.S, Oslo, 
Norway) were washed with ice-cold high-salt buffer and then with ice-cold low-salt buffer 
prior to washing with ice-cold 1 x RNAP/DEPC buffer. The lysate was added to the beads 
and mixed for 1 h at 4 °C. Supernatant was recovered and incubated overnight at 4 °C with 5 
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This typically resulted in the immobilisation of ~5-10 RU of biotinylated DNA 
(molecular weights of Telo and Anti biotinylated DNA were 3951 and 3840 g/mole 
respectively whereas the molecular masses of hnRNP A2 and His-tagged A3 are 36,000 
and 44,000 g/mole respectively). 
 
2.4.3.3 Binding of hnRNPs to immobilised telomeric sequences 
Recombinantly expressed hnRNP proteins were diluted in HBS-T to concentrations 
ranging from 0-100 nM, and each concentration injected simultaneously across the 
desired flow cells at a flow rate of 40 µL for 3 min.  Following injection, bound proteins 
were allowed to dissociate in HBS-T for 3 min before regenerating the binding surface 
with a single injection of Regeneration Buffer for 40 sec at a flo  rate of 40 µL/min.  
The results were plotted in a sensogram and expressed in response units (RU) against 
time.  In some experiments, heparin ade up in HBS-T buffer, wa included in the 
injected sample at a concentration of 1.2 g/L.  Some concentrations were tested in 
duplicate to ensure reproducibility. 
 
2.4.3.4 Data Analyses for surface plasmon resonance 
All sensograms were analysed for mass transport and linked-reaction-influenced 
kinetics.  Additionally, sensogram data recorded was reference subtracted from an 
unmodified flow cell and analysed using the BIAevaluation 4.1 software as 
recommended by the manufacturer.  For experiments containing heparin, the sensogram 
data was fitted using a 1:1 Langmuir binding interaction model, which describes a 1:1 
binding interaction between analyte (hnRNP; A) and ligand (immobilised DNA; B): 
A + B ! AB 
k
a
 
 k
d
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µg of primary anti-rabbit antibodies of interest (A1, A2, A3, and IgG) and rotation. The IP 
complex was incubated with new washed beads (ice-cold buffers) for 1 h at 4 °C with 
rotation; a magnetic holder was used to recover the beads, and beads were washed 3 x 
1xRNAP/DEPC buffer followed by 3 x 1xCHAPS buffer and suspended in 8 µl of 1 x 
CHAPS buffer. Two microliters of each sample were subjected to telomeric repeat 
amplification protocol (TRAP). 
 
2.6.2 TRAP PCR 
2.6.2.1  PCR Amplification 
Tubes were placed in the thermocycler block and incubated at 30°C for 30 min. (b) 3-step 
PCR was performed as follows  
 
Denaturation               94 °C for 30 s 
Annealing                   59 °C for 30 s 
Extension                    72 °C for 1 min  
Heat-inactivated control: 4-5 µl of IP sample incubated for 15 min at 85 °C in a thermocycler. 
Two microliters of IP cell extract were added into heat-inactivated control tubes. 
 
2.6.3 PAGE and Data Analysis 
 
Five microliters of 6 x loading dye was added to 20 µl of PCR products and separated on 
12.5% non-denatured PAGE (40% Polyacrylamide/bisacrylamide stock solution (19:1); no 
urea) in 0.5x Tris/Borate/EDTA (TBE) buffer. The gel then was run for 1.5 h at 300V on a 
15x15 cm vertical gel until the xylene cyanol had run 70-75% the length of the gel. The 
smallest telomerase product band should be 50 bp and the S-IC internal control band is 36 bp. 
After electrophoresis, the gel was stained with SYBR® Green Stain for 30 min and destained 
for 20-30 min in deionised water at room temperature, prior to being visualised by the 
PhosphoImager. 
30-33  
cycles 
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Figure 2.5: Amplification of TS-telomerase products by PCR. The TRAP assay is based on 
the original method described by Kim and Wu (1997). Elongation: Telomerase (cloud), which 
is contained within the protein lysate, recognises the TS primer (rectangle) and adds telomeric 
repeats (TTAGGG) onto the 3’ end of a substrate oligonucleotide (TS). PCR: The resulting 
DNA product is then used as a template for PCR amplification. During the first cycle, an 
anchored return primer (RP diamond) recognises and anneals to the telomeric repeats and 
synthesises the complementary strand. Subsequent PCR cycles generate a ladder of products 
with 6 base increments starting at 50 nt. 
 
2.6.4 Preparation of telomerase RNA templates 
 
Several constructs comprising different regions of the human telomerase RNA (hTR) 
template were prepared and ligated into the pGEM-T Easy cloning vector (Promega). hTR1-57 
and hTR1-72 were made by PCR amplification of the corresponding fragments, using full-
length hTR-pGem-T plasmid as a template. hTR35-65 and hTR57-72 were prepared by initially 
annealing complementary oligonucleotides (GeneWorks) encompassing those regions and 
TS#####+####Telomerase#
TS#####TTAGGGTTAGGGTTAGGGTTAGGG#
Telomerase#
TS# TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG#
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG#TS#
AATCCCAATCCCAATCCCAATCCCAATCCCAATCCCAATCCC#
Elonga2
on#
PC
R
#
RP#
RP#
TS#
#
TS#
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then ligating the resultant dsDNA into the pGEM-T Easy vector. Templates were linearised 
with SalI under conditions specified by the vendor (NEB, Genesearch). Linearised templates 
were purified by gel extraction (QIAquick gel extraction kit; QIAGEN Melbourne, Australia) 
and concentrated by ethanol precipitation before dissolving the pellet in RNase-free water. 
2.6.4.1 In-vitro transcription 
 
 In-vitro transcription reactions were performed using the Riboprobe T7/SP6 in vitro 
Transcription System (Promega) and α-32P UTP (Perkin Elmer, Melbourne, Australia). 
Reaction conditions were as recommended by the manufacturer. Run-off transcription 
reactions were performed with T7 polymerase. Following transcription and DNase treatment 
(RQ1 RNase-free DNase; Promega), labelled RNA reactions were terminated by the addition 
of stop solution (95% formamide, 5% glycerol, bromophenol blue). Transcripts were 
denatured at 80 °C for 10 min and transferred to ice to prevent RNA denaturation. Transcript 
labelled RNA were extracted with citrate-saturated phenol: chloroform: isoamyl alcohol and 
vortexed for 1 min and centrifuged at 12,000 × g for 2 min. The upper aqueous phase was 
removed into a new tube and the extraction step was repeated. A 0.5 volume of 7.5 M 
ammonium acetate and 2.5 volumes of 100% ethanol were added to the upper aqueous phase 
and placed at -80 °C for 30 min and then centrifuged for 20 min. Supernatant was removed 
and the pellets were washed with 70% ethanol, then dried under vacuum before being re-
dissolved in 10-20 µl nuclease-free water and stored at -80 °C.  
 
2.6.5 RNA Electrophoretic Mobility Shift Assay (REMSA) 
 
REMSA was performed to investigate if the hnRNPs A1, A2 and A3 could interact directly 
with the RNA component of hTR. Binding assays of transcribed RNAs to hnRNPs A1, A2 
and A3 including their short derivatives A1ΔGRD, A2ΔGRD, A3ΔGRD and hnRNP A2 
domains were performed in a buffer containing 10 mM Hepes, pH 7.6, 0.1 mM EDTA, 2.5 
mM MgCl2, 75 mM KCl, 1 mM DTT, and 5 g/L heparin, with the addition of recombinant 
protein always being last. The reaction mixtures were incubated on ice before the addition of 
RNA loading buffer (30 mM Tris-HCl, pH 7.5, 40% sucrose, bromophenol blue, made up in 
nuclease-free water) before separation though a 15 x 15 cm non-denaturing 5% 
polyacrylamide gel (19:1 acrylamide/bis-acrylamide, 50 mM Tris-HCl, pH 8.8, 50 mM 
glycine, 5% glycerol). Samples were run in Tris-glycine buffer (50 mM Tris-HCl, pH 8.8, 50 
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mM glycine) at constant voltage of 250 v for 2 h at 4 °C. Following separation, gels were 
exposed to a PhosphorImager screen until the desired signal intensity was achieved. 
                                 
2.6.6 Competitive binding of hnRNP A2 to DNA and hTR57-72 
 
Radio-labelled DNA and RNA was prepared and incubated with and without protein, as 
previously mentioned, as negative and positive controls. The DNA and RNA competition was 
slightly modified. The Riboprobe was incubated with 50 x Telo1 in 10 x binding buffer prior 
to adding 10 µM of recombinant hRNP A2 protein and then topped up to 10 µl with H2O. The 
reaction mixtures were incubated on ice for 10 min before the addition of RNA/Protein 
loading buffer and UV-XL. The reaction mixture was run on a non-denaturing 5% 
polyacrylamide gel and visualised using a phosphor-screen and Typhoon scanner. 
 
2.6.7 Binding assay on streptavidin-coated magnetic particles agarose beads columns  
 
This assay was performed including washings and elution buffers as described by Fiset and 
Chabot (Fiset and Chabot, 2001); the only modifications were the telomeric oligonucleotide 
Telo4 was biotin-labelled and used to couple with SA agarose beads according to the 
manufacturer’s recommendation (Roche Applied Science). Fifty microliters of SA-coated 
magnetic particles (Roche Applied Science) were washed twice wih 700 µl of high-salt buffer 
(0.1 M NaOH, 0.5 M NaCl) and 1x in low-salt buffer 700 µl (0.1 M NaCl) and then re-
suspended in 250 µl of TEN (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.1 M NaCl) buffer 
(RNA binding buffer). Telo4 (100 pmol/ µl of each) was added and incubated for 15 min at 25 
°C with rotation or at 4 °C overnight. Beads were washed with 1M TEN buffer 2 x (similar to 
TEN buffer but with 1 M NaCl) and 2x of 1xRNAP buffer (10 mM HEPES, 5 M NaCl, 100% 
glycerol). Biotin-labelled telomeric DNA (Telo4) oligonucleotides were covalently coupled to 
SA agarose magnetic beads. Beads were washed and eluted by centrifugation at 2000 × g for 
5 s in all steps. The Telo4 column was loaded with a mixture containing 32P-labelled hTR57-72 
and full-length hnRNP A2 including the domains RRM1, RRM2, RRM1+2 and RRM1+2+L 
in DN buffer (20 mM HEPES pH 7.9, 100 mM KCl, 5% glycerol, 0.2 mM EDTA, 0.5 mM 
PMSF, 0.5 mM DTT and 0.1% NP-40).  
 
Each column was washed several times with 200 µl (4 x 50 µl) of DN buffer. The bound 
material was eluted in four steps using DN buffer containing 250, 500, 750 mM and 1 M KCl. 
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For each salt concentration, elution was performed with 200 µl (4 x 50 µl). Loading controls 
were performed with 32P-labelled hTR57-72 only and POT1. Input, flow-through, washes and 
elutions were divided into two tubes and each tube was processed separately. The first set 
determined the protein profile by staining after fractionation using SDS-PAGE at 130 volt for 
ninety min. The other set, labelled hTR, was extracted with phenol/ chloroform/ 
isoamylalcohol, 70% ethanol precipitated and fractionated on a 5% acrylamide gel contain 8 
M urea at 130 v for 90 min and then the gels were incubated with phosphor-screen prior to be 
visualised by Typhon scanner.  
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Chapter	3	
3 hnRNPS AND DNA INTERACTIONS 
3.1 INTROUDUCTION  
 
This chapter describes the expression and subsequent purification of several protein-
constructs or a variety of deletion constructs designed around their constitutive structural 
domains. The subsequent expression and purification of these recombinant proteins in large 
amounts and relatively pure has allowed characterisation of their role in telomere biology, 
namely their interactions with telomeric DNA and with telomerase, as outlined in 
subsequent sections. The recombinant proteins produced in E. coli expression systems 
encoding full-length hnRNPs and deletion constructs covering a variety of combinations of 
their modular domains. This chapter will elucidate their function in telomere biology, by 
using them in a series of in vitro experiments addressing their possible interaction with 
telomeric DNA and with telomerase.  
 
Chromosome protection is mediated by telomeres; they prevent end-to-end fusion and 
nucleolytic degradation and also maintain the integrity of coding and regulatory DNA regions 
(Fiset and Chabot, 2001). Glycine-rich 3’overhang strand presence proposes that ssDNA-
binding proteins play a crucial role in telomere function (Collins, 2000). Several studies have 
proposed that hnRNP proteins are significantly involved in telomere biogenesis, including 
their capability to interact with single-stranded telomeric repeats and telomerase.  
The crystal structure of UP1 (proteolytic product of hnRNP A1 encompassing the two N-
terminal RRM domains; residues 1-189) was the initial evidence of an interaction that formed 
between UP1 and a 12-nucleotide single-stranded telomeric repeat [d (TTAGGG)
2
], 
highlighting the residues important in telomeric contact (Ding et al., 1999).  Although the co-
crystal structure of UP1/ telomeric DNA reveal both RRM1 and RRM2 were required to 
interact with telomeric DNA, other studies have been reported that RRM1 of hnRNP A1 is 
sufficient for stable and specific binding (Dallaire et al., 2000, Fiset and Chabot, 2001) 
(Figure 3.1). 
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Figure 3.1: Structure of the UP1 complex with d(TTAGGG)2.  Overall view of the UP1–
TR2 complex. The yellow or green showed protein molecules as a ribbon model and the ball-
and-stick model showed DNA molecules in red. One protein molecule and one strand of DNA 
showed as asymmetric unit. The protein monomers are related by a dyad axis (labelled in 
blue) vertical to the plane of the figure. The antiparallel DNA strands have the same 
symmetry relationship. The DNA and protein termini are labelled in blue. This figure was 
taken from (Ding et al., 1999). 
 
hnRNPs A1/UP1, A2/B1, C1/C2 and D have all been implicated in several other studies and 
shown to bind directly and specifically in vitro to vertebrate single-stranded telomeric repeats 
demonstrating the role of these proteins in telomere biogenesis (Dallaire et al., 2000, Ding et 
al., 1999, Ishikawa et al., 1993, Moran-Jones et al., 2005). Nuclease protection assays have 
demonstrated that binding of hnRNPs A1/UP1, A2/B1 and D results in the protection of 
telomeric substrates from the activities of endo-and exo-nucleases (Dallaire et al., 2000, 
Kamma et al., 2001). Furthermore, it was demonstrated that hnRNP A1 not only has the 
ability to disrupt the higher-ordered G-quadruplex structures formed by telomeric DNA in 
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vitro (Nakagama et al., 2006), but is also associated with telomeres in vivo (Zhang et al., 
2006). hnRNP A2 has also been shown to disrupt G-quadruplex structure (Wang et al., 2012) 
and localise to telomeric DNA-ends in metaphase spreads from telomerase-positive cell lines 
in addition to preferentially localising with telomeric chromatin and TRF2 in alternative 
lengthening of telomeres (ALT)-associated promyelocytic leukemia bodies (PMLs) known as 
APBs (Moran-Jones et al., 2005). 
3.2 RESULTS 
3.2.1 Purification of human recombinant hnRNP A1 
 
The pET-19b expression plasmid encoding the RRMs of human hnRNP A1 was kindly 
donated by Dr. Munro (AINB, UQ) (His-tagged N terminal, His-tagged C terminal and both 
terminals His-tagged). Expression and purification methods followed a previously optimised 
protocol (Dr Trent Munro, personal communication). Following IPTG induction and cell 
lysis, the soluble cleared lysate was concentrated by AKTAprime plus chromatography using 
a His trap IMAC column (GE Healthcare Life Science). Elution of bound protein was 
achieved using a linear 0–0.15 M NaCl gradient. hnRNP A1-containing fractions were 
analysed by SDS-PAGE (Figure 3. 2). 
 
Figure 3.2: Bacterial induction and expression of recombinant human hnRNP A1. His-
tagged terminals C, N and NC samples from each step of the purification procedure were 
taken and analysed by SDS-PAGE and visualised by Coomassie Blue staining. The molecular 
weight (MW) standard is represented on the left in units of kDa lane 1. Lane 2 contains 
uninduced BL21 (DE3) cells transformed with pET-19b containing human hnRNP A1 cDNA. 
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Lane 3-5 contain lysates hnRNP A1, while lane 6-8 represent semi-purified soluble hnRNP 
A1 following AKTAprime. 
 
 
Once identified, concentrated hnRNP A1 fractions were loaded onto an IMAC column. 1 mL 
fractions were collected and analysed by SDS-PAGE (Figure 3. 3). Partially purified 
fractions of hnRNP A1 were, as a final step, subjected to reverse-phase HPLC using either an 
analytical or semi-preparative C4 column (Figure 3.4). Eluted protein was monitored at 214 
and 280 nm and analysed by SDS-PAGE. Acetonitrile and TFA were removed from the 
purified samples by freeze-drying and the resulting lyophilised protein was redissolved in 
Milli-Q water. 
The purity and identification of the protein was confirmed by matrix-assisted laser desorption 
ionisation time-of-flight (MALDI-TOF) mass spectrometry, which produced the average 
mass for the purified recombinant protein which are 23.5, 27.5 and 26 KDa, which was of the 
predicted mass for recombinant human hnRNP A1/UP1 of 24 - 28 KDa corresponding to the 
first 199 amino acid residues of hnRNP A1. Once the hnRNP A1 His-tagged constructs were 
purified, the eluted proteins were subjected to Western blot for validation. Proteins were 
separated by SDS-PAGE and transferred to PVDF cellulose membranes and probed with 
polyclonal anti-rabbit antibodies. Primary antibodies were directed against the hnRNP A1 
protein. Following secondary antibodies, PVDF was visualised by Odyssey imaging system 
(LI-COR Biosciences, NE, USA) (Figure 3.5). 
 
An assortment of methods were initially sought to purify, in particular, the full-length 
hnRNP proteins. hnRNPs were initially purified to homogeneity without the use of an affinity 
tag by ion-exchange chromatography followed by size-exclusion chromatography and 
reverse-phase HPLC. The introduction of denaturing conditions though the use of RP-
HPLC as a final purification step proved to be a difficult as the recombinant protein was 
insoluble in buffer, except for water. This low solubility is presumed to result from either 
the incorrect folding of the recombinant protein, or the presence of the glycine-rich 
domain. Since the glycine-rich domain, which is weakly hydrophobic, is responsible for 
protein-protein interactions, it can be envisaged that it could promote protein aggregation 
by the close association of independent glycine-rich domains. Indeed, this hypothesis seems 
plausible as solubility issues resulting from the expression of full-length recombinant 
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hnRNP proteins has been observed by others (Prof. Adrian Krainer and Dr Trent 
Munro). Additionally, the expression of deletion constructs lacking the glycine-rich domain 
has resulted in soluble protein, which has been successfully used in vitro (Landsberg et al., 
2006). In order to elucidate binding functions of hnRNPs A2 and A3, deletion constructs 
based around the structural domains, namely the tandem RRMs and the glycine-rich 
domain, were obtained from previous lab members (Drs Michael Landsberg and Kim 
Moran-Jones) and also purified to homogeneity. Their identity was also confirmed by 
mass spectroscopy. 
 
Recombinant hnRNP A3 was cloned with an N-terminal hexa-histidine fusion tag, 
allowing for easy purification by affinity chromatography. Soluble purification conditions 
were initially sought but resulted in recovery of extremely low-levels of protein 
obtained. As determined by SDS-PAGE, greater than 90 % of the recombinant protein was 
present in inclusion bodies. As a result, purification of recombinant hnRNP A3 to 
homogeneity was achieved by solubilising it in a high concentration of guanidine- 
hydrochloride. Denatured protein was affinity purified by metal chelating chromatography 
and RP-HPLC. As with hnRNP A2, purified hnRNP A3 was soluble in water, which does 
not display buffered capabilities and therefore may lead to subsequent solubility issues 
when these proteins were used in experiments using buffered conditions, was the only 
option for re-solubilising the recombinant proteins generated. As with the hnRNP A1, A2 
and A3 deletion constructs lacking the glycine-rich domain were soluble at higher 
concentrations and solubility issues were not a concern following denaturing RP-HPLC as a 
final purification step. 
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Figure 3.3: Purification summary of the hnRNP A1 His-tagged constructs. Purified hnRNP 
A1 fractions comprising the different His-tagged constructs were IMAC purified and analysed 
by SDS-PAGE and visualised by Coomassie Blue staining. The molecular weight (MW) 
standard is represented on the left in units of kDa. Overnight culture cells (O/N) represent the 
insoluble proteins; supernatants (S/N) contain the soluble fractions of the proteins; F.TH, 
represents the flow-through fractions; W1 and W2 represent the washing steps. Elution steps 
(E1 and E2) contain the tagged hnRNP A1 constructs NC, N and C (construct not containing 
the glycine-rich domain). 
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Figure 3.4: Revers-phase HPLC purification of short construct of recombinant hnRNP A1-
N. (Top Panel) Fractions obtained from size exclusion were purified using a 10 
mm x 250 mm C4 reverse phase HPLC column. Bound protein was eluted at a flow 
rate of 2 mL/min using a linear gradient of 5-65% acetonitrile (green) over 30 min 
and monitored at 214 nm (blue) and 280 nm. The major peak identified was 
collected and identified by SDS PAGE and mass spectrometry to contain highly purified 
hnRNP A1. (Bottom Panel) MALDI mass spectrum of purified recombinant human 
hnRNP A1. Reverse-phase HPLC purified recombinant human hnRNP A1 was analysed 
using MALDI-TOF mass spectrometry. Following data reconstruction, a sample mass of 
26,178 was generated. The peak observed at 69766. Da is believed to be a low 
abundance dimer form of the recombinant protein. 
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Figure 3.5: Western blot summary of the hnRNP A1 His-taged constructs. Purified hnRNP 
A1 fractions comprising the different His-tagged constructs were analysed by SDS-PAGE, 
and transferred to PVDF membranes and visualised by the Odyssey imaging system. The 
molecular weight (Mw) is represented on the left in units of kDa. hnRNP A2 is used as the 
known full-length control, and purified proteins contain the His-tagged hnRNP A1 constructs 
C, N and NC are indicated with antibodies (construct not containing the glycine-rich domain). 
 
3.2.2 Purification of recombinant hnRNP A2 and A3 deletion constructs. 
 
TALON-purified fractions of His-tagged recombinant A2 and A3 deletion constructs were 
obtained from Drs Michael Landsberg and Kim Moran-Jones. These deletion constructs 
encompass a variety of combinations of their modular domains (Figure 3.6 A). Their cDNAs 
were cloned into a thrombin-modified pET-30b+ expression vector, which is a vector for 
expression of N-termially S-tagged proteins with an enterokinase site. The partially purified 
TALON fractions of the RRM1, RRM2, RRM1 + RRM2 and RRM1 + RRM2 + 10-residue 
linker region deletion constructs were purified to homogeneity by reverse-phase HPLC using 
a semi-preparative C4 column and analysed by SDS PAGE (Figure 3.6 B). Following the 
removal of acetonitrile and TFA, samples were dissolved in Milli-Q water and their identities 
confirmed by MALDI-TOF mass spectrometry (Figure 3.7). The hnRNP A3 deletion 
construct (RRM1+RRM2+10-residue linker region) was TALON-purified then further 
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purified by size-exclusion chromatography by Andy Wang, University of Queensland, and the 
purity was assessed by SDS-PAGE.  
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RRM1 
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RRM1+2+10L 
 
 
 
G-rich domain 
 
 
 
 
hnRNPA3 
 
 
                                  1               115  127                         205     220                                                                                  379 
 
RRM1+2+15L 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 (A): Schematics of the full-length and deletion construct of recombinant hnRNP 
proteins generated. cDNAs encoding either full-length hnRNPs A2 and A3, or deletion 
constructs were cloned into appropriate bacterial expression vectors and expressed in E.coli 
BL21 cells. The orange sections represent RNA Recognition Motifs (RRMs) whilst the glycine-
rich domain is highlighted in green. The linker regions connecting the motifs are represented in 
yellow. Numbers indicating residues are outlined. 
  
 85 
	
  
 86 
Figure 3.6 (B): Reverse-phase HPLC purification of hnRNP A2-deletion 
constructs. Fractions obtained from TALON-purification were purified using a 10 mm 
x 250 mm C4 reverse phase HPLC column. Bound protein was eluted at a flow rate of 
2 mL/min using a linear gradient of 5-65% acetonitrile (green) over 30 min and 
monitored at 214 nm (blue) and 280 nm. (A). A; RRM1, (B). B; RRM2, (C). AB; 
RRM1+2, (D). ABC; RRM1+2+10-residue linker region. 
 
A) 
 
B) 
 
 
  
 
F
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Figure 3.7: SDS-PAGE of the hnRNP A2 deletion constructs. Fractions comprising the 
different deletion constructs were analysed by SDS-PAGE and visualised by Coomassie Blue 
staining. The molecular weight (MW) is represented on the left in units of kDa. Lanes 1-5 
contain the tagged A2-deletion constructs RRM1, RRM2, RRM1+2, RRM1+2+10L and GRD 
(glycine-rich domain). (B) Mass spectrometry of RRM1, RRM2, RRM1+2, RRM1+2+10L, 
and GRD. Expected and apparent masses are as follows (in KDa): RRM1 - 10696 ±1; RRM2 
– 9837 ± 1; RRM1+2 – 20975 ± 2; RRM1+2+10L – 10999 ± 1; and GRD – 19700 ± 2. 
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3.3 Protein/DNA interaction results 
 
hnRNP A/B family bind to ssDNA of the telomere repeat region and to the hTR template. In 
this study, we will test our recombinant proteins binding ability to ss-telomeric DNA and 
telomerase RNA. The hTR sequences to which these proteins bind have been determined. 
Also, it has been specifically defined which RRM of hnRNP A2 is involved in telomeric 
DNA binding as well as telomerase RNA (TR) binding and a model to illustrate the 
mechanism of the hnRNP A2 protein-DNA-RNA has been generated.  
3.3.1 Separation of single-stranded telomeric DNA binding proteins 
 
Synthesised biotinylated tetramers of telomeric-DNA Telo2, Telo4 and non-specific (NS) 
DNA (Appendix, Table B), labelled and control non-labelled, were immobilised on SA-
coated magnetic particles and incubated with HeLa cell extract. The Coomassie Blue stained 
gel identified a predominant group of proteins ranging from 31-44 kDa that bound to 
telomeric DNA, but not to the unlabelled beads and the non-specific DNA labelled beads 
(Figure 3.8). 
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Figure 3.8: Telomere repeat DNA-binding proteins recovered by an affinity pull-down 
assay. This figure shows putative hnRNPs bound to telomeric DNA Telo2 and Telo4. 
Streptavidin-coated magnetic particles were labelled with biotinylated Telo2, Telo4 and non-
specific DNA; NS. Telomeric DNA; Telo2 and Telo4 (Telo2: 5'- TAGGGTTAGGG) (Telo4: 
5'-TAGGGTTAGGGTTAGGGTTAGGG-3') were used to affinity-purify telomeric DNA 
binding proteins from HeLa cells extracts. Controls no-oligo (whole cell lysates) and NS (5'-
CAAGCACCGAACCCGCAAGTG- 3') showed no specific binding protein attached to the 
beads at expected Mw ranging from 30-45 kDa. Bound proteins were resolved on 12.5% 
SDS-PAGE and stained with Coomassie Blue. 
 
3.3.2 Analysis of predominant hnRNPs proteins by western blot 
 
To confirm that the hnRNP proteins were pulled down in the previous assay, immuno-blotting 
experiments were performed. Western blot analysis was performed on the eluted bead-bound 
proteins to determine the identity of the predominant group of polypeptides pulled down with 
telomeric DNA. POT1 was used as a positive control because it specifically binds telomeric 
ssDNA (Baumann and Cech, 2001). These showed that hnRNPs A1, A2 and A3 were bound 
to single-stranded telomeric DNA supporting earlier studies (Dallaire et al., 2000, Mckay and 
Cooke, 1992, Moran-Jones et al., 2005). The blots were probed with polyclonal anti-rabbit 
antibodies directed against hnRNPs A1, A2, A3 and POT1 (Figure 3. 9). These studies 
demonstrate that hnRNPs A/B bound specifically and robustly to telomeric DNA. 
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Figure 3.9: Analysis of telomere-binding proteins recovered by an affinity pull-down assay. 
Following resolution by SDS-PAGE, hnRNPs that pulled-down with telomeric DNA (Telo4) 
were transferred to PVDF. The membrane was then cut into sections and individually probed 
with polyclonal anti-rabbit antibodies directed against hnRNPs A1, A2, A3 and POT1 
(Sapphire Bioscience). Previous members of the laboratory had generated the rabbit anti-
peptide antibodies. The molecular masses of the telomere-end binding proteins were 
estimated by comparison with molecular weight standards (Lane 1). 
 
3.3.3 hnRNP A/B associate with telomeric ssDNA in vivo. 
 
Previous studies using ChIP assays have established that telomerase and hnRNP A1 are 
independently bound to telomeres in mammalian cells (Sharma et al., 2003, Zhang et al., 
2006) and protective of telomeres POT1 (Hockemeyer et al., 2006, Yang et al., 2005). In 
order to establish whether hnRNP A2 and A3 proteins can likewise access telomere ends in 
vivo, ChIP experiments were performed with whole cell lysates prepared from asynchronous 
HeLa cells. Ten percent of the original input sample prior to IP was also blotted to 
demonstrate enrichment of telomeric DNA following immune-precipitation. Each of the 
immune-precipitated hnRNP A/B paralogs was found to be associated with telomeric repeat 
DNA, indicating that there is an interaction of these proteins with the telomeric repeats in 
HeLa cells (Figure 3.10). These ChIP data do not prove that there is direct interaction 
between these molecules, but in concert with the results from the ICC, in vitro UV-cross- 
linking and biosensor experiments described below, demonstrate a specificity of direct 
interaction appears highly likely. 
 
Figure 3.10: Cheomatin immunoprecipitation of telomereic DNA using anti-rabbit hnRNP 
antibodies. Telomeric association of hnRNPs A1, A2, A3 and POT1 in asynchronous HeLa 
^0(.'
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cells as determined by ChIP. IP of telomeric DNA was achieved using antibodies directed 
against hnRNPs A1 and POT1 (positive control), A2, A3, or rabbit IgG (negative control). An 
additional no antibody (-Ab) negative control was also used. Following IP, samples were dot 
blotted and the presence of telomeric DNA was detected by hybridisation with a 32P-labelled 
telomeric probe. Ten percent of the original input sample prior to IP was also dot blotted to 
demonstrate enrichment of telomeric DNA. 
 
3.3.3.1 Immunocytochemistry (ICC) 
ICC experiments have shown that the hnRNP A/B proteins are mostly distributed within the 
nucleus but this localization is isoform dependent (Friend et al., 2008). Their nuclear 
localization is consistant with roles such as maintaining telomere length and biogenesis in 
nucleus. hnRNPs A/B colocalisation with each other was investigated in more detail by 
immuno-staining of endogenous and transfected GFP constructs, which found that their intra-
nuclear distribution was dependent on RNA integrity and active transcription (Friend et al., 
2008). 
 
The hnRNP A/B proteins were found to be distributed around the nucleoli during S-phase, 
(which is the part of cell cycle in which DNA is replicated). This conforms with their 
biogenesis role in various cell cycle stages. POT1 was used as a positive control (Figure 3. 11 
left panel). A recent study has shown that TERRA also stimulates POT1 binding to telomeric 
ssDNA by displacing hnRNPA1 from the ssDNA (Flynn et al., 2011). In early S-phase POT1 
reaches a critical concentration at telomeres, suggesting that the re-accumulation of TERRA 
after the S-phase helps to complete the RAP-to-POT1 switch on telomeric ssDNA (Flynn et 
al., 2011, Flynn et al., 2012) that forms a protective structure along with other proteins 
involved in the Shelterin complex (Baumann and Cech, 2001). For negative controls, HeLa 
cells were incubated with primary and secondary antibodies alone and counter-stained with 
DAPI (Figure 3. 11 right panel). 
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Figure 3.11: Immunocytochemistry to determine the distribution of hnRNPs in HeLa cells. 
HeLa cells were grown, synchronized, fixed and permeabilized at S-phase and the localization 
of hnRNPs A1, A2 and A3 was determined using rabbit polyclonal antibodies. The secondary 
anti-rabbit Alexa Fluor® 488 conjugated monoclonal antibody (green) and Alexa Fluor® 546 
conjugated monoclonal antibody (red) were combined with the primary antibodies. 
Enrichment of hnRNPs in S-phase is shown (Left panel): hnRNP A1 and A3 (green), and 
hnRNP A2 (red). POT1 protein was used as a positive control since gel-shift assays have 
shown that it binds telomeric DNA (Loayza et al., 2004). Overlay images show the 
enrichment of the proteins in green and red against the background DNA (blue). Negative 
controls (Right panel) show cells in combination with DAPI by itself, primary antibodies 
alone and secondary antibodies alone. 
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3.3.4 Electrophoretic mobility shift assay (EMSA) UV-cross-linking of hnRNPs A1, A2 
and A3 to telomeric DNA repeats 
 
Irradiation of protein-nucleic acid complexes with ultraviolet light causes covalent bonds to 
form between the nucleic acid and proteins that are in close contact with the nucleic acid. 
Thus, UV crosslinking may be used to selectively label DNA-binding proteins based on their 
specific interaction with a DNA recognition site. 
 
I used electrophoretic mobility shift assays (EMSA) to determine the minimum number of 
telomeric-DNA repeats needed for binding by hnRNP A/B proteins. Earlier studies had 
proposed that multiple repeats were necessary for binding by these proteins (Dreyfuss et al., 
1993, Huang et al., 2008, Wang et al., 2012). The EMSA showed that hnRNPs A1, A2 and 
A3 all bound to telomeric ssDNA and notably, only a single telomeric repeat was required for 
a robust interaction with the hnRNP A/B paralogs (Figure 3.12). In the latter experiments 
SPR and REMSA showed that the RRM domain of hnRNP not only specifically bound to 
telomeric DNA but was also able to bind to telomerase RNA (Figures 3.15 & 4.5). That 
binding requires only one telomeric repeat is consistent with the finding by (Wang et al., 
2011) that human telomerase requires a minimum of 8 nucleotides or 12 nucleotides of 
ssDNA at the 3′ end of the telomere to facilitate elongation. If the hnRNPs A/B compete with 
telomerase for access to the binding site on the telomeric DNA, this would hinder the 
extension process and contradict the proposed role of hnRNP A/B in recruiting telomerase to 
telomeric ssDNA. 
 
Since the magnetic particle pull-down assays had indicated a strong and specific interaction 
between telomeric DNA and hnRNP A/B proteins, electrophoretic mobility shift assays 
(EMSA) were initially used to address the binding interaction between single-stranded 
telomeric DNA and hnRNPs A2 and A3. Early attempts at EMSA experiments proved to be 
inconclusive as no DNA-protein complex was resolved following native PAGE separation 
(data not shown). Two possible reasons for this failure to detect a protein-DNA complex were 
either that the protein had precipitated in the wells of the native gel, or alternatively, the 
isoelectric points of the proteins (which range between 8.46 and 9.2) were too close to the pH 
of the native gel and therefore did not migrate under the conditions used in the EMSAs. 
Problems with hnRNP A/B proteins solubility in EMSA experiments have been observed by 
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another member of the laboratory (Dr Moran-Jones). To overcome this, UV-crosslinking 
experiments were employed in which, following incubation of the recombinant protein with 
DNA, samples were UV-crosslinked before SDS-PAGE separation. 
 
	
Figure 3.12: EMSA UV-cross-linking of telomeric DNA with recombinant hnRNP A1, A2 
and A3 proteins. Recombinant hnRNPs proteins were titrated at (0.0, 0.5, 1.0, 1.5, 3.5, 7.5, 
15 and 30 pmol), and UV-cross-linked with 32P end-labelled telomeric probe (Telo1 (A); 
Telo6 (B)). The resulting DNA-protein complex was resolved by 12% SDS-PAGE and 
exposed to a phosphor screen. Recombinant hnRNPs A1 and A2 were successfully bound to 
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single telomeric DNA (Top and Middle of panel A) at a concentration of 1.5 to 30 pmol and 
to Telo6 at a concentration 1.5 to 30 pmol (Top and Middle of panel B). hnRNP A3 was 
successfully bound to single telomeric DNA at higher concentrations compared to A1 and A2, 
from 7.5, 15 and 30 pmol (Bottom of panel A) and to Telo6 at concentration 7.5, 15 and 30 
pmol (Bottom of panel B). 
 
A complex comprising hnRNPs A1, A2 and A3, along with either the single or hexameric-
repeat telomeric probe was observed (Figure 3.12). In contrast, faint or no complex band was 
visualised by incubating hnRNPs A1, A2 and A3 with anti-sequences (either the monomeric 
or the hexameric DNA repeats) and non-specific DNA sequence (NS). Given that these 
proteins possess a non-specific DNA binding site (Shan et al., 2000) it was expected that they 
would efficiently bind the anti-telomeric sequences and the non-specific DNA sequence non-
specifically in the absence of heparin (Figure 3. 13). 
 
Previous studies (Moran-Jones et al., 2005, Munro et al., 1999, Shan et al., 2000) have shown 
that hnRNPs A2 and A3 have two binding sites for oligonucleotides, one that is non-specific 
(i.e., shows little differential binding to a variety of different sequences) and another more-
selective site. Binding to the non-specific site is eliminated in the presence of 5–10 mg/ml 
heparin. In our UV-cross-linking experiments heparin was excluded to eliminate the 
possibility that heparin may also block the specific site and hinder the binding of recombinant 
proteins. Under these conditions we expected that the non-specific site would bind the 
Anti1oigonucleotide, as is (faintly) evident (Figure 3. 13). To investigate hnRNP binding 
specificity to telomeric ssDNA more closely, competitive EMSA was conducted. 
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Figure 3.13: Interaction of telomeric DNA sequences and hnRNPs A1, A2 and A3 as 
detected by EMSA. Recombinant hnRNP A1 (Top), A2 (Middle) and A3 (Bottom) were UV-
cross-linked with 32P end-labelled telomeric probe (Telo1; Telo6) or its reverse complement 
(Anti1; Anti6) and non-specific (NS) DNA. The resulting DNA-protein complex was 
resolved by 12% SDS-PAGE and exposed to a Phosphor screen. DNA probes without protein 
were used as controls. DNA-protein complexes formed are indicated. Recombinant hnRNPs 
were able to bind with high specificity and intensity to Telo1 and Telo6, whereas non-specific 
bindings showing faint bands were detected with other DNA probes. 
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3.3.5     Competitive EMSA of hnRNPs A2 and A3 bind telomeric DNA through its 
specific site 
 
Previous work has shown that endogenous hnRNP A2 has a site that is capable of binding to 
ssDNA sequences with little or no sequence preference (Moran-Jones et al., 2005, Shan et al., 
2000). Given the high degree of sequence identity at the protein level, the same conclusions 
can be inferred for hnRNPs A1 and A3. To investigate whether hnRNPs A1, A2 and A3 are 
interacting with telomeric DNA via their sequence-specific binding site, competitive UV-
cross-linking experiments were employed to show that the specific binding between the 
recombinant proteins with 32P-labelled telomeric repeats can not be interrupted in the 
presence of unlabelled excess anti-telomeric repeat or non-specific DNA NS.  
 
A 32P end-labelled Telo1 oligonucleotide was incubated with 30 pmol of purified recombinant 
protein in the presence or absence of a 50-fold molar excess of unlabelled (cold) Telo1, Anti1, 
or NS DNA. Pre-incubation of recombinant hnRNPs A1, A2 and A3 with a 50-fold excess of 
the unlabelled single-repeat Telo1 probe was sufficient to significantly diminish the complex 
formed between these proteins and labelled telomeric DNA (Figure 3. 14). With hnRNP A3 
the 50-fold excess of cold Telo1 was successful in diminishing the complex formation 
compared with labelled Telo1 and hnRNP A3 showed a clear signal. The anti telomeric DNA 
sequence (Anti1) is a good candidate as a control, based on a previous study that showed that 
hnRNPs A1 and A2/B1 do not bind strongly to the C-rich sequence complementary to the 
TTAGG ssDNA. Further more, telomerase RNA template (AAUCCC) that complement to 
telomeric repeats posed a question mark; if hnRNP A/B proteins showed binding ability to it. 
Thus, Anti telomeric repeat was necessary to be used in order to eliminate any possibility that 
hnRNPs A/B proteins could block DNA and RNA sites.  
 
A 50-fold excess of Anti1 (and Anti6) was unable to out-compete Telo1 binding to the 
specific sites of hnRNPs A1, A2 and A3. However, a non-specific DNA sequence (NS) was 
able to interact with hnRNPs A1, A2 and A3 and reduced the signal between the proteins 
and labelled Telo1 suggesting that NS was acting as a competitor. The decrease in complex 
formation seen when the NS-DNA was used as a competitor may be attributable to a portion 
of the labelled telomeric DNA being sequestered in a double-stranded form by 
complementary base pairing with the NS-DNA. Given that hnRNPs A/B bind single-
stranded, not double-stranded DNA/RNA (Dreyfuss et al., 2002, Dreyfuss et al., 1993, 
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Huang et al., 2010, Huang et al., 2008), the formation of double-stranded DNA, and the 
concomitant reduction in the available single-stranded Telo DNA, could account for the 
decrease in the observed of single- stranded Telo-hnRNP A/B complex. 
 
It has been previously shown that hnRNP A2 binding fits a two-binding site model 
system, possessing sequence-specific and non-specific DNA and RNA binding sites 
(Moran-Jones et al., 2005, Munro et al., 1999, Shan et al., 2000). The non-specific binding 
site is blocked by the addition of heparin, which is a polyanionic glycosaminoglycan 
commonly used to counter non-specific DNA-protein interactions. Given that hnRNPs did 
not bind Anti DNA non-specifically, SPR experiments were employed to determine 
whether the interaction between hnRNP proteins and telomeric DNA was mediated 
through the sequence-specific or non-specific by including Anti DNA. 
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Figure 3.14: Competitive EMAS UV-cross-linking of telomeric DNA sequences and 
hnRNPs A1, A2 and A3. Recombinant hnRNPs A1 (Top), A2 (Middle) and A3 (Bottom) 
were incubated with 32P end-labelled Telo1 probe in the presence or absence of a 50-fold 
molar excess unlabelled competitor probe Telo1, Anti1, and NS. The excess unlabelled Telo1 
probe reduced the signal between the radiolabelled Telo1 probe and hnRNPs A1, A2 and A3, 
indicating that the recombinant proteins were able to bind the “cold competitor”. In contrast, 
the excess unlabelled Anti1 DNA did not diminish the complex formed with the radiolabelled 
Telo1 probe and hnRNPs, indicating that Anti1 “cold competitor” was unable to outcompete 
binding of Telo1 to the specific site of hnRNPs A1, A2 and A3. The NS competitor was 
capable of interacting with hnRNPs A2 and A3 via the non-specific binding site and reduced 
the signal between the proteins and labelled Telo1 probe, except for hnRNP A1. 
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3.3.6 Surface Plasmon Resonance (SPR) shows the intensity of binding of hnRNPs to 
the telomeric repeats 
 
Surface plasmon resonance (SPR) is a sensitive technique which produces high quality 
binding data for bimolecular interactions including protein-DNA interaction analysis. This 
technique was used to derive the rate and equilibrium constants for telomeric DNA repeat 
binding in vitro to hnRNPs A1, A2 and A3 to extend the conclusions, drawn above from 
UV-cross-linking experiments. A single-repeat biotin-labelled telomeric DNA (Telo1) and 
its reverse complement (Anti1) were immobilised in separate flow cells on a SA-coated 
biosensor chip and recombinant proteins were passed through the flow cell. It was found that 
all hnRNP A/Bs (A1, A2 and A3) bound to the immobilised Telo1 but not to Anti1 (Figure 3. 
15 A). Additionally, the RRM2 of hnRNP A2 was found to be bind to telomeric ss-DNA 
sufficiently and the tandem RRMs such as RRM1+2 and RRM1+2+10 were strengthened 
this binding.  
 
Furthermore, in the SPR experiments, hnRNPs A1, A2 and A3 have shown rapid recognition 
and binding with Telo1 characterised by a high association constant rate. To evaluate the 
strength of an interaction and the extent to which that interaction might occur in the cell, a 
kinetic binding assay was conducted. Each protein was injected with increasing 
concentrations (0.0 µM to 100 µM) through the flow cell, and the biosensor response was 
recorded on binding of individual hnRNPs to Telo1. The association rate constant (Ka) of 
hnRNP A1, A2 and A3 has ahown a variation interaction of these proteins with Telo1, and 
estimated to be 5.85 x 104 Ms, 7.71 x 104 Ms and 9.6 x 104 Ms, respectively (Table. 3.1).  
 
The high-affinity interaction that was expressed as the equilibrium dissociation constant (KD) 
of the hnRNPs A1 and A2 was a comparatively strong interaction with Telo1 compared to A3 
with values of 2.02 nM, 1.36 nM and 7.8 nM, respectively, based on the response unit 
difference of seven different concentrations (Figure 3. 15 B, C and D). In addition, the hnRNP 
A2 domains that interacted with the telomeric repeat were identified from biosensor data 
which showed that both RRMs of the hnRNP A2 are necessary to form strong binding with 
single-stranded telomeric DNA (Figure 3. 15 E), and low stringency binding for RRM2, more 
explanations of the results come in detail in discussion section.  
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Earlier studies undertaken in our laboratory (unpublished data) showed that following the 
addition of heparin, the binding response  (RU) obtained at seven concentrations of 
hnRNP A2 binding to immobilised telomeric DNA diminished by slightly over half. 
This indicated that under the presence of heparin (which blocks the non-specific site), 
binding of hnRNP A2 to telomeric DNA was mediated solely through the specific site 
whereas, the absence of heparin allowed binding to proceed through both the sequence-
specific and non-specific site. The kinetic data was analysed using BIAevaluation 
software, version 4.1. The dissociation constant (KD) obtained by hnRNP A2 in the 
presence of heparin reflects binding of single-stranded telomeric DNA to the specific site 
only. An appropriate model was chosen to globally fit the experimental data as reflected 
by the *2 values obtained (which are below background noise; 2 RU).  
 
The individual binding and dissociation curves of hnRNP A2 were aligned at t = 0 (the start 
of each injection) and background noise was removed to give rise to the final data set. 
Following this, the interaction between hnRNP A2 and ssTelo-DNA (Figure 3.15 F) 
(black sensograms) was fitted globally across the data sets using the 1:1 Langmuir 
binding interaction (red traces), which describes 1:1 binding between analyte (hnRNP 
A2; A) and ligand (Telo DNA; B) (Figure 3.15 F). 
 
Our SPR finding is consistent with a previous report in that when the co-crystal structure of 
UP1 complexed with telomeric DNA, 31 amino acid residues of UP1 make direct contact 
with the telomeric repeats (Ding et al., 1999). Given the high sequence identity between the 
hnRNPs A1 and A2, 70%; A1 and A3, 80%; and A2 and A3, 75% identity across the tandem 
RRMs at the protein level (Tang et al., 2012), it was predicted that the residues in direct 
contact with telomeric DNA would be conserved within the hnRNPs A2 and A3 as well. This 
prediction has been tested and confirmed by bioinformatics using a ClustalW protein 
alignment program of the hnRNP A/B proteins, and UP1-telomeric DNA-binding (Figure 3. 
16). However, it has been noted that hnRNPs A1 and A2/B1 do not bind strongly to the C-
rich sequence complementary to the single-stranded TTAGGG repeat (Bandiera et al., 2005, 
Dallaire et al., 2000, Eversole and Maizels, 2000, Kamma et al., 2001). This is consistent with 
this study’s biosensor data shown below and with what has been proposed by a recent study 
showing that the active site of hTR (CCAUC) is unoccupied during template translocation (Qi 
et al., 2012). 
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Table 3.1: Rate constant and affinities obtain from the interaction between recombinant 
hnRNP proteins and telomeric DNA. The 1:1 Langmuir binding model was used to fit 
kinetic data for the interaction between hnRNP A2 and single-stranded telomeric 
DNA. Association rates (ka), dissociation rates (kd) and dissociation constants 
(KD=kd/ka) are given. 
hnRNPs	 ka	(1/Ms)	 Kd	(1/s)	 KA	(1/M)	 KD	(uM)	
hnRNP	A1	 5.85	x	104	 1.18	 4.95	x	107	 20.2	
hnRNP	A2	 7.71	x	104	 1.05	 7.36	x	107	 13.6	
hnRNP	A3	 9.6	x	104	 7.5	 1.3	x	107	 78	
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Figure 3.15: Biosensor measurements of recombinant hnRNPs A1, A2 and A3 with 
telomeric DNA (Telo1).  (A) Biosensor measurements of interactions of Telo1 and Anti1 with 
hnRNPs were performed. Recombinant hnRNPs A1, A2 and A3 full-length (80 µM) were 
injected across the biosensor surface bearing either single-stranded telomeric DNA Telo1, or 
its complement Anti1. Biosensor responses were recorded at a flow rate of 40 µl/min in HBS-
T running buffer (B, C and D). Biosensor kinetic measurement of DNA-hnRNPs recombinant 
proteins showed binding of telomeric ssDNA to hnRNPs A2, A1 and A3 respectively. 
hnRNPs concentrations in µM are given at right from 0-100 µM. The protein solution was 
passed over the immobilised telomeric DNA at a flow rate of 40 µl/ min in HBS-T running 
buffer. (E) Biosensor analysis of the association of hnRNP A2 domains and single-stranded 
telomeric DNA (all at 80 µM) were separately passed over a single-stranded telomeric DNA 
biosensor surface. The biosensor responses were recorded at a flow rate of 40 µl/min in HBS-
T running buffer. (F) Biosensograms are presented for the interaction of hnRNP A2 and 
single-stranded telomeric DNA. A concentration range (0-100 nM) of hnRNP A2 was 
analysed across the immobilised telomeric DNA at a flow rate of 40 µL/min in HBS 
running buffer. The black traces represent the experimental data whereas the red traces 
represent the global fit of the data to a 1:1 Langmuir binding model. 
 
3.4 DISCUSSION 
 
This chapter has described the expression and purification of protein constructs encompassing 
either full-length hnRNPs or a variety of deletion constructs designed around their 
constitutive structural domains.  
The solubility issues resulting from the expression of full-length recombinant hnRNPs has 
been observed by others (Prof. Adrian Krainer and Dr Trent Munro, personal communication) 
and previously reported for hnRNP A1 (Casas-Finet et al., 1993). In addition, because of the 
homology shared by hnRNP A/B family members, pre-existing purification methods of this 
protein tend to result in insufficiently pure protein, and the loss of large portion of the protein. 
As such a recombinant protein system is used in order to study this protein. With respect to 
hnRNP A3, little is known about it and no purification system has been detailed, although it is 
likely that existing purification methods for other hnRNP A/B proteins could be used. 
However, because of the homology, it is possible that multiple proteins would be isolated, 
leading to contamination from other hnRNP A/B proteins. Moreover, rom tissue studies 
performed in Xenopus laevis, the expression of hnRNP A3 mRNA appears to be 1/10th that of 
hnRNP A2 in most tissues (Good et al., 1993) making it even more practical to use a 
recombinant protein system to study this protein. 
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One of the most problems of using recombinant proteins, is the possibility that the proteins 
expressed within the bacteria are not folded correctly, and thus have either no function, or a 
function differing from that of the native protein. Although no attempt was made to determine 
the conformational stability of the expressed proteins during the course of this project, the fact 
that the individual proteins exhibited differential binding of nucleotide sequences, and, for 
hnRNPs A1, A2, and A3 binding similar to that of native protein, suggests that these 
recombinant proteins are in fact correctly folded. Additionally, a number of studies have been 
documented in the literature whereby recombinant proteins containing single RRMs have 
been produced, and their structures examined by NMR or X-ray crystallography. These 
papers are contain no mention or describing of having to perform denaturation/renaturation 
procedures to ensure correct folding, and as such, it was felt that these techniques were less 
important, as long as, that the results gained with the recombinant proteins are indicative of 
function of the native proteins.  
 
It was found that diluted samples (<1 mg/ml) were less likely to precipitate. Protein solutions 
were kept at –20 °C for storage.  Deletion constructs lacking the glycine-rich domain were 
found to produce soluble products, which have been successfully used in vitro (Landsberg et 
al., 2006). The early work on these proteins was mainly done on the UP1 peptide probably 
because it is soluble and therefore amenable to biochemical analysis. Additionally, the 
identities of recombinant full-length and deletion products were confirmed by mass 
spectrometry (see figure 3.4 and 3.7). 
 
As with the hnRNP A/B deletion constructs lacking the glycine-rich domain were soluble at 
higher concentrations and solubility issues were not a concern following the denaturation 
process of RP-HPLC as a final purification step. The experiments in this chapter have 
characterised the interaction of vertebrate single-stranded telomeric DNA repeat (TTAGGG) 
with recombinant hnRNPs A1, A2 and A3. Several observations by others have suggested 
hnRNPs play an important role in telomere biology. A role for hnRNPs A1, A2 and A3 in 
telomere biology was hypothesised from the observations that hnRNPs A/B share high 
sequence conservation and have many redundant roles within the cell. hnRNPs A2 and A3 
share greater than 80% sequence identity with hnRNP A1 across the tandem RRMs and are 
therefore likely to share the typical RRM fold that is adopted by hnRNP A1, and its 
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telomeric-DNA binding capabilities. hnRNPs A2 and A3 both interact with the cis-acting 
A2RE transport element contained within the 3’ UTR of MBP mRNA.  
 
The bioinformatic analysis of the UP1 residues involved in telomere binding was a first 
attempt investigation. As (Figure 3.16) demonstrates, alignment of the region involved in 
binding telomeric DNA along with the corresponding regions in hnRNPs A2 and A3 showed 
that of the 31 residues identified in making direct contact with telomeric repeats, all but two 
were completely conserved. The other two residues also represent conservative substitution 
involving basic residues, with an arginine (residue 178) to lysine substitution between 
hnRNPs A1 and A3, and a lysine (residue 183) to arginine substitution between hnRNPs A1 
and A2. Thus, because of the high sequence identity between the telomere-binding UP1 and 
hnRNPs A2 and A3, it is unlikely that they would preclude an interaction with single-stranded 
telomeric DNA. 
 
The co-crystal structure of unwinding protein 1 (UP1) complexed with telomeric DNA has 
been revealed and the residues involved in binding have been identified. Thirty-one amino 
acid residues of UP1 make direct contact with telomeric repeats (Ding et al., 1999). Given the 
high degree of sequence identity between the hnRNPs (A1 and A2, 70%; A1 and A3, 80%; 
and A2 and A3, 75% identity across the tandem RRMs at the protein level), it was predicted 
that the residues in direct contact with telomeric DNA would be conserved within the A/B 
family. This prediction has been tested by using a ClustalW protein alignment program of the 
hnRNP A/B proteins, and UP1-telomeric DNA-binding residues were emphasised (Figure 
3.16). 
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Figure 3.16: ClustalW aligment between hnRNP A/B family members and the region in 
UP1 shown to interact with telomeric DNA. The residues that make direct contact with 
telomeric DNA are highlighted in yellow, whilst the red asterisks indicates telomeric DNA 
contact residues lysine and arginine that are not conserved amongst the A/B family members. 
The regions corresponding to the RNA Recognition Motifs (RRM1, RRM2) are underlined in 
blue. The residue numbers are shown at the end of each line. 
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The in vitro affinity assays identified a group of polypeptides ranging from 35 to 46 kDa in 
size that were pulled-down with telomeric DNA oligonucleotides but not by oligonucleotides 
containing a randomised DNA sequence or beads alone (Figure 3. 8). In 1998, Hoek 
conducted a similar experiment with oligonucleotides containing the hnRNP A2 response 
element (A2RE) and found an identical pattern of protein bands (Hoek et al., 1998). These 
proteins were investigated by Western blot analysis and identified as hnRNPs A1, A2/B1, and 
A3 (Figure 3. 9). Although hnRNP A/B proteins were pulled-down by the immobilised 
telomeric DNA; other proteins such as POT1 (both alternative spliced isoforms 38 and 71 
kDa) (Baumann and Cech, 2001), known to specifically bind and interact with the single-
stranded telomeric overhangs (Lei et al., 2004), were successfully pulled down as well and 
identified by Western blot (Figure 3. 9). It is likely that other less abundant proteins may be 
hidden amongst hnRNP A/B or background staining. Therefore, other single-stranded 
telomere binding proteins were visible on the Coomassie Blue-stained gel, which are nuclear 
proteins other than histones. POT1 only associates with telomeres whereas hnRNPs A1, A2 
and A3 participate in other nuclear tasks (such as alternative splicing) and are therefore far 
more abundant and easy to detect. The lack of ability to visualise other single-stranded 
telomeric DNA binding proteins was additionally supported by a similar experiment 
conducted by McKay and Cooke, which also identified hnRNP A2 as the predominant protein 
interacting with immobilised single-stranded telomeric oligonucleotides (Mckay and Cooke, 
1992). Magnetic beads also were able to selectively purify the hnRNP A/B polypeptides. The 
magnetic particle pull-down assay was specific as heparin was included at a concentration of 
10 mg/ ml, which is regularly used to reduce non-specific DNA-protein interactions. 
At the same time as the magnetic particle binding assay addressed the issue of non-specific 
binding by using heparin, it did not distinguish or classify if the pull-down of hnRNPs A/B by 
telomeric DNA was attempted by a direct (protein-DNA) or indirect (protein – protein) 
interaction. The latter interaction was a strong possibility as hnRNP A/B are capable of 
protein-protein interactions, probably though their glycine-rich C-terminal domain (Haynes, 
1992), however, the EMSA and other evidence supported a direct interaction of hnRNPs A1, 
A2 and A3 with single-stranded telomeric DNA. 
Other experiments such as UV-cross-linking, SPR and ChIP have confirmed that telomeric 
DNA, either the single or hexameric repeat, was bound specifically by hnRNPs A, A2 and 
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A3. A very weak interaction was seen when hnRNPs A1, A2 or A3 were incubated with the 
non-specific sequence of DNA (NS) and Anti probe, which represents the cytosine-rich strand 
of telomeres (Figures 3.13). Whereas in figure 3.14, NS was able to compete with telo to the 
binding site of hnRNP A/B family, this will be discuss in page 132. 
Although heparin was not involved in these experiments because it may have occupied the 
binding site and precluded the binding interaction between the protein and the DNA, non-
specific DNA-protein interactions mediated by the non-specific hnRNP-binding site should 
have taken place. Earlier studies undertaken in the current study’s laboratory indicated that 
hnRNPs A2 and A3 consist of two binding sites, one that does not discriminate between 
nucleic acid sequences, and another which is specific for particular DNA/RNA sequences 
(Hoek et al., 1998, Moran-Jones et al., 2005, Munro et al., 1999, Shan et al., 2000). Moreover, 
the non-specific binding site has been shown to recognise widely different sequences and also 
bind in lower affinities (Shan et al., 2000, Snee et al., 2002). 
This favours their suggested roles in multiple RNA processing steps. To confirm that the lack 
of interaction observed was not due to DNA length requirements of the non-specific site, a 
hexameric single-stranded Anti DNA (36-mer) was included, which demonstrated similar 
findings. 
Figure 3.14 of the competitive UV-cross-linking experiments validates that the interaction 
between hnRNPs A1, A2 and A3 and telomeric DNA was direct and highly specific. The 
telomeric DNA-hnRNP complex detected was either entirely abolished or considerably 
reduced when excess unlabelled single-stranded Telo1 DNA was involved as a competitor. 	
UV-cross-linking experiments have elicted an additional finding; hnRNPs A1, A2 and A3 
bound quite robustly to the single-repeat of single-stranded telomeric DNA. In addition to in 
vitro experiments using recombinant hnRNPs A1 and D and the co-crystal structure of 
UP1/telomeric DNA, all showed that these proteins only bound as a minimum, 
oligonucleotides bearing dimeric-TTAGGG repeats (Ding et al., 1999, Eversole and Maizels, 
2000, Zhang et al., 2006). Although, these proteins have an analogous tertiary structure, their 
mode of binding to telomere is not same.  
Surface plasmon resonance SPR experiments (Figures 3.15), which were used to characterise 
and distinguish between the two modes of binding telomeric DNA (specific and non-specific), 
showed that the interaction was mediated though the sequence-specific binding site. And that 
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because in the delineated RRMs SPR experiment, RRM2 bound specifically to the telomeric 
DNA, while RRM1 nor GRD domains were able to bind to the same ssDNA in absence of 
heparine. The disassociation constant (K
D
) was obtained for the specific sites of hnRNPs A1, 
A2 and A3 based on the response unit difference of seven different concentrations and globe 
fits data for hnRNP A2 (Figure 3.15 B, C, D and F).  
The delineated regions (RRMs) of hnRNP A2 that are involved in binding telomeric DNA 
were tested as well by SPR experiments. An earlier study proposed that while RRM2 bound 
single-stranded telomeric DNA, the tandem RRMs were strengthened and found to be 
sufficient and necessary for the interaction (Moran-Jones et al., 2005). Furthermore, the 
glycine-rich domain, which is able to interact with nucleic acid sequences, was not directly 
involved in binding the telomeric sequence. In agreement with those findings, the biosensor 
assay (Figure 3.15 E) suggests that the single domains (RRM1 or the glycine-rich domain) 
were unable to interact with telomeric DNA. These experiments indicate that RRM2 is able 
minimally to mediate an interaction, whereas both RRMs of hnRNP A2 are essential for an 
interaction to be formed.  
Finally, while the specificity of hnRNPs A/B binding ability to telomeres has been 
demonstrated in vitro, it is unclear whether these proteins can access telomeric ends in vivo or 
not. It has been confirmed by ChIP experiments that nuclear-bound hnRNPs A1, A2 and A3 
in human HeLa cells are telomere-associated in vivo (Figure 3.10). This finding has revealed 
direct binding in vivo, and supported by previous study in 2005, by Moran-Jones and 
colleagues that presented a co-localisation, with telomeric DNA in both telomerase-positive 
and ALT positive cell lines instead of direct interaction. Moreover, another study identified in 
ChIP experiments that hnRNP A1 substantially associated with telomeric DNA, and also 
revealed that hnRNP A1 bound telomeric DNA in vivo (Zhang et al., 2006). 
3.5 SUMMARY 
 
This chapter has thoroughly explained the large-scale expression and purification of full-
length hnRNPs A/B, in addition to the hnRNP A2-deletion constructs to homogeneity. 
The experiments described previously were performed in order to optimise the interaction of 
the vertebrate single-stranded telomeric repeat with hnRNPs A1, A2 and A3 in a comparison 
with hnRNP A1. UV-cross-linking EMSA confirmed the interaction between telomeric DNA 
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and recombinant hnRNPs A1, A2 and A3 were mediated requiring at least the presence of a 
single or a mono repeat of telomeric DNA, in contrast to the dimer. Additionally, SPR 
experiments determined the KD of the three recombinant hnRNPs A1, A2 and A3 in the nano-
molar range. These experiments identified that the hnRNP A2 tandem RRM domains were 
essential and adequate to mediate an interaction with telomeric DNA. Furthermore, both UV-
cross-linking and SPR experiments determined that hnRNPs A1, A2 and A3 were unable to 
bind the C-rich (Anti) telomeric repeat. Lastly, hnRNPs A1, A2 and A3 are telomere-
associated in vivo, as has been revealed by ChIP experiments, might count as the first stated 
study of a direct in vivo association of these proteins with telomeric DNA. 
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Chapter	4:	
4 PROTEINS AND RNA INTERACTION RESULTS 
4.1 INTRODUCTION 
 
This chapter is investigating the possible binding of hnRNP recombinant proteins to hTR 
segments including the short derivatives (hnRNP A1ΔGRD), (hnRNP A2ΔGRD) and (hnRNP 
A3ΔGRD). Also to shed alight on the mechanism of binding between the hnRNPs A2 with 
telomeric DNA and telomerase RNA. 
 
Telomerase is a large RNP complex in vertebrates estimated to be about 1000 kDa that is 
required to outreach the linear chromosome ends in order to facilitate the elongation process. 
Telomerase in all species comprises two essential subunits. They is a unique reverse 
transcriptase (TERT; 127 kDa in humans), and an important RNA component (TR; 451 nt in 
humans) that are composed of a template of specific sequence that synthesize the telomere 
repeats (Greider et al., 1994). TRs (hTR and mTR) (Figure 4.1) of mammals are generally 
expressed in many tissues and throughout development progress, even in tissues without 
telomerase activity (Harrington, 2003). In addition, telomerase binding proteins, as suggested 
by biochemical and genetic evidence, may be involved in the biogenesis or assembly of 
telomerase, as well as in regulating and recruiting its access to telomeres (Cong et al., 2002). 
Accessing telomeres by telomerase has been suggested to be facilitated by telomerase 
alignment to the 3' end of telomeric ssDNA. In its “closed” T-loop structure, telomerase 
extension is inhibited. Whereas, during S-phase when the telomere ends are in an “open” 
linear form due to the disassembly of T-loops by the DNA replication machinery, telomerase 
can access and align to extend the 3' single-stranded overhang. In budding yeast, a model 
proposed that telomerase (comprising the catalytic subunit Est2 and the RNA template TLC1) 
is bound to capped telomeres in G1 phase through an interaction of TLC1 with the Ku 
heterodimer. Telomerase is removed from the telomere in early S phase, while Ku remains 
associated with chromosome ends. In late S phase the replication fork passage leads to the 
transient disruption of telomeric chromatin. For the telomere that derives from the replication 
of the leading strand, unidentified exonuclease activities (Exo) contribute to the formation of 
G-rich overhangs through a telomeric 5' resection that is controlled by Tel1 (the orthologue of 
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the DNA-damage-checkpoint kinase ATM), the Mre11–Rad50–Xrs2 complex (MRX) and the 
cyclin-dependent kinase Cdk1. ("The generation of G-tails creates binding sites for Cdc13, 
the extent of the resection being controlled by the heterotrimer Cdc13–Stn1–Ten1 (CST) and 
Rap1" (Gilson and Geli, 2007)). Telomerase recruitment remarkably shows a important 
preference for shorter telomeres, most extensively studied in budding yeast, in which a 
coherent picture of telomerase recruitment is beginning to emerge; the extent of conservation 
of these processes in mammalian cell is still unclear. Due to the insufficiency of both 
telomeres and telomerase within the nucleus, an active recruitment mechanism has been 
proposed (Collins and Mitchell, 2002). 
 
Many studies have suggested that hnRNP proteins are candidate proteins in undertaking the 
active recruitment role between telomeres and telomerase. Fiset and Chabot (2001) have 
shown that recombinant hnRNP A1 is able to bind simultaneously to the first 71 nt of hTR 
and telomeric DNA. Recombinant hnRNP C1/C2 is also capable of interacting particularly 
with a six base uridylate tract located 5’ to the template region of hTR in vitro (Ford et al., 
2000). Lastly, co-immuno-purified endogenous telomerase activity from cellular extracts was 
successfully achieved by using antibodies directed against hnRNPs A1, C1/C2 and D 
(Eversole and Maizels, 2000, Ford et al., 2000, Labranche et al., 1998). 
In vitro transcription experiments have demonstrated that both hnRNPs A1 (Fiset and Chabot, 
2001) and A2 (Moran-Jones et al., 2005) interact with the first 71 nt of hTR. This study 
assesses whether hnRNPs A1, A2 and A3 including their deletion constructs like other A/B 
members, are also able to bind hTR In vitro.  
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Figure 4.1: Human telomerase RNA. Diagrammatic representation of the predicted 
secondary structure of mammalian hTR with its telomeric template sequence (nucleotides 46 
to 53). Four universally conserved structural elements are boxed in grey. Arrows indicate the 
nucleotide position 5´ to 3´. Figure taken from Bachand and Autexier (2001). 
 
4.2 RESULTS  
4.2.1 Proteins-endogenous telomerase interaction 
 
hnRNPs A1, A2 and A3 were able to interact with single-stranded telomeric DNA repeat in 
previous experiments such as EMSA, Chip assay and SPR (See sections 3.3.4 – 3.3.6), and an 
interaction with native human telomerase was also investigated to identify if, like hnRNP A1, 
hnRNPs A2 and A3 are capable of interacting with telomeres and telomerase. The TRAP 
assay was applied to investigate a possible interaction with endogenous telomerase using 
HeLa cell extracts (Figure 4.2).  
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Figure 4.2: Amplification of TS-telomerase products by PCR. This figure was taken from 
TRAPEZE detection kit 7700. TS primer is elongated by telomerase to add telomeric repeats 
TTAGGG onto the 3’ end of a substrate oligonucleotide TS (step 1) at 37 ̊C. Amplification 
(PCR) of TS-telomerase products by using reverse primer (RP) and synthesis the 
complementary strand. Subsequent PCR cycles generate a ladder of products with 6 base 
increments starting at 50 nt (step 2). 
 
Telomerase activity in HeLa cell lysates was measured using TRAP (Figure 4.2) (Kim and 
Wu, 1997) and anti hnRNPs A1, A2 and A3 antibodies were used. Negative controls included 
no antibody, rabbit IgG, no lysate (lysate buffer alone), and heat-inactivated telomerase- 
lysate were used as recommended by the TRAPEZE detection kit 7700. Telomerase cell 
extracts and R8, which is an oligonucleotide with the same sequence as TS primer extended 
with 8 telomeric repeats AG(GGTTAG)7, were used as positive controls. These controls 
served as a standard estimating the amount of TS primers with telomeric repeats extended by 
telomerase in a given immunoprecipitated extract.  
 
Telomerase activity was detected in the immunoprecipitated proteins from HeLa cell lysates. 
This is consistent with the role of hnRNPs A/B in promoting telomere elongation and their 
ability to bind telomerase. Telomerase was selectively precipitated with antibodies to hnRNPs 
A1, A2 and A3. PCR products from an internal control eliminated the possibility of 
contamination or inhibitory factors in the PCR reactions. No activity was observed in the 
! 20!
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4. FURTHER MATERIALS/METHODS NECESSARY O COMPLETE THE PROJECT: 
A series of experiments need to be conducted to complete the project. For instance, Surface 
Plasmon Resonance (SPR) is a useful technique to inspect the interaction of recombinant 
hnRNPs proteins with presence or absence of their RRMs, against telomeric DNA. RNA 
Electrophoretic Mobility Shift Assay (REMSA) is one of the most important assays that allow 
me to investigate the i te action of the recombinant hnRNPs protein  and their RRMs against 
transcribed RNA hTR. Furtherm r , Fluorescence in situ hybridization (FISH) or Chromatin 
Immunoprecipitation (ChIP) will help to identify weather these proteins can gain access to the 
ends of the chro osomes or not in order to aintain an adequate telomeres length. 
 
 
4.1 Surface plasmon resonance (SPR) 
SPR is a real-time kinetic measurement of the interaction of unlabeled biological molecules at 
surfaces. I will use this technique to investigate the interaction between hnRNPs (A1, A2 and 
A3) and telomeric DNA using a BIAcore 3000 surface plasmon resonance (SPR) biosensor 
instrument (BIAcore AB, Uppsala, Sweden) in order to calculate the rate constants and 
affinities for the interactions between hnRNP paralogs and telomeric DNA. 5’ biotinylated 
oligonucleotides will anchored on research grade streptavidin- coated (SA) Chips (BIAcore). 
!
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absence of hnRNP A/B antibodies, anti-IgG immunoprecipitation, or following heat 
inactivation of the cell lysate. Thus, active telomerase can be pulled down with hnRNP A/B in 
HeLa cells. TRAP reactions are very sensitive and therefore even small amounts of 
telomerase activity (remaining after washing of IP samples) can give rise to false signals. For 
example in (Figure 4.4) the IgG lane shows a trace signal at 50 bp this band is not a 
representation of telomerase activity that has been pulled-down but showed a background of 
non-specific antibody binding. 
 
 
Figure 4.3: Detection of telomerase activity. Telomerase positive extracts (+ve) were 
supplied with the Kit; anti-hnRNP A1, anti-hnRNP A2 and anti-hnRNP A3 antibodies were 
immunoprecipitated and assayed by TRAP analysis. Heat-inactivated telomerase (HI), rabbit 
IgG (IgG), no Ab, or lysis buffer were used as TRAP negative controls. A synthetic 
telomerase product (R8, which corresponds to the primer TS extended with eight telomeric 
repeats) and an internal PCR control (IC) (which produces a 36 bp band) were both used as 
positive PCR controls. The extended products were amplified by PCR using the TS and RP 
(reverse) primers, generating a ladder of products with 6 base increments starting at 50 
nucleotides: 50, 56, 62, 68, etc. Following TRAP-PCR, amplified products were resolved on a 
non-denaturing polyacrylamide gel. 
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4.2.2 Full-length hnRNP A2 binds to the hTR1-72, hTR35-65 and hTR57-72 fragments of 
human telomerase RNA. 
 
Full-length hTR, hTR1-72, hTR72-598, hTR1-57, hTR35-65 and hTR57-72 were linearised with SalI 
and transcribed in vitro using α-
32
P UTP. The transcribed RNA was incubated with increasing 
concentrations of protein (hnRNPs and their deletion constructs) and the complexes formed 
were resolved on a non-denaturing 5% polyacrylamide gel. Non-specific RNA-protein 
interactions were minimised by the addition of heparin (5 g/L) (Figure 4.4). 
 
 
Figure 4.4: hTR deletion constructs. Schematic showing the hTR deletion constructs cloned 
into pGemT-Easy, linearised with SalI and transcribed with T7 polymerase in vitro. The 
telomeric template (residues 46-53) is indicated in green. 
 
hTR deletion constructs incorporating segments of the 5ʹ end of the RNA, the whole hTR as 
well as a negative control were transcribed in vitro. The 32P-labelled hTR full-length, hTR72-
598, hTR1-72, hTR1-57, hTR57-72, and hTR35-65 were added to increasing concentrations (0-10 
µM) of recombinant full-length proteins hnRNPs A1, A2 and A3. Interactions with the hTR 
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transcripts were detected by changes in RNA mobility on non-denaturing 5% polyacrylamide 
gels (Figure 4.5). Full-length hnRNP A1 has shown no clear interaction with the short hTR1-
72 (Figures 4.5 A), unlike hnRNP A2 that has manifested a clear interaction with the short 
hTR1-72 (Figure 4.5 B) and consequently this region was defined more closely to hTR1-57, 
hTR35-65 and hTR57-72.  In addition, hnRNP A3 has shown a similar no interaction as hnRNP 
A1 with the short hTR1-72 (Figure 4.5 C). Furthermore, hnRNP A2 showed interaction with 
hTR35-65 and hTR57-72 but not with hTR1-57 (Figures 4.5 D). In contrast, neither full-length 
hnRNP A1 and A3 manifested a clear interaction with the short hTR segments (Figure 4.6 A 
and B), possibly as a result of likely of full-length recombinant proteins hnRNP A1 and A3 
have a specific binding site on hTR. The presence of a glycine-rich domain could play a role 
in the proteins’ characteristics in vitro and largely disordered (Idriss et al., 1994). Although, 
the glycine-rich domain showed no interaction with telomeric DNA or no role in binding, the 
full-length recombinant proteins showed strong binding with telomeric DNA in SPR data. To 
assess whether the lack of binding between the full-length hnRNPs and hTR RNA was due to 
the glycine-rich domain, short hnRNPs constructs with two domains RRM1 and RRM2 and 
exclusion of a glycine-rich domain were conducted in REMSA experiments as well.  
 
The region within hTR1-72 that interacts with hnRNP A2 was defined more closely with 
shorter RNAs (Figure 4.5 D). hTR1-57 appeared not to interact with hnRNP A2, whereas there 
were associations of 31-nt hTR35-65 and 16-nt hTR57-72 with hnRNP A2, which possess a 
single-stranded region centred on conserved region 1 (Chen et al., 2000) or the core domain 
(Zhang et al., 2011). The subdomains of hnRNP A2 were defined more closely. RRM2, as 
shown in Figure 3.15 E, bound to single telomeric repeats, whereas RRM1, but not RRM2, 
specifically interacted with hTR57-72 to form a complex (Figure 4.5 E). This finding is 
opposite to the role of hnRNP A1/UP1 domains, where RRM1 is necessary for A1/UP1 
binding to a telomeric DNA oligonucleotide (Fiset and Chabot, 2001, Nagata et al., 2008). It 
conforms the proposal raised by Jones and colleagues (Moran-Jones et al., 2005) and is 
validated by the SPR results in this study (see Figure 3.15 E). 
 
Whether a complex is formed or not, all three hnRNP paralogs incubated with full-length hTR 
and hTR72-598 showed clear bands upon overexposure of the gel; this could be either un-
shifted bands; or higher shifted molecular complexes enhanced by UV-cross-linked RNA; or 
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that more than one protein interacts with the labelled RNA. Whether or not protein was 
added, such bands existed. Full hTR and hTR72-598 could have formed a secondary structure 
and created double-stranded RNA forms during the experiment. Hence there may have been 
many copies of transcribed hTR and hTR72-598 in the reaction mix that are likely interacted 
with each other and formed an intricate structure (Figure 4.1). This does not rule out the 
presence of an interaction between hnRNPs A1, A2 and A3 and full-length hTR. To 
demonstrate the high-specificity of this assay, the binding of the recombinant proteins to a 
control sequence (pGEMT/Sal1) was not observed, and no shifted band was observed.  
 
This finding is consistence with reported results of Francois Bachand (2001), they have 
anticipated that the radiolabeled hTR1-451 result in formation of a complex that hinder the 
migration of full-length hTR (REMSA) under conditions or buffers enhance reversible RNA 
binding. In addition, Fiset and Chabot (2001) have shown similar finding with hTR1-576 (F). 
They have shown that the hnRNP A1/UP1 (with increased concentrations) binding to radio-
labelled hTR-F (576 nt) have formed a higher molecular mass complexes and determined that 
as >50% of the hTR-F existed in the complexes. In contrast, formation of RNA-protein 
complex with hnRNP A2 was evident for hTR1-72, which includes a 5ʹ single-stranded region, 
as shown previously with hnRNP A2 (Moran-Jones et al., 2005).  
Furthermore, RRM1+2 domains have shown the formation of larger complexes with protein-
RNA interaction (Figure 4.5 E). This difference points to the manner of interaction for 
hnRNPs A1 and A2, with the latter probably not imitating the anti-parallel dimeric molecular 
arrangement observed in the crystalline state, in which oligonucleotides bind RRM2 of one 
hnRNP A2 molecule and RRM1 of the other (Moran-Jones et al., 2005). In addition, the 
RRM1 domain, but not the RRM2 and glycine-rich domains, of hnRNP A2 has shown a 
binding ability with hTR57-72, and strong binding of the domains including A2ΔGRD have 
been significantly formed with hTR57-72 (Figure 4.5 E). This finding has suggested that the 
RRM1 domain can bind telomerase RNA specifically and RRM2 binds telomeric DNA with 
specificity as well (Figure 3.15 E), while the A2ΔGRD can strengthen this binding in both 
cases. 
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Figure 4.5: Association of hnRNPs A1, A2 and A3 with hTR deletion fragments. 32P-
labelled full-length hTR1-598, hTR1-72, hTR72-598 and pGemT-Easy/SalI (negative control) were 
incubated with increasing concentrations (0, 2.5, 5 and 10 µM) of full-length recombinant 
proteins (A) hnRNP A1, (B) hnRNP A2, and (C) hnRNP A3. The RNA-protein complexes 
were resolved on non-denaturing 5% polyacrylamide gels, and detected by Typhoon scanner. 
The assays were performed in the presence of 5 g/L heparin. The region of the hTR that binds 
hnRNP A2 was more closely defined by using shorter deletion nucleotides (D). hTR deletion 
constructs hTR1-57, hTR35-65, and hTR57-72 were transcribed in vitro, radio-labelled with 32P, 
and incubated with increasing concentration of hnRNP A2. This protein binds 31-nt and 
shorter 16-nt regions of hTR, hTR35-65 and hTR57-72, respectively. The brackets mark the 
RNA-protein complex and arrows mark the free RNA probe. An individual domain (RRMs) 
of hnRNP A2 (100 µM) A, B, A+B and ABC were incubated with 32P-labelled hTR57-72 and 
separated on acrylamide-urea gel, RRM-RNA complexes were marked and free RNA probe 
(E). 
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Figure 4.6: Association of hnRNPs A1 and A3 with hTR deletion fragments. 32P-labelled 
hTR1-57, hTR35-65 and hTR57-72 were incubated with increasing concentrations (0, 2.5, 5 and 10 
µM) of full-length recombinant proteins (A) hnRNP A1 and (B) hnRNP A3. The RNA-
protein complexes were resolved on non-denaturing 5% polyacrylamide gels, and detected by 
Typhoon scanner. The assays were performed in the presence of 5 g/L heparin. These proteins 
did not bind shorter regions of human telomerase RNA, hTR1-57, hTR35-65 and hTR57-72 
respectively. The arrows mark the free RNA probe at the bottom of the gel. 
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4.2.3 Short variants hnRNP A1ΔGRD, A2ΔGRD and A3ΔGRD bind to the hTR1-72, 
hTR35-65 and hTR57-72  fragments of human telomerase RNA. 
 
There was no interaction of full-length hnRNPs A1 and A3 with hTR1-72, and that could be 
due to a solubility problem (Figure 4.6 A and B). This low solubility is presumed to result 
from the presence of the glycine-rich domain. Thus deletion constructs that lack the 
glycine-rich domain of the three recombinant hnRNPs and are soluble (hnRNP A1/UP1, 
hnRNP A2/RRM1+2+10 linker and hnRNP A3/ RRM1+2+15 linker) were tested in 
REMSAs. Labelled hTR probes; hTR1-72, hTR57-72, and hTR35-65 were t added with increasing 
concentrations (0–10 µM) of the short recombinant derivatives of A1, A2 and A3. Notably, 
all three proteins showed binding complexes with 32P-labelled hTR1-72, hTR35-65 and hTR57-72 
(Figures 4.7 A, B and C). The	short	derivatives	hnRNPs showed successful interaction with 
32P-labelled hTR35-65 and hTR57-72. This finding has revealed a preferable study of the short 
derivatives of hnRNP A1/UP1 rather than full-length hnRNP A1 and hnRNP A3. 
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Figure 4.7: Association of short derivatives hnRNPs A1ΔGRD, A2ΔGRD and A3ΔGRD 
with hTR deletion fragments. 32P-labelled hTR1-72, hTR35-65, hTR57-72 and pGemT-Easy/SalI 
(negative control) were incubated with increasing concentrations (0, 2.5, 5 and 10 µM) of 
short sequence (excluding glycine-rich domain) recombinant proteins (A) hnRNP A1ΔGRD, 
(B) hnRNP A3ΔGRD, and (C) hnRNP A2ΔGRD. The RNA-protein complexes were resolved 
on non-denaturing 5% polyacrylamide gels, and detected by Typhoon scanner. The assays 
were performed in the presence of 5 g/L heparin. All truncated short derivative proteins have 
formed binding complexes with 32P-labelled hTR1-72, hTR35-65 and hTR57-72. The brackets 
mark the in vitro transcribed RNA and the arrows mark the free RNA probe, brackets mark 
the RNA-protein complex.  
 
4.2.4 Cold telomeric DNA cannot compete with hTR57-72 to recombinant hnRNP A2 
binding site. 
 
The ability of hnRNP A2 to bind to both telomeric repeats and telomerase RNA through the 
RRM domains raises the question of whether A2 binds to the telomeric ssDNA ends and hTR 
simultaneously or sequentially. To address this question, a competitive experiment was 
performed. 32P-labelled DNA and hTR57-72 were incubated with and without hnRNP A2 
recombinant protein. A 50x higher concentration telomeric Telo1 (cold) was incubated with 
hTR57-72 in binding buffer prior to addition of recombinant protein, hnRNP A2. The reaction 
mixtures were UV-cross-linked and separated on polyacrylamide gel. In the absence of 
protein there was no complex formation observed with radio-labelled DNA and RNA (Figure 
4.8 lanes 1 and 3). In contrast, there was a significant complex formation between the 
recombinant protein and both radio-labelled DNA and RNA (Figure 4.8 lanes 2 and 5).  
 
The binding of hTR57-72 to hnRNP A2 in the presence of excess cold Telo1 (Figure 4.8. lane 
4) indicates that the hTR-protein interaction is not out-competed or diminished by high 
concentrations of Telo1 and points to independent binding sites on A2 for hTR and the 
telomeric repeat. This finding is supported by previous data that showed that RRM1 is 
specifically bind to hTR (Figure 4.6 E) and RRM2 binds specifically to telomeric ss-DNA 
(Figure 3.15) suggesting that these sites have independent roles in telomere biology. This 
leads to an assumption that the non-competition between the hTR and ss-DNA to the binding 
site of hnRNP A2, is predicted, and because each one of them has its one specific RRM to 
bind with, assuming that, even if the affinity of the binding of one is greater than the other. 
This result also demonstrates the existence of a complex containing recombinant hnRNP A2, 
hTR57-72, and telomeric DNA. Which confirm the earlier report, that UP1, can form binary 
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and ternary complexes with telomerase RNA (hTR56-71) and telomeric ssDNA (Nagata et al., 
2008). The differences are; our finding showed that the full-length of hnRNP A2 was capable 
to form this interaction, while Nagata showed that UP1 was capable of forming binary and 
ternary complexes, with no mention of hnRNP A1, and that could be due to the low solubility 
of the full-length hnRNP A1. In addition, the RRM2 of UP1 is necessary and specifically 
binding to hTR, and RRM1 binds to telomeric ss-DNA. Our data showed the opposite, 
regarding to the binding ability and specificity of hnRNP A2 RRMs to hTR and telomeric ss-
DNA. Although these proteins could perform the same interaction and role, in some respects, 
substantial differences exist between the proteins, indicating that evolution has made use of 
the many forms of the ancestral hnRNP A/B protein. For example, although the exon/intron 
structure is maintained between the two genes, major differences exist between the promoters 
of hnRNPs A1 and A2.   
 
 
 
Figure 4.8: The binding signal between hnRNP A2 and hTR57-72 did not diminish with 
high molar excess of telomeric DNA. 32P-labelled DNA Telo1 and RNA hTR57-72 alone, were 
used as negative controls (lanes 1 and 3), while recombinant hnRNP A2 was incubated with 
32P end-labelled Telo1 probe and 32P-labelled RNA hTR57-72 in the absence of 50-fold molar 
excess unlabelled competitor probe Telo1 (lanes 2 and 5). The excess unlabelled Telo1 probe 
when incubated with protein-RNA complex, did not reduce the signal between the radio-
labelled RNA hTR57-72 and recombinant protein, indicating that the recombinant protein was 
able to bind to both “cold competitor” and RNA hTR57-72 (lane 4). 
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4.2.5 hnRNP A2 simultaneously interaction with telomerase RNA and telomeric DNA 
 
The previous experiment suggests that these interactions can occur simultaneously and form a 
stable trimeric complex. The approach used was similar to that described by (Fiset and 
Chabot, 2001) who looked for hnRNP A1/UP1 retention on agarose adipic hydrazide column: 
see section (2.6.7). In the present study, I showed that in the absence of hnRNP A2, the 32P-
labelled hTR57-72 oligonucleotide was not retained on a column comprising biotin-labelled 
telomeric DNA (Telo4) coupled to SA-coated agarose beads, as manifested by the presence of 
hTR57-72 in only the flow-through fraction (Figure 4.9 A, lane ft (left)). While in the presence 
of hnRNP A2, hTR57-72 was retained and eluted at low concentration of KCl (Fig 4.9 B, E1 
left panel), and continued to be retain with increasing salt concentration (Figure 4.9 B, E2-
E4 right panel). More importantly, the 3 rounds of washing steps were sufficient and enough 
to reduce the non-specific background and that demonstrated by including (fraction that does 
not contain any protein or probe, run on acrylamide gels) (see figure 4.9 A right panel). The 
washing step also it is suitable for screening the stability of protein/RNA interactions and 
allows various degrees of investigation by controlling the number of times the protein/RNA 
complex is eluted. These results show the existence of a trimeric complex containing 
recombinant hnRNP A2, hTR57-72 and telomeric DNA, and demonstrate that hnRNP A2 can 
interact with both telomeric DNA and telomerase RNA simultaneously. To establish the 
specificity of this interaction, the single-stranded nucleic acid binding protein, POT1 was 
used in place of hnRNP A2. The binding of POT1 to telomeric DNA oligonucleotides had 
been demonstrated using the Telo4 column assay. I found that POT1 bound to the column but 
was unable to retain the hTR oligonucleotide (Figure 4.9 C). 
 
The affinities of the hnRNP A2 subdomains for hTR57-72 were tested individually and in 
combination by loading recombinant domains onto Telo4-agarose magnetic beads column. 
RRM1 showed a very weak binding as was able to retain the hTR probe (Figure 4.10A) and 
RRM2 showed no binding to hTR probe. Therefore one washing step was involved in the 
simultaneous experiment that includes subdomains to avoid being washed off by extra 
washing steps. RRM1 and RRM2 could not resist the low salt concentration 100-250mM KCl 
and were eluted, while the RRM1+2 demonstrated a simultaneous interaction with telomeric 
DNA-hTR57-72. The RRM1+2 was investigated by running the fractions eluted at high KCl 
concentrations on both acrylamide-urea gels (for examination of the oligonucleotides) and 
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SDS gels (for the protein fraction). The positions of hTR57-72 and hnRNP A2/RRM domains 
are indicated (Figure 4.10 D). This experiment has indicated that both RRMs are essential for 
simultaneous binding. In the same experiment RRM1 was indicated on protein gel at elution 
steps (Figure. 4.10 A. right panel E1) but not RRM2 (Figure. 4.10 B. right panel E1), this 
is another evidence that RRM1 is specifically binding hTR57-72 and eluted at low 
concentration KCl buffer. A portion of hnRNP A2 contains RRM1 is sufficient for binding 
the hTR as in (Figure. 4.10 A). Given that RRM1 has a weaker affinity for telomeric 
sequences than the RRM2 (Figure 3.15 E), thus we would see RRM1 eluted in 250 or 500 
mM KCl with very faint band on protein gel (Figure. 4.10 A Right panel). In (Figure 4.10 
C), both domains are in the same condition but RRM2 which has strong binding affinity to 
telomeric sequences has occupied the telomeric DNA and RRM1 no longer able to bind the 
telomeric sequences, thus both of them were eluted at low KCl concentration. The radio-
labeled hTR could be indicated in elution 500 mM of KCl (Fig. 4.10 A left panel urea gel) 
as residual or left over fragments from 250 mM KCl elution, but does not necessary contain 
RRM1 or it may has very tiny amount of RRM1. 
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Figure 4.9: hnRNP A2 simultaneous interaction with telomeric DNA sequence and hTR. 
(A) 32P-labelled RNA hTR57-72 alone, (B) mixture of 32P-labelled RNA hTR57-72 and hnRNP 
A2 protein, (C) mixture of 32P-labelled RNA hTR57-72 and POT1 protein, were loaded onto 
Telo4 columns. Right panels represent stained protein gels, whereas, left panels represent the 
acrylamide gels exposed to a phosphor screen to visualise 32P-labelled RNA hTR57-72 in 
presence and absence of recombinant proteins, in different fractions. I, input; Ft, flow-through 
fraction; W, washing fraction 1-3, are successive washes with each of 4 x 50 µl of loading 
buffer (DN buffer). E, elution 1-4, are successive elutions with each of 4 x 50 µl of DN buffer 
containing 0.25, 0.5, 0.75 and 1 M KCl, respectively. The positions of the proteins and hTR57-
72 are marked. 
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Figure 4.10: Both domains of hnRNP A2 are essential for simultaneous binding. Mixtures 
contain 32 P-labelled RNA hTR57-72 and the individual domains (A) RRM1, (B) RRM2, (C) 
RRM1+RRM2 and (D) joined RRMs 1+2 were loaded onto Telo4 columns. Left panels show 
polyacrylamide-urea gels used to separate the fractions: I, input; Ft, flow-through fraction; W, 
washing fraction with loading buffer (DN buffer). E, elution 1-4, are successive elutions of 
each of 4 x 50 µl of DN buffer containing 0.25, 0.5, 0.75 and 1 M KCl, respectively, the 
positions of the hTR57-72 are marked. The position of protein domains are marked on the right 
panels and separated on the protein gel. 
 
  
 131 
 
4.3 DISCUSSION 
 
The experiments in this chapter have identified an interaction between endogenous telomerase 
and hnRNPs A/B and have also narrowed the hnRNP A2-binding site within the hTR. 
hnRNPs A1, C1/C2 and D have demonstrated in previous work their capability to interact 
with endogenous telomerase. This was demonstrated by various IP experiments, as well as 
studies on mouse cells deficient in hnRNP A1 expression, which revealed telomere length 
was increased when the hnRNP A1 level had been restored (Labranche et al., 1998). The 
result in this study (Figure 4.3) has demonstrated that hnRNPs A1, A2 and A3 were 
associated with endogenous telomerase, as IP experiments using antibodies against these 
proteins successfully pulled-down telomerase, whose activity was subsequently detected in 
the TRAP assays.  
Knowing that hnRNPs A/B are single-stranded nucleic acid binding proteins, it was initially 
suggested that their association with telomerase would be mediated via the RNA template. 
hnRNPs A1 (Fiset and Chabot, 2001), A2 (Moran-Jones et al., 2005) and C1/C2 (Ford et al., 
2000) have all been shown to interact in vitro with the telomerase RNA subunit. Like hnRNPs 
A1 and A2, the tandem-RRM containing regions of hnRNPs were shown to also interact with 
the first 71 nt of hTR. Furthermore, hRNP A1/UP1 also has been shown to interact in vitro 
with 15 nt of hTR (Nagata et al., 2008), our results of the short constructs of recombinant 
proteins hnRNP A2ΔGRD and hnRNP A3ΔGRD were also able to interact in vitro with 16 nt 
of hTR (Figure 4.7). Moreover, REMSA has shown a second binding site, with hnRNP A2 
(RRM1) (but not with A3ΔGRD, or hnRNP A1ΔGRD) (Fiset and Chabot, 2001), binding a 
region contained within residues 57-72 of hTR (Figure 4.5 E). pGemT-Easy linearised with 
SalI, which contained the sequence from pGemT-Easy present in all T7-transcribed deletion 
constructs and therefore acted as a negative control, did not show an association with 
increasing concentrations of recombinant hnRNPs A1, A2 and A3 even with the short 
constructs of the three proteins A1ΔGRD A2ΔGRD A3ΔGRD.  
It is interesting to note that in vivo hTR probing experiments demonstrated that within the first 
71nt, only the G44 and C46-A61 nucleotides are single-stranded, with the remaining regions 
forming double-stranded helix or stem structures (Antal et al., 2002). Since these residues, 
which encompass the telomeric template sequence (residues 46-53) are contained within the 
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hTR 35-65 deletion construct, Antal and colleagues’ (2002) observations further support the 
finding that one of the hTR binding sites for hnRNP A2, which is a single-stranded nucleic 
acid binding protein, lies between residues 35-65. Given the homology shared between 
hnRNPs A1, A2 and A3 and the fact that they all bind the first 71nt of hTR, it is likely that 
hnRNPs A1 and A3, like A2, interact with hTR via a single-stranded binding site located 
within residues 35-65, which has been demonstrated by this thesis’ results.  
Furthermore, Nagata and colleagues (2008) have shown that hnRNP A1/UP1 binds the 15 nt 
of hTR with the sequence lying between 56-71 of RNA template. For the same reasons used 
above, like hnRNP A1/UP1, hnRNP A2 including A2ΔGRD and hnRNP A3ΔGRD were able 
to bind to hTR RNA within residues 57-72, which has been demonstrated by REMSA 
experiments (Figure 4.5). Therefore, the suggested binding site of hnRNPs from these data is 
contained within hTR57-72, which represents an authentic binding site for hnRNP A2 and 
hnRNP A3. 
However, in the current experiments, purified recombinant hnRNPs A1, A2 and A3 including 
the short constructs A1ΔGRD, A2ΔGRD and A3ΔGRD proteins were added to in-vitro 
transcribed hTR sequences in the presence of heparin (5 g/L), which at a high concentration is 
enough to abolish non-specific RNA-protein interactions. Furthermore, binding of 
recombinant hnRNP A2 including A2ΔGRD, hnRNP A1 including A1ΔGRD and hnRNP A3 
including A3ΔGRD proteins, to a control sequence (pGMT/Sal1) was not observed, 
demonstrating the high-specificity of the assay. 
Finally. hnRNP A2 has shown its binding capability to telomere and telomerase 
simultaneously. This interaction was compared with recombinant protein POT1, while the 
later does not retrieve the radio-labelled hTR57-72 riboprobe activity. Moreover, to determine 
the specificity of these experiments, hnRNP A2 domains that interact with hTR57-72 were 
loaded individually onto Telo4-labelled agarose magnetic beads (packed in column). Both 
RRM1 and RRM2, which have shown a non-simultaneous binding, appeared by themselves 
(Figure 4.10 C), whereas hnRNP A2ΔGRD has demonstrated a simultaneous interaction with 
telomeric DNA-hTR57-72. When investigated by eluting the fractionated materials at high 
concentration of KCl buffer the conclusion drawn was that both RRMs are essential to form 
this kind of simultaneous interaction. 
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4.4 SUMMARY 
 
The experiments detailed in this chapter were performed to identify if hnRNPs A2 and A3 
were capable of interacting with telomerase holoenzyme. These proteins were selectively 
pulled-down endogenous telomerase, as assessed by TRAP assays. In vitro transcription 
experiments showed that hnRNP A2ΔGRD and hnRNP A3ΔGRD, like hnRNPs A1/UP1, 
interact with the first 71 nt of telomerase and more precisely with 56-72 nt. Deletion mapping 
studies indicated that the binding site of hnRNP A2 with hTR was mediated by RRM2, while 
strong binding was monitored by both RRMs. Additionally, a second and authentic hnRNPs 
A2 and A3 binding site was also demonstrated in a region of hTR57-72, which interacted with 
hnRNP A1/UP1 in an earlier study. 
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Chapter	5:	
5 General Discussion 
5.1 hnRNPs A/B bind telomeric DNA 
 
This study confirmed that hnRNPs A1, A2 and A3 bind to single-stranded telomeric DNA, 
and that one repeat was enough for this binding. The interaction of hnRNPs A1, A2 and A3 
with telomeric DNA was demonstrated by in chapter 3 (Figure 3.8), Western blot (Figure 
3.9), ChIP assay (Figure 3.10), immunocytochemistry (Figure 3.11), UV-cross-linking 
(Figures 3.12 and 3.12) and SPR (Figure 3.15). By contrast, the recombinant hnRNPs did 
not bind to Anti1 or Anti6 (Figure 3.13) which is in accord with earlier observations showing 
that these hnRNPs do not bind to the C-rich motif that is complementary to the TTAGGG 
sequence of the mammalian ssDNA repeat (Bandiera et al., 2005, Bandiera et al., 2003, 
Dallaire et al., 2000, Eversole and Maizels, 2000, Huang et al., 2008, Kamma et al., 2001).  
 
This was an interesting and unexpected observation, given that heparin was not included in 
these experiments and therefore non-specific DNA-protein interactions mediated by the non-
specific hnRNPs A1, A2 and A3 binding site should have taken place. Previous work 
undertaken in this study’s laboratory showed that hnRNPs A2 and A3 possess two binding 
sites, one that is specific for particular DNA/RNA sequences, and another which does not 
discriminate between nucleic acid sequences (Hoek et al., 1998, Moran-Jones et al., 2005, 
Munro et al., 1999, Shan et al., 2000). Furthermore, the non-specific binding site has been 
shown to not only recognise widely different sequences, but also bind them with lower 
affinities than the sequence-specific site (Shan et al., 2000). This is in accord with their 
proposed roles in multiple RNA processing steps.  
 
EMSA confirmed that the weak interaction observed between recombinant hnRNPs and Anti1 
was not due to a minimum DNA length requirement for the non-specific site. Single-stranded 
DNA Anti6 demonstrated similar findings. The Anti DNA and NS sequences are pyrimidine-
rich (Appendix 2, table B) and other investigators have shown that hnRNPs A1 and A2/B1 
are unable to bind to the C-rich telomeric motif (Bandiera et al., 2003, Dallaire et al., 2000, 
Eversole and Maizels, 2000, Kamma et al., 2001). This theory of hnRNP A/B binding C-rich 
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telomeric motif initially appeared to be contradicted by the observations shown in (Figure 
3.14), which suggested that a 50-fold molar excess of unlabelled NS was capable of out-
competing some of the labelled-telomeric DNA, and hence binding non-specifically to both 
hnRNPs A/B. However, such a finding can be explained because in the competitive UV-
cross-linking experiments, the excess unlabelled ssNS DNA could possibly form a double-
stranded complex with the single-stranded Telo1 DNA.  
 
Competitive UV-cross-linking experiments (Figure 3.13) demonstrated that the interaction 
between hnRNPs A1, A2 and A3 was direct and specific. The telomeric DNA-hnRNP A1, A2 
and A3 complex observed was either completely abolished or significantly reduced when 
excess unlabelled ssTelo1 DNA was used as a competitor. An additional finding from UV-
cross-linking experiments was that both hnRNPs A2 and A3 bound quite robustly to the 
single-repeat single-stranded telomeric DNA, in agreement with earlier work (Moran-Jones et 
al., 2005). Furthermore, the UV-cross-linking experiments have demonstrated strong binding 
by hnRNP A1 to monomeric ssDNA and with high specificity (Figure 3.12) and this was 
confirmed by SPR (Figure 3.15 A).  
 
In addition, a cold competitor in 50-fold excess was unable to compete with 32P-telo1 for the 
binding site of hnRNP A1 (Figure 3.14). This was somewhat surprising given that the co-
crystal structure of UP1/telomeric DNA in addition to in vitro experiments using recombinant 
hnRNPs A1 and D all indicated that these proteins only bound as a minimum, 
oligonucleotides bearing dimeric-TTAGGG repeats (Ding et al., 1999, Eversole and Maizels, 
2000, Zhang et al., 2006). SPR experiments have shown that hnRNPs have a variation in 
which of the three recombinant proteins (full-length) have high-affinity interaction, 
recognition and stability of protein/DNA complex formation.  
Earlier results from gel-shift experiments of previous studies, have shown that a RRM1 of 
hnRNP A1 or UP1 binds to a telomeric oligonucleotide (d (TTAGGG)2) and that RRM2, 
binds to the RNA strand of hTR (Dallaire et al., 2000, Fiset and Chabot, 2001, Nagata et al., 
2008). This study has determined that the RRM2 domain of hnRNP A2 elicited SPR response 
with telomeric DNA. Moreover the hnRNP A2ΔGRD has produced a strong interaction 
(Figure 8 c). As seen from the interaction of hnRNP A2 with DNA telomeric repeat, this 
association with Telo1 was strengthened by inclusion of 10 residues C-terminal to 
RRM2(RRM1 + RRM2 + C) and to some extent, by the glycine-rich region (hnRNP A2 full-
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length) (Figure 3.15 E). Furthermore, although others have proposed it that hnRNP A/B 
requires a minimum of two telomeric repeats (Ding et al., 1999, Huang et al., 2010, Huang et 
al., 2008, Zhang et al., 2006), a robust interaction with just a single Telo1 repeat was observed 
in this study. 
 
The ChIP assays have indicated that hnRNPs bind telomeric DNA in HeLa whole-cell lysates. 
Although, this leaves open the possibility that the interaction between the hnRNPs and 
telomeric DNA is mediated by other factors, the evidence from both in vivo and in vitro 
experiments supports the proposal of a direct interaction. The hnRNPs A1, A2 and A3 clearly 
bind single-stranded DNA repeats, as exemplified by the Telo1 and Telo6, which bind with 
comparable dissociation constants. Thus, the 2’OH group appears to play little part in the 
nucleic acid-protein interaction. Despite their sequence similarities, the three paralogs do not 
behave identically. 
 
It is likely that the binding sites for A2RE11 and Telo1 on hnRNP A2 and A3 overlap. Yet the 
three paralogs show distinct binding preferences; whereas A2 binds to A2RE11 and Telo1, A1 
shows a strong interaction with Telo1 but not with A2RE (Shan et al., 2000). Furthermore, 
while the arginine residues of the RGG box domain of hnRNP A1 and A3 is almost 
symmetrical, asymmetrically dimethylated A2 is dimethylated at only a single residue (Arg-
254). It is speculated that arginine methylation could play a role in a mode of hnRNP A/B 
binding preferences and regulates the distribution of hnRNPs A/B (Friend et al., 2013). 
 
5.2 hnRNP A/B bind telomerase hTR 
 
The study data have demonstrated that hnRNPs A2 and A3 along with A1 proteins are 
associated with endogenous telomerase, as IP experiments using antibodies against these 
proteins successfully pulled-down telomerase, whose activity was subsequently detected in 
TRAP assays (Figure 4.3). This contradicts what had been proposed earlier that only UP1 can 
recover telomerase activity from cell lysate (Labranche et al., 1998). The study finding is 
further supported by the observation that the depletion of hnRNPs A1 and A2 from a 
telomerase extract resulted in a marked decrease in telomerase activity and reconstitution of 
these proteins fully restored telomerase activity in a concentration-dependent manner (Zhang 
et al., 2006), demonstrating that hnRNPs A1 and A2 stimulate telomerase activity. TRAP 
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assays have not only identified an interaction between endogenous telomerase and hnRNPs 
A2 and A3 compared to A1, but have also narrowed the hnRNP A2-binding site within the 
human telomerase RNA. Previous work had demonstrated that hnRNP A1, C1/C2 and D 
proteins were all capable of interacting with endogenous telomerase. This was demonstrated 
by various immune-precipitation experiments, as well as studies on mouse cells deficient in 
hnRNP A1 expression, which showed telomere lengthening when hnRNP A1 levels were 
restored (Labranche et al., 1998). 
 
However, in the REMSA experiments, the recombinant hnRNPs A1, A2 and A3 were added 
to in vitro transcribed hTR sequences in the presence of heparin (5 g/L), which is at a high 
enough concentration to abolish non-specific RNA-protein interactions. hnRNPs A1 and A3 
have shown no complex formation with short hTR, unlike hnRNP A2 which has shown a 
complex formation with short hTR (Figure 4.5 A, B and C). Both hnRNP A1 and UP1 have 
shown a binding with the first 276 nt of TR hTR in vitro and it has been expected that UP1 
binds to the first 71 nt (Fiset and Chabot, 2001). UP1 (but not hnRNP A1) was shown to bind 
the telomerase holoenzyme (Dallaire et al., 2000, Labranche et al., 1998), and to 15-mer TR, r 
(UGAGA AGGGCGUAGG), corresponding to residues 56-71 of TR (Nagata et al., 2008). 
The same suggestion is referred to hnRNP A3 as fact that hnRNP A3 is similar to hnRNP A1 
at high sequence identity of 80% across the tandem RRMs at the protein level. The results 
herein have shown that the short derivatives of hnRNP A1ΔGRD, hnRNP A2ΔGRD and 
hnRNP A3ΔGRD successfully bind to the short sequence of hTR (Figure 4.7 A, B and C). 
 
Furthermore, binding of the three recombinant hnRNP proteins to a control sequence 
(pEGMT/Sal1) was not observed, demonstrating the high-specificity of the assay. In humans, 
the 3D structure of telomerase has revealed that the spatial relationship between hTR and 
protein subunits offers insights into telomerase architecture (Sauerwald et al., 2013). The 
RNA/DNA binding affinity of telomerase has determined that the active site of TR 
(CAAUCCCAAUC) is unoccupied during template translocation, which suggests that the 
RNA strand separation and defined template realignment (CAAUC) (Drosopoulos et al., 
2005) occur outside the active site of TERT, dragging the realigned DNA/RNA to the active 
site (Berman et al., 2011, Qi et al., 2012).  The shortest segment that binds hnRNP A2 has 
previously been shown to be within the 71 nucleotides at the 5ʹ end of hTR (Moran-Jones et 
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al., 2005). It includes the first of the eight vertebrate (CR1-CR8) regions that are highly 
conserved and a single-stranded segment comprising nucleotides 38-61 (Antal et al., 2002). 
Given that hnRNP A/B binds ssDNA/RNA, the hTR-accessible binding sites for A2 must 
either be residues C52-C56, as suggested by (Qi et al., 2012), or C56-A61 with U38-U45 
being inaccessible to single-stranded binding reagents. This is consistent with my result that 
G1-U57 did not bind hnRNP A/B. Since C56-A61 and U57-C72 are immediately 3' to the 
hTR template; bound hnRNP A/B could juxtapose the end of the growing telomeric DNA 
strand and the RNA template to facilitate addition of the new repeat. In yeast, junction 3 (J3), 
which is located between the pseudoknot (PK) and immediately 3' to the hTR template, is 
postulated to be not occupied during telomere elongation where it facilitates the telomere 
single-strand entering the telomerase circle structure at the active site and aligns itself with the 
RNA template (Mefford et al., 2013). The other conserved structural elements such as J1, J2, 
J4, PK and CEH must remain connected with the whole telomerase molecule to stabilise the 
secondary structure and coordinate telomerase activity (Mefford et al., 2013). Mefford and 
colleagues also proposed that J3 was not necessary for telomere elongation, as illustrated in 
their schematic figure (9), this could likewise apply to human telomerase given the high 
degree of conservation. That the hTR56-72 region may be unnecessary for elongation is 
consistent with the current study showing that the hnRNP A/B proteins bind to the region just 
3' of the TR template, and supports a model where hnRNP A/B binds telomeric ssDNA and 
TR simultaneously through both domains, RRM1 and RRM2 respectively for hnRNP A1 and 
the opposite for hnRNP A2. 
 
In accord with this, a deletion of the U182 residue in the CR4/CR5 binding pocket abolished 
TR-binding domain (TRBD) or (RRM) binding affinity (Bley et al., 2011). The hTR binding 
site has now been verified for hnRNP A2 and the three short derivatives A1ΔGRD, A2ΔGRD 
and A3ΔGRD, as shown in the data, hnRNP A/B did not bind the inverse complement of the 
telomeric repeat C50-A55. It is thus unlikely that the hnRNPs bind solely within the template 
region of hTR, but they may recognise an element in hTR35-65 that is outside the template 
region or overlaps with it.  
 
This study’s data have verified that the three short derivatives A1ΔGRD, A2ΔGRD and 
A3ΔGRD including the full-length hnRNP A2 were successfully interacted with the short 
segment of TR hTR57-72 (Figure 4.5 B and Figure 4.7 A, B and C). This finding is consistent 
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with the fact that UP1 binds to residues 56-71 of hTR56-71 (Nagata et al., 2008). As hTR1-57, 
which includes the template region, does not bind to hnRNP A1 (Figure 4.6 A), hnRNP A2 
(Figure 4.5 D) or hnRNP A3 (Figure 4.6 B), it suggests that this sequence lacks a binding 
site for these proteins. In addition, an earlier study found that hnRNP A1 has low binding 
affinity for poly (U) and poly (C) (Okunola and Krainer, 2009). It is therefore unlikely that 
hnRNPs A1, A2 and A3 control telomerase by binding to the template region and thus 
blocking its use in synthesis of DNA repeats, as these proteins do not bind this element 
strongly, and it enhances, rather than inhibits, telomerase activity. REMSA has shown that a 
second binding site, within hnRNP A2, (RRM1) binding a region contained within residues 
57-72 of hTR (Figure 4.5 E). It has been proposed that the hnRNP A/B binding site is 
adjacent, or close to, the template segment of hTR. The close proximity of the hnRNP A/B 
binding site to the template region on hTR, and thus to the end of the ssDNA 3' overhang, 
supports the proposal that these proteins play an active role in addition of telomeric synthesis.  
 
Furthermore, the UV-cross-linking experiment showed that the protein-hTR complex was not 
diminished in the presence of a 50-fold molar excess of unlabelled Telo1 and did not compete 
with hTR to the binding site of hnRNP A2 (Figure 4.8, lane 4). This raises the question of 
whether this protein interaction is simultaneous or sequential to telomeric DNA and TR.  
 
Significantly, this study has shown that the interaction of hnRNP A2 with both telomeric 
DNA and hTR57-72 is simultaneous in vitro. Although, hnRNPs have the ability to bind DNA 
and RNA, POT1 has been reported to interact with telomeric DNA, and did not retain 32P-
hTR57-72 in chromatography assays, unlike hnRNP A2, which retained it (Figure 4.9). 
Moreover, the short constructs of hnRNP A2 domains were unable to mediate the 
simultaneous interaction individually, although the presence of domains established this kind 
of interaction, emphasising the role of those domains in TR interactions (Figure 4.10). 
Despite the fact that heparin was not used in the chromatography assays, the stringency of this 
assay was increased by performing it at higher salt concentrations in washing and elution 
steps to minimise low affinity interactions, and using full-length recombinant proteins, which 
suggest that assay should detect strong interaction. 
 
Finally, it appears that all hnRNPs A/B, which have dual RNA/DNA binding sites, bind to a 
region of the telomerase machinery and its product. In this location the protein could position 
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the 3' end of the growing telomeric single strand appropriately for addition of the next 
TTAGGG repeat as it is assembled on the hTR template. It is of interest that hnRNP A/B 
appeared to bind as well to Telo1 as it did to Telo6, suggesting that these proteins may 
preferentially associate with one of the conserved terminal repeat regions of TR, CR1. These 
interactions are depicted schematically in (Figure 1.15 A). 
 
One of the important observations to emerge from this work is that three important sites are 
brought together in the telomeric complex: the hTR template, the nearby binding site for 
hnRNP A2 on hTR, and the end of the telomeric ssDNA repeat, which is thereby positioned 
for elongation (Figure 1.15 B). This study provides evidence for hnRNP A2 functioning as 
adaptors between telomeric DNA and hTR to help recruit telomerase at the ends of the 
chromosomes. While telomerase is known to be up-regulated in most cancer cells (Shay and 
Keith, 2008) and aberrant expression of hnRNPs A/B has been linked with cancer as well 
(Carpenter et al., 2006, Golan-Gerstl et al., 2011) and it is supposed that hnRNPs A/B recruit 
telomerase to telomeric DNA, thus understanding the mechanism of interaction between 
hnRNPs and telomerase, which could provides a new target for anticancer drug development. 
 
5.3 Future direction:  
 
Telomeres are necessary structures at the ends of linear chromosomes. Maintenance of 
telomere short tandem repeats ensures a secure end-capping structure, which is imperative for 
preserving genome stability and integrity. The discovery that telomeres are elongated by a 
functional enzyme contains an RNA component (TERC) has transformed our understanding 
of the biogenesis of this region. Many studies have shown that the protective structure of the 
chromosome end is maintained by a group of interacting proteins known as (Shelterins). It has 
been proposed that these proteins could stabilise the chromosome ends. The shelterins are 
implicated in the generation of the T-loop, and control the synthesis of telomeric DNA by 
telomerase. 
 
In order to facilitate the access of telomerase to take action, other studies have demonstrated 
that other proteins like hnRNP A/B play an important role in disrupting the highly protective 
structure and recruit telomerase to the end of the chromosome. Studies of hnRNP A1/UP1 
(Zhang et al., 2006) and hnRNP A2 (Wang et al., 2012) have shown the ability of these 
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proteins to disrupt the protective structure and gain access to the end of the chromosome. This 
thesis’s data along with others have successfully identified the hnRNPs A1, A2 and A3 in 
CHIP assays, leading to a potential direct contact with telomeric DNA. Moreover, hnRNP 
A1/UP1 has been demonstrated to recruit telomerase to the telomeric DNA by binding to both 
elements simultaneously (Fiset and Chabot, 2001). This study’s data have identified also that 
hnRNP A2 is capable of recruiting telomerase to the end of chromosomes through a 
simultaneous binding with both nucleic acids of TR and telomeric DNA. 
Although, hnRNPs A1, A2 and A3 have affinity for binding single-stranded telomeric repeats 
and the TR template, they might be displaced by other telomere- binding proteins, such as 
POT1 (Flynn et al., 2011), which binds to telomeric repeats in the glycine-rich single-strand, 
and shields the newly synthesised DNA, possibly in association with TRF2 in vivo. 
Even though the hnRNPs are implicated in regulation of telomeres and telomerase, the 
multiple isoforms of hnRNPs A1, A2 and A3 and their alternative splicing and/or post-
translational modifications have been suggested to regulate hnRNP functions, either by 
altering their cellular distribution, or by protein phosphorylation. The role of hnRNPs A/B in 
positive regulation may not be redundant. It has been suggested that they are functional in a 
net hnRNP A/B concentration dependent manner, the missing of one protein may not lead to 
the whole being impaired of function of the whole process and therefore direct effects may 
not be simple to detect. The glycine-rich domain of hnRNP A/B has been proposed to play a 
role in protein-DNA, protein-RNA and protein-protein interaction; this thesis demonstrates 
that the glycine-rich domain has no effects in protein-DNA and RNA interaction. The absence 
of the glycine-rich domain in the in vitro REMSA has enhanced short construct proteins, 
hnRNP A1ΔGRD, hnRNP A2ΔGRD and hnRNP A3ΔGRD, to interact with small sequences 
of hTR, whilst the full-length recombinant proteins, hnRNP A1 and hnRNP A3 but not 
hnRNP A2, were unsuccessful in mediating this kind of interaction.   
 
Could the hnRNP A/Bs’ role in telomere maintenance explain the link between aberrant 
expression of these proteins and cancer? For example, overexpression of the B1 isoform has 
been correlated with the subsequent development of lung cancer, breast cancer, liver cancer 
and glioblastoma, and its expression levels are associated with poor prognosis (Carpenter et 
al., 2006, Pu et al., 2009, Bouchal et al., 2013, Cui et al., 2010, Golan-Gerstl et al., 2011, 
Katsimpoula et al., 2009). It may be fruitful to examine the therapeutic effectiveness of 
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reducing or knocking-down hnRNP A/B expression in cancer cells, either individually or as a 
group. Several questions on the hnRNP A/Bs remain to be addressed. The work in this study 
and that of others (Moran-Jones et al., 2005, Fiset and Chabot, 2001) has failed to observe 
any meaningful differences in their functionality suggesting a large degree of redundancy. 
Why have so many hnRNP proteins evolved and why are these paralogous genes maintained 
in mammals given that they appear to perform the same functions? Do they function as both 
homo and hetro multimers and is their function determined by the ratio of the different 
paralogs in these multimers? If these proteins have equivalent tasks, why then is only the 
hnRNP B1 isoform up-regulated in cancer? Does overexpression of the B1 result in isoform-
specific changes to telomere biogenesis? An understanding of the functional contribution of 
each member of the hnRNP A/B family is required to address these questions. 
 
Thus, understanding the role of these proteins in telomere and telomerase regulation would 
represent potential targets for inhibiting telomerase activity as a treatment of cancer. 
Although, the expression of telomerase has been reported to be involved in around 85% of all 
human cancers (Collins, 2006), hnRNPs interactions and effects on telomerase will provide 
novel approaches in how to inhibit telomerase, and thereby block further regulatory pathways 
essential for cancer cell proliferation and survival. Moreover, even though telomerase is 
somehow essential for maintaining cancer cells with unlimited proliferation potential, its 
expression in normal cells potentially precludes cellular senescence. Thus, knocking down 
telomerase activity in normal cells could inhibit cellular ageing. With all this knowledge, 
more studies and efforts need to be done to improve our understanding of the transcriptional 
and post-transcriptional pathways regulating telomerase, and by that, ultimate discoveries and 
development of novel targeted therapies can be used clinically as a treatment for cancer and 
various age- associated diseases. 
Furthermore, discovering cancer in its early stages can be achieved by quantifying telomerase 
activity. This would give insight to the severity of the cancer and help in maintaining an 
adequate therapeutic plan. Clinically, diagnostic telomerase tools are not yet available, so 
more investigations are necessary to develop such instruments or kits to detect telomerase in 
cancer and perhaps its wider use in disease diagnosis. 
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7 APPENDICES 
7.1 APPENDIX 1 
 
Table A: Primer sequences. Sequences are written in the 5’ to 3’ direction. 
Names Sequence (5’-3’) Orientation  
T7 TAATACGACTCACTATAGGG 
 
Forward 
SP6 GCTATTTAGGTGACACTATAG 
 
Reverse 
TS – TRAP AATCCGTCGAGCAGAGTT 
 
Forward 
RP- TRAP GCGCGG[CTTACC]3CTAACC 
 
Reverse 
K1- TRAP ATCGCTTCTCGGCCTTTT 
 
N/A 
TSK1 AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAG CGA 
T 
 
N/A 
R8-TRAP AATCCGTCGAGCAGAGTTAG[GGTTAG]7 
 
N/A 
hTRqF (1) GGGTTGCGGAGGGTGGGCCTG 
 
Forward 
hTRqF (57) TGAGAAGGGCGTAGGCGC 
 
Forward 
hTRqR (57) CTATAGGTTAGGGTTAGACAAAAAATGGCC 
 
Reverse 
hTRqR (72) CTATAGGCCTACGCCCTTCTCAGTTAGGG 
 
Reverse 
hTRqR (598) CTATAGCGACTTTGGAGGTGCCTTCACG 
 
Reverse 
hTR (35-65) CCATTTTTTGTCTAACCCTAACTGAGAAGGGAT 
ATCA 
N/A 
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7.2 APPENDIX 2 
 
Table B: Oligonucleotide sequences utilised. Oligonucleotide sequences are written in the 5’ 
to 3’ direction and the experiments in which they are involved are indicated. 
Name Sequence (5’-3’) Experiments 
Telo 1B CAAGCTTAGGG 5’ biotin 
 
SPR 
Anti 1B CAAGCCCCTAA 5’ biotin 
 
SPR 
Telo1 CAAGCTTAGGG 
 
UV-cross-linking 
Telo4 (TTAGGG)4  3’ biotin 
 
Magnetic pull–down 
and RNA 
simultaneous binding 
assay 
Telo6 (TTAGGG)6 
 
UV–cross-linking 
Anti1 CAAGCCCCTAA 
 
UV–cross-linking 
Anti6 (CCCTAA)6 
 
UV-cross-linking 
NS CAAGCACCGAACCCGCAAGTG 3’ biotin 
 
UV–cross-linking 
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7.3 APPENDIX 3 
 
Table C: Amino acid sequences utilised.  Amino acid sequences are written in the 5’ to 3’ 
direction and the experiments in which they are involved are indicated. 
Name  Sequence (5’-3’) Experiments 
hnRNP A1 
C (UP1) 
Msksespkep eqlrklfiggls fettdeslrshfe qwgtltdcvvm 
rdpntkrsrgfg fvtyatveevda amnarphkvd grvvepkravs 
redsqrpgahlt vkkifvggike dteehhlrdyfe qygkievieim 
tdrgsgkkrgfa fvtfddhdsvdk iviqkyhtvngh ncevrkalskqe 
masasssqrgr sgslehhhhhh* His- Tagged 
UV-cross-linking 
REMSA 
hnRNP A1 
N 
Mghhhhhhhhhh ssghiddddk hmsksespke peqlrklfiggl 
sfettdeslrsh feqwgtltdcv vmrdpntkrsr gfgfvtyatve 
evdaamnarp hkvdgrvvep kravsredsqr pgahltvkkif 
vggikedteeh hlrdyfeqygk ievieimtdrg sgkkrgfafvt 
fddhdsvdki viqkyhtvng hncevrkalsk qemasasssq 
rgrsgsledpa ankarkeael aaataeq* His-tagged 
 
N/A 
hnRNP A1 
NC 
Mghhhhhhhhhh ssghiddddk hmsksesp kepeqlrklf 
igglsfettde  slrshfeqw gtltdcvvm rdpntkrsrg fgfvtyatve 
evdaamna rphkvdgrv vepkravsr edsqrpgah ltvkkifvgg 
ikedteehhl rdyfeqygk ievieimtdr gsgkkrgfa fvtfddhdsv 
dkiviqkyht vnghncevrk alskqemasa sssqrgrsgslehhhhhh* 
His-tagged 
 
N/A 
hnRNP A2 
RRM1  
MEREKEQFRK LFIGGLSFETT EESLRNYYEQ 
WGKLTDCVV MRDPASKRSG FVTFSSMAEV 
DAAMAARPH SIDGRVVEPA VAREESGhhhhhh* His-
tagged 
SPR, UV-cross-
linking 
REMSA 
hnRNP A2 
RRM2  
KLFVGKEDTE EHHLRDYFEE YGKIDTIEIITD 
RQSGKFGFVT FDDHDPVDKI VLQKYHTING 
HNAEVALSRQhhhhhh* His-tagged 
SPR, UV-cross-
linking 
REMSA 
hnRNP A2  
(RRM1+2) 
MEREKEQFRK LFIGGLSFETT EESLRNYYEQ 
WGKLTDCVM RDPASKRSGF VTFSSMAEVD 
AAMAARPHS IDGRVVEPAV AREESGKPGA 
HVTVKKLFVG KEDTEEHHLR DYFEEYGKID 
TIEIITDRQSGK KFGFVTFDDH DPVDKIVLQKY 
HTINGHNAEV ALSRQhhhhhh* His-tagged 
SPR, UV-cross-
linking 
REMSA 
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Name  Sequence (5’-3’) Experiments 
hnRNP A2 
(RRM1+2+
10L)/UP2 
MEREKEQFRK LFIGGLSFET TEESLRNYYE 
QWGKLTDCV MRDPASKRSG FVTFSSMAEV 
DAAMAARPHS IDGRVVEPAV AREESGKPGA 
HVTVKKLFVG KEDTEEHHLR DYFEEYGKID 
TIEIITDRQSGK KFGFVTFDDH DPVDKIVLQK 
YHTINGHNAE  VALSRQEMQE VQSSRShhhhhh* His-
tagged 
SPR, UV-cross-
linking 
REMSA 
 
hnRNP A2 
GRD  
RGGNFGFGDS RGGGGNFGPG PGSNFRGGSD 
GYGSGRGFGD GYNGYGGGPG GGNFGGSPGY 
GGGRGGYGGG GPGYGNQGGG YGGGYDNYGG 
GNYGSGNYND FGNYNQQPSNY GPMKSGNFGG 
SRNMGGPYGG GNYGPGGSGG 
SGGYGGRSPYhhhhhh* His-tagged 
SPR, UV-cross-
linking 
REMSA 
hnRNP A3 
RRM1+2+1
5L 
MEVKPPPGRP QPDSGRRRRR RGEEGHDPKE 
PEQLRKLFIGG LSFETTDDSLR EHFEKWGTLT 
DCVVMRDPQT KRSGFVTYSCV EEVDAAMCAR 
PHKVDGRVVEP AVSREDSVKPG AHLTVKKIFVG 
KEDTEEYNLRD YFEKYGKIETIE VMEDRQSGKK 
FAFVTFDDHD TVDKIVVQKYH TINGHNCEVAL 
SKQEMQhhhhhh* His-tagged 
UV-cross-linking 
REMSA 
 
  2 
 
